[go: up one dir, main page]

WO2008053194A2 - Pyridine carboxamides as 11-beta-hsd1 inhibitors - Google Patents

Pyridine carboxamides as 11-beta-hsd1 inhibitors Download PDF

Info

Publication number
WO2008053194A2
WO2008053194A2 PCT/GB2007/004131 GB2007004131W WO2008053194A2 WO 2008053194 A2 WO2008053194 A2 WO 2008053194A2 GB 2007004131 W GB2007004131 W GB 2007004131W WO 2008053194 A2 WO2008053194 A2 WO 2008053194A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
acetic acid
propylsulfanyl
piperidyl
cyclohexylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/004131
Other languages
French (fr)
Other versions
WO2008053194A3 (en
Inventor
William Mccoull
Martin Packer
James Stewart Scott
Paul Robert Owen Whittamore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009535119A priority Critical patent/JP5165688B2/en
Priority to HK10101460.7A priority patent/HK1135090B/en
Priority to AU2007315955A priority patent/AU2007315955B2/en
Priority to HR20100522T priority patent/HRP20100522T1/en
Priority to PL07824375T priority patent/PL2086939T3/en
Priority to UAA200903812A priority patent/UA97119C2/en
Priority to SI200730335T priority patent/SI2086939T1/en
Priority to KR1020097010339A priority patent/KR101465275B1/en
Priority to AT07824375T priority patent/ATE475649T1/en
Priority to CA2668006A priority patent/CA2668006C/en
Priority to BRPI0717970A priority patent/BRPI0717970C1/en
Priority to DE602007008137T priority patent/DE602007008137D1/en
Priority to EP07824375A priority patent/EP2086939B8/en
Priority to CN2007800491675A priority patent/CN101573336B/en
Priority to DK07824375.5T priority patent/DK2086939T3/en
Priority to NZ576501A priority patent/NZ576501A/en
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Priority to MX2009004707A priority patent/MX2009004707A/en
Publication of WO2008053194A2 publication Critical patent/WO2008053194A2/en
Publication of WO2008053194A3 publication Critical patent/WO2008053194A3/en
Priority to IL198231A priority patent/IL198231A0/en
Priority to NO20091603A priority patent/NO20091603L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to chemical compounds, or pharmaceutically-acceptable salts thereof. These compounds possess human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (l l ⁇ HSDl) inhibitory activity and accordingly have value in the treatment of disease states including metabolic syndrome and are useful in methods of treatment of a warm-blooded animal, such as man.
  • the invention also relates to processes for the manufacture of said compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit 1 l ⁇ HSDl in a warm-blooded animal, such as man.
  • Glucocorticoids Cortisol in man, corticosterone in rodents
  • Glucocorticoids are also important in the differentiation of pre-adipocytes into mature adipocytes which are able to store triglycerides (Bujalska IJ et al. 1999; Endocrinology 140, 3188-3196).
  • Endocrinol. Metab. 80, 3155-3159 leads to increased insulin sensitivity indicating that 1 l ⁇ HSDl may well be regulating the effects of insulin by decreasing tissue levels of active glucocorticoids (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159).
  • Gushing' s syndrome is associated with Cortisol excess which in turn is associated with glucose intolerance, central obesity (caused by stimulation of pre-adipocyte differentiation in this depot), dyslipidaemia and hypertension. Gushing' s syndrome shows a number of clear parallels with metabolic syndrome. Even though the metabolic syndrome is not generally associated with excess circulating Cortisol levels (Jessop DS et al. 2001; J. Clin. Endocrinol. Metab. 86, 4109-4114) abnormally high 1 l ⁇ HSDl activity within tissues would be expected to have the same effect.
  • 1 l ⁇ HSDl knock-out mice show attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting and lower plasma glucose levels in response to stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad. Sci USA 94, 14924-14929) indicating the utility of inhibition of 1 l ⁇ HSDl in lowering of plasma glucose and hepatic glucose output in type 2 diabetes. Furthermore, these mice express an anti-atherogenic lipoprotein profile, having low triglycerides, increased HDL cholesterol and increased apo-lipoprotein AI levels. (Morton NM et al. 2001 ; J. Biol. Chem.
  • 1 l ⁇ HSDl comes from recent studies of transgenic mice over-expressing 1 l ⁇ HSDl (Masuzaki H et al. 2001; Science 294, 2166-2170). When expressed under the control of an adipose specific promoter, 1 l ⁇ HSDl transgenic mice have high adipose levels of corticosterone, central obesity, insulin resistant diabetes, hyperlipidaemia and hyperphagia. Most importantly, the increased levels of 1 l ⁇ HSDl activity in the fat of these mice are similar to those seen in obese subjects.
  • Hepatic 1 l ⁇ HSDl activity and plasma corticosterone levels were normal, however, hepatic portal vein levels of corticosterone were increased 3 fold and it is thought that this is the cause of the metabolic effects in liver.
  • 1 l ⁇ HSDl tissue distribution is widespread and overlapping with that of the glucocorticoid receptor.
  • l l ⁇ HSDl inhibition could potentially oppose the effects of glucocorticoids in a number of physiological/pathological roles.
  • 1 l ⁇ HSDl is present in human skeletal muscle and glucocorticoid opposition to the anabolic effects of insulin on protein turnover and glucose metabolism are well documented (Whorwood CB et al. 2001; J. Clin. Endocrinol. Metab. 86, 2296-2308). Skeletal muscle must therefore be an important target for 11 ⁇ HSD 1 based therapy.
  • Glucocorticoids also decrease insulin secretion and this could exacerbate the effects of glucocorticoid induced insulin resistance.
  • Pancreatic islets express 1 l ⁇ HSDl and carbenoxolone can inhibit the effects of 11-dehydocorticosterone on insulin release (Davani B et al. 2000; J. Biol. Chem. 275, 34841-34844).
  • 1 l ⁇ HSDl inhibitors may not only act at the tissue level on insulin resistance but also increase insulin secretion itself.
  • Skeletal development and bone function is also regulated by glucocorticoid action.
  • 1 l ⁇ HSDl is present in human bone osteoclasts and osteoblasts and treatment of healthy volunteers with carbenoxolone showed a decrease in bone resorption markers with no change in bone formation markers (Cooper MS et al 2000; Bone 27, 375-381). Inhibition of 1 l ⁇ HSDl activity in bone could be used as a protective mechanism in treatment of osteoporosis.
  • Glucocorticoids may also be involved in diseases of the eye such as glaucoma.
  • 1 l ⁇ HSDl has been shown to affect intraocular pressure in man and inhibition of 11 ⁇ HSD 1 may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042).
  • 11 ⁇ HSDl has been shown to affect intraocular pressure in man and inhibition of 11 ⁇ HSD 1 may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042).
  • 11 ⁇ HSDl has been shown to affect intraocular pressure in man and inhibition of 11 ⁇ HSD 1 may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042).
  • the Adult Treatment Panel (ATP III 2001 JMA) definition of metabolic syndrome indicates that it is present if the patient has three or more of the following symptoms: Waist measuring at least 40 inches (102 cm) for men, 35 inches (88 cm) for women; Serum triglyceride levels of at least 150 mg/dl (1.69 mmol/1);
  • HDL cholesterol levels of less than 40 mg/dl (1.04 mmol/1) in men, less than 50 mg/dl (1.29 mmol/1) in women; Blood pressure of at least 135/80 mm Hg; and / or
  • Blood sugar serum glucose of at least 110 mg/dl (6.1 mmol/1).
  • the WHO consultation has recommended the following definition which does not imply causal relationships and is suggested as a working definition to be improved upon in due course:
  • the patient has at least one of the following conditions: glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance; together with two or more of the following:
  • Raised Arterial Pressure Raised plasma triglycerides Central Obesity Microalbuminuria
  • the compounds defined in the present invention are effective ll ⁇ HSDl inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome.
  • the compounds of the invention have improved properties, which would make them better candidates for use as pharmaceuticals.
  • the compounds of the invention have good oral bioavailability whilst retaining potency. Therefore this group of compounds would be expected to provide superior oral exposure at a lower dose and thereby be particularly suitable for use in the treatment or prevention of a disease or medical condition treatable by inhibiting 11 ⁇ HSD 1.
  • the compounds of the invention may also have superior potency and/or advantageous physical properties and/or favourable toxicity profiles and/or favourable metabolic profiles in comparison with other 1 l ⁇ HSDl inhibitors known in the art. Accordingly there is provided a compound of formula (1):
  • Q is a single bond, -O-, -S- or -N(R 15 )- wherein R 15 is hydrogen, C 1-3 alkyl or C 2-3 alkanoyl or R 15 and R 1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl,
  • R 5 and R 5 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C 1-3 alkoxy, carboxy and cyano or R 5 and R 5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)] and optional substituents for heterocyclyl and the heterocyclyl group in heterocyclylC 1-3 alkyl are additionally selected from R 21 , R 21 CO- R 2I S(O) k (wherein k is 0, 1 or 2) and R 21 CH 2 OC(O)- wherein R 21 is phenyl optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, cyano and trifluoromethyl; or when Q is a bond R 1 may also be hydrogen;
  • R 2 is selected from C 3-7 cycloalkyl(CH 2 ) m -, and C 6 -i 2 polycycloalkyl(CH 2 ) m - (wherein the cycloalkyl and polycycloalkyl rings optionally contain 1 or 2 ring atoms independently selected from nitrogen, oxygen and sulphur; m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from R 6 ); R 3 is selected from hydrogen, C 1-4 alkyl C 3-5 cycloalkyl and C 3-5 cycloalkylmethyl;
  • R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R 7 ;
  • R 4 is independently selected from halo, C 1-2 alkyl, cyano, Ci -2 alkoxy, and trifluoromethyl;
  • R 6 and R 7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl,
  • R 9 is independently C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from C 1-4 alkyl, hydroxyl, cyano, trifluoromethyl, trifluoromoxy, halo, C 1-4 alkoxy, C 1-4 alkoxyC 1-4 alkyl, amino, N-C 1-4 alkylamino, di-N,N-(C 1-4 alkyl)amino, N-C 1-4 alkylcarbamoyl, di-N,N-(C 1-4 alkyl)carbamoyl, Ci -4 alkylS(O) r , C 1-4 alkylS(O) r Ci -4 alkyl (wherein r is 0, 1 and 2)]; R 9 is independently C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently io selected from hydroxyl, halo, C 1-4 alkoxy, carboxy and cyano;
  • R 9 , R 9 and R 9 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by hydroxyl, halo, C 1-4 alkoxy, carboxy or cyano); p is 0, 1 or 2; either X is -O(CH 2 ) q -, -S(CH 2 ) q - or -N(R 12 )(CH 2 ) q - wherein R 12 is hydrogen, C 1-3 alkyl or Ci- i 5 3 alkanoyl and q is 0 or 1; and Y is:
  • R 20 independently selected from hydrogen, C 1-3 alkyl, C 1-3 alkoxy and hydroxyl or R x and R y together with the carbon atom to which they are attached form a C 3-7 cycloalkdiyl ring and v is 1, 2, 3, 4 or 5) and when v is more than 1 the -[C(R x )(R y )] v - group may optionally be interrupted by a -O-, - S- or -N(R 20 )- group wherein R 20 is hydrogen or C 1-3 alkyl; or
  • ring A is linked to the pyridine group and -(Z) t [C(R 13 )(R I4 )] s - is linked to the carboxy group;
  • A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
  • Z is -O-, -S- or -N(R 16 )- wherein R 16 is hydrogen, C 1-3 alkyl or C ⁇ alkanoyl; t is 0 or 1 provided that when s is 0 then t is 0;
  • R 10 is independently selected from C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, Ci -3 alkylS(O) n - (wherein n is 0, 1, 2 or 3), R 11 CON(R 11' ),
  • R 11 and R 11 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by hydroxyl, halo, C 1-3 alkoxy, carboxy or cyano) or R 11 and R 11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2; R 13 and R 14 are independently selected from hydrogen and C 1-3 alkyl or R 13 and R 14 may together with the carbon atom to which they are attached form a C 3-7 cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof. provided the compound is not: ⁇ (35)-l-[5-(adamantan-l-ylcarbamoyl)pyridin-2-yl]piperidin-3-yl ⁇ acetic acid; or
  • Q is a single bond, -O-, -S- or -N(R 15 )- wherein R 15 is hydrogen, Ci -3 alkyl or C 2-3 alkanoyl or R 15 and R 1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl,
  • R 5 OC(O)- and (R 5 ' )(R 5" )NSO 2 - (wherein R 5 is C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo and cyano; and
  • R 5 and R 5 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C 1-3 alkoxy, carboxy and cyano or
  • R 5 and R 5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)]; or when Q is a bond R 1 may also be hydrogen;
  • R 2 is selected from C 3 . 7 cycloalkyl(CH 2 ) m -, and C 6- i 2 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from
  • R 3 is selected from hydrogen, C 1-4 alkyl C 3-5 Cy cloalkyl and C 3-5 cycloalkylmethyl;
  • R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R 7 ;
  • R 4 is independently selected from halo, C 1-2 alkyl, cyano, C 1-2 alkoxy, and trifluoromethyl;
  • R 6 and R 7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R 9 , R 9 O-, R 9 CO-, R 9 C(O)O-, R 9 CON(R 9' )-, (R 9' )(R 9 ")NC(O)-, (R 9' )(R 9 ")N-, R 9 S(O) 3 - wherein a is O to 2, R 9 OC(O)-, (R 9' )(R 9 ")NSO 2 -, R 9 SO 2 N(R 9" )-, (R 9' )(R 9" )NC(O)N(R 9'” )-, phenyl and heteroaryl [wherein the phenyl and heteroaryl groups are optionally fused to a phenyl, hetero
  • R 9 , R 9 and R 9 ' are independently selected from hydrogen and Ci -3 alkyl optionally substituted by hydroxyl, halo, C 1-4 alkoxy, carboxy or cyano); p is O, 1 or 2; X is -O-, -S- or-N(R 12 )- wherein R 12 is hydrogen, C 1-3 alkyl or C 1-3 alkanoyl;
  • Y is either:
  • ring A is linked to the pyridine group and -[C(R 13 )(R 14 )] S - is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
  • R 10 is independently selected from Ci -3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1-3 alkylS(O) n - (wherein n is 0, 1, 2 or 3), R 11 CON(R 11' ), (R U ' )(R U" )NC(O)-, R 11 OC(O)- and (R i r )(R ⁇ " )NSO 2 - (wherein R 11 is Ci -3 alkyl optionally substituted by hydroxyl, halo or cyano; and R 11 and R 11 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by
  • R 13 and R 14 are independently selected from hydrogen and Ci -3 alkyl or R 13 and R 14 may together with the carbon atom to which they are attached form a C 3-7 cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt thereof.
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl” are specific for the straight chain version only.
  • C 1-4 alkyl includes propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as 'propyl' are specific for the straight chain version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only.
  • C 1-4 alkoxyC 1-4 alkyl would include l-(C 1- 4alkoxy)propyl, 2-(C 1-4 alkoxy)ethyl and 3-(C 1-4 alkoxy)butyl.
  • halo refers to fluoro, chloro, bromo and iodo.
  • a 4-7 membered saturated ring (for example formed between R 1 and R 15 or R 5 and R 5 and the nitrogen atom to which they are attached) is a monocyclic ring containing the nitrogen atom as the only ring atom.
  • Heteroaryl unless otherwise specified, is a totally unsaturated, monocyclic ring containing 5 or 6 atoms of which at least 1, 2 or 3 ring atoms are independently chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon-linked.
  • a ring nitrogen atom may be optionally oxidised to form the corresponding N-oxide.
  • heteroaryl examples and suitable values of the term "heteroaryl” are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyrimidyl, pyrazinyl, pyridazinyl and pyridyl. Particularly “heteroaryl” refers to thienyl, furyl, thiazolyl, pyridyl, imidazolyl or pyrazolyl.
  • Heterocyclyl is a 4-7 saturated, monocyclic ring having 1-3 ring heteroatoms selected from nitrogen, oxygen and sulphur. Examples of heterocyclyl include piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl
  • a polycycloalkyl ring is a ring system in which either at least 2 rings are fused together or in which 2 rings have one ring atom in common (spiro).
  • the polycycloalkyl ring has 2, 3 or 4 rings.
  • An example of a polycycloalkyl ring is adamantyl.
  • a "saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur", unless otherwise specified contains 4-14 ring atoms. Particularly a mono ring contains 4 -7 ring atoms, a bicyclic ring 6-14 ring atoms and a bridged ring system 6-14 ring atoms. Examples of mono rings include piperidinyl, piperazinyl and morpholinyl. Examples of bicyclic rings include decalin and 2,3,3a,4,5,6,7,7a-octahydro-lH-indene.
  • Bridged ring systems are ring systems in which there are two or more bonds common to two or more constituent rings.
  • Examples of bridged ring systems include l,3,3-trimethyl-6- azabicyclo[3.2.1]octane, 2-aza-bicyclo[2.2.1]heptane and 7-azabicyclo(2,2,l)heptane, 1- and 2- adamantanyl.
  • a “saturated, partially saturated or unsaturated monocyclic ring” is, unless otherwise specified, a 4-7 membered ring. Examples include, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and phenyl.
  • a "C 3-7 cycloalkdiyl ring” is a saturated monocyclic carbocyclic ring. It is the di-radical of the cycloalkane ring.
  • Adamantdiyl is the di-radical of an adamantane ring system.
  • Phenylene is the diradical of the benzene ring. In a particular aspect the radicals are on different ring atoms.
  • Examples of "5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur" include piperazinyl, piperidinyl and morpholinyl.
  • a "4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur" is a saturated ring system being monocyclic, bicyclic or a spiro ring system having 4 to 7 ring atoms.
  • Examples of the "4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur" include piperidinyl, piperazinyl and morpholinyl.
  • Examples of a "saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur” include piperidinyl, piperazinyl and morpholinyl.
  • Examples of "Ci -4 alkoxy” include methoxy, ethoxy and propoxy.
  • Examples of “Ci -4 alkoxyC 1-4 alkyl” include methoxymethyl, ethoxymethyl, propoxymethyl, 2-methoxyethyl, 2- ethoxyethyl and 2-propoxyethyl.
  • Examples of "Ci -4 alkylS(O) n wherein n is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • alkyl wherein q is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methylthiomethyl, ethylthiomethyl, methylsulphinylmethyl, ethylsulphinylmethyl, mesylmethyl and ethylsulphonylmethyl.
  • Examples of "C 1-4 alkanoyl” include propionyl and acetyl.
  • Examples of "iV-(C 1-4 alkyl)amino” include methylamino and ethylamino.
  • Examples of " ⁇ N-(C 1-4 alkyl) 2 amino” include ⁇ iV-dimethylamino, N,N-diethylamino and N-ethyl-JV-methylamino.
  • Examples of "C 2-4 alkenyl” are vinyl, allyl and 1-propenyl.
  • Examples of "C 2-4 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
  • Examples of "N-(C 1-4 alkyl)carbamoyl” are methylaminocarbonyl and ethylaminocarbonyl.
  • Examples of “N,iV-(C 1-4 alkyl) 2 carbamoyl” are dimethylaminocarbonyl and methylethylaminocarbonyl.
  • Examples of “C 3-7 cycloalkylC 1-3 alkalkyl” include cyclopropymethyl, 2-cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.
  • Examples of “C 3-7 cycloalkylC 2- 3 alkalkenyl” include 2-cyclopropylethenyl, 2-cyclopentylethenyl and 2-cyclohexylethenyl.
  • C 3-7 cycloalkylC 2-3 alkalkynyl examples include 2-cyclopropylethynyl, 2-cyclopentylethynyl and 2-cyclohexylethynyl.
  • C 3-7 cycloalkyl(CH 2 ) m - include cyclopropymethyl, 2-cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.
  • Examples of C 6- i 2 polycycloalkyl(CH 2 ) m - include norbornyl bicyclo[2.2.2]octane(CH 2 ) m -, bicyclo[3.2.1]octane(CH 2 ) m- and 1- and 2-adamantanyl(CH 2 ) m -.
  • a suitable pharmaceutically-acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically-acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, tert-butylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • An in- vivo hydroly sable ester of a compound of the invention containing a carboxy or a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically- acceptable esters for carboxy include C 1 to C 6 alkoxymethyl esters for example methoxymethyl, Ci to 6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 to 8cycloalkoxycarbonyloxyCi to 6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters, for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C 1- 6 alkoxycarbonyloxyethyl esters.
  • An in- vivo hydrolysable ester of a compound of the invention containing a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in- vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s.
  • inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in- vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s.
  • ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
  • a selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • Some compounds of the formula (1) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess 1 l ⁇ HSDl inhibitory activity.
  • the invention relates to any and all tautomeric forms of the compounds of the formula (1) that possess l l ⁇ HSDl inhibitory activity.
  • the 2-position refers to the position which is substituted by the -Q-R 1 group and the other positions are numbered accordingly.
  • Q is a single bond, -O-, -S- or -N(R 15 )- wherein R 15 is hydrogen, Ci -3 alkyl or C 2-3 alkanoyl or R 15 and R 1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring and R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3- 7cycloalkylC 1-3 alkyl, C 3-7 cycloalkylC 2-3 alkenyl, C 3-7 cycloalkylC 2-3 alkynyl, phenyl, phenylC 1-3 alkyl, heteroaryl, heteroarylCi -3 alkyl, heterocyclyl, or [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyL C 1-3 alkoxy, C 1-3
  • R 5 and R 5 are independently selected from hydrogen and C ⁇ alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C 1-3 alkoxy, carboxy and cyano or R and R 5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)].
  • Q is a single bond, -O-, -S- or -N(R 15 )- wherein R 15 is hydrogen, C 1-3 alkyl or C 2-3 alkanoyl or R 15 and R 1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring and R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3- 7 cycloalkylC 1-3 alkyl, C 3-7 Cy cloalkylC 2-3 alkenyl, C 3-7 cycloalkylC 2-3 alkynyl, phenyl, heteroaryl, heterocyclyl, or heterocyclylC 1-3 alkyl [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1-3 alkylS(O) n - (
  • Q is O, S or a single bond and R 1 is C ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3- 7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl, C 3-7 cycloalkylC 2-3 alkenyl or C 3-7 cycloalkylC 2-3 alkynyl, [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from C 1-3 alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1-3 alky IS (O) n - (wherein n is O, 1, 2 or 3), R 5 CON(R 5' )-, (R 5' )(R 5 ")NC(O)-, R 5 OC(O)- and (R 5' )(R 5 ")NSO 2 - (wherein R 5 is Ci -3 alkyl optionally substituted by 1, 2
  • the invention relates to a compound of the formula (I) as hereinabove defined wherein Q is a single bond. .
  • Q is -N(R 15 )-.
  • R 15 is hydrogen.
  • R 15 is C 1-3 alkyl.
  • R 15 is methyl. In one aspect Q is O. In another aspect Q is S.
  • R 1 is C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl, [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1-3 alkylS(O) n - (wherein n is 0, 1, 2 or 3).
  • R 1 is C 1-6 alkyl, C 3-7 cycloalkyl or C 3-7 cycloalkylCi -3 alkyl.
  • R 1 is C 3-4 Cy cloalkyl optionally substituted by 1, 2 or 3 substituents independently selected from C 1-3 alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and C 1-3 alkoxy.
  • R 1 is C 3-4 cycloalkyl.
  • R 1 is C 3-4 cycloalkylC 1-2 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from C 1-3 alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and Ci -3 alkoxy.
  • R 1 is C 3-4 cycloalkylC 1-2 alkyl.
  • R 1 is C 1-4 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from C 1-3 alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and C 1-3 alkoxy.
  • R 1 is C 1-4 alkyl.
  • R 1 is propyl optionally substituted by 1 or 2 substituents independently selected from C 1-3 alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and C 1-3 alkoxy. In another aspect R 1 is propyl.
  • R 1 is phenylC 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl and C 1-3 alkoxyln another aspect R 1 is phenylCi -3 alkyl.
  • R 1 is heteroarylC 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl and Cj -3 alkoxy. In another aspect R 1 is heteroarylC 1-3 alkyl.
  • R 1 is phenyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl and C 1-3 alkoxy. In another aspect R 1 is phenyl.
  • R 1 is heteroaryl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, ox ⁇ , cyano, trifluoromethyl and C 1-3 alkoxy.
  • R 1 is heteroaryl.
  • -Q-R 1 is hydrogen.
  • R 3 is C 1-4 alkyl.
  • R 3 is hydrogen, methyl or ethyl.
  • R 3 is hydrogen
  • R 3 is methyl. In another aspect, R 3 is ethyl.
  • R 4 is methyl
  • p 0.
  • p is 1 or 2.
  • p is 0 or 1. In another aspect, p is 1.
  • p is 2.
  • p is 1 and R 4 is in the 5-position.
  • R 2 is selected from C 3-7 cycloalkyl(CH 2 ) m -, and C 6-12 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1 , 2 or 3 substituents independently selected from R 6 as hereinabove defined).
  • R 2 is selected from C 3 . 7 cycloalkyl(CH 2 ) m -, and C 6-
  • R 12 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1 or 2 substituents independently selected from R 6 , wherein R 6 is independently selected from hydroxyl, halo and trifluoromethyl).
  • R 2 is selected from C 3-7 cycloalkyl, and C 6-12 polycycloalkyl each of which is independently optionally substituted by 1 R 6 , wherein R 6 is selected from hydroxyl, halo and trifluoromethyl).
  • R 2 is selected from C 5-7 Cy cloalkyl(CH 2 ) m - and Cg.i 2 polycycloalkyl(CH 2 ) m - (wherein the rings are optionally substituted by 1, 2 or 3 substituents independently selected from R 6 ) and wherein m is 0, 1 or 2.
  • R 2 is selected from C5 -7 cycloalkyl(CH 2 ) m -, C 7- i 0 bicycloalkyl(CH 2 ) m - and Ciotricycloalkyl(CH 2 ) m - (wherein the cycloalkyl, bicycloalkyl and tricycloalkyl rings are optionally substituted by 1, 2 or 3 substituents independently selected from R 6 ) and wherein m is 0, 1 or 2.
  • R 2 is selected from C 5-7 cycloalkyl(CH 2 ) m -, C 7-10 bicycloalkyl(CH 2 ) m - and adamantyl (wherein the cycloalkyl, bicycloalkyl and tricycloalkyl rings are optionally substituted by 1, 2 or 3 substituents independently selected from R 6 ) and wherein m is 0, 1 or 2.
  • m is 0 or 1.
  • R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, 6-12 membered bicyclic or 6-12 membered bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially-saturated or aryl monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R 7 .
  • R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially-saturated or aryl monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R 7 .
  • R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, ring system optionally containing 1 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and is optionally substituted by 1 or 2 substituents independently selected from R 7 .
  • R 6 is independently selected from hydroxyl, R 9 O-, R 9 CO- and R 9 C(O)O- wherein R 9 is as hereinabove defined.
  • R 6 is independently selected from hydroxyl, R 9 O-, R 9 CO- and R 9 C(O)O- wherein R 9 is C 1-3 alkyl optionally substituted by C 1-4 alkoxy or carboxy.
  • R 6 is independently selected from R 9 CON(R 9' )-, R 9 SO 2 N(R 9" )- and (R 9' )(R 9" )NC(O)N(R 9'” )-; wherein R 9 is as hereinabove defined.
  • R 6 is independently selected from R 9 CON(R 9' )-, R 9 SO 2 N(R 9" )- and (R 9' )(R 9" )NC(O)N(R 9'” )-;
  • R 9 is Ci -3 alkyl optionally substituted by C 1-4 alkoxy or carboxy;
  • R 9 , R 9 and R 9 are independently selected from hydrogen and d ⁇ alkyl optionally substituted by
  • R 6 is independently selected from (R 9' )(R 9 ")NC(O)- and (R 9' )(R 9 ")N-; wherein R 9 and-R 9 are as hereinabove defined.
  • R 6 is independently selected from (R 9' )(R 9 ")NC(O)- and (R 9' )(R 9 ")N-; wherein R 9 and R 9 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by Q ⁇ alkoxy or carboxy.
  • R 6 is selected from methyl, trifluoromethyl, chloro, fmoro, bromo, methoxy, ethoxy, trifluormethoxy, methanesulfonyl, ethanesulfonyl, methylthio, ethylthio, amino, N- methylamino, N-ethylamino, N-propylamino, N,N-dimethylamino, N,N-methylethylamino or N,N-diethy lamino . In one aspect R 6 is selected from hydroxy, halo and trifluoromethyl.
  • R 6 is optionally substituted phenyl, pyridyl or pyrimidyl.
  • R 6 is optionally substituted pyrid-2-yl, pyrid-3-yl or pyrid-4-yl.
  • R 6 is carboxy
  • R 7 is selected from hydroxy, halo and trifluoromethyl.
  • X is -O-, -S- or -N(R 12 )- wherein R 12 is hydrogen, C 1-3 alkyl or C 1-3 alkanoyl.
  • X is -O- .
  • X is -N(R 12 )-, wherein R 12 is as hereinabove defined.
  • X is -N(R 12 )-, wherein R 12 is hydrogen.
  • X is -S-.
  • Y is a C 3-7 cycloalkdiyl ring, a 5-7 membered saturated heterocyclic ring
  • Y is a C 3-7 cycloalkdiyl ring or a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur.
  • Y is a C 3-7 cycloalkdiyl ring.
  • Y is a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur.
  • Y is of the formula -[C(R x )(R y )] v - (wherein R x and R y are independently selected from hydrogen and methyl and v is 1, 2, 3, 4 or 5) and when v is more than 1 the - [C(R x )(R y )] v - group may optionally be interrupted by a-O-, -S- or -N(R 20 )- group wherein R 20 is hydrogen or C 1-3 alkyl.
  • Y is of the formula -[C(R x )(R y )] v - (wherein R x and R y are independently selected from hydrogen and methyl and v is 1, 2, 3, 4 or 5).
  • -X-Y- together represents a group of the formula:
  • ring A is linked to the pyridine group and -[C(R 13 )(R 14 )] S - is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; R 10 is independently selected from C ⁇ alkyl, hydroxy, halo and trifluoromethyl; u is 0, or 1 ;
  • R 13 and R 14 are independently selected from hydrogen and C ⁇ alkyl or R 13 and R 14 may together with the carbon atom to which they are attached form a C 3-7 cycloalkyl ring; and s is 0, 1 or 2.
  • -X-Y- together represents a group of the formula:
  • ring A is linked to the pyridine group and -[C(R 13 )(R 14 )] S - is linked to the carboxy group; and A is a 4-7 membered mono- or bi- heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; u is O; R 13 and R 14 are independently selected from hydrogen and methyl; and s is 0, 1 or 2.
  • R x and R y are hydrogen.
  • v is 3, 4 or 5.
  • A is a 5 or 6 membered mono-heterocyclic ring containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur.
  • A is piperidino, pyrrolidino, azabicyclo[3.1.0]hexane, morpholino or thiomorpholino. In another aspect A is piperidino, morpholino or thiomorpholino.
  • A is piperidino.
  • A is piperidino in which the ⁇ (Z) t [C(R 13 )(R 14 )] s -COOH group is in the 3-position.
  • A is piperidino in which the -(Z) t [C(R I3 )(R 14 )] s -COOH group is in the 4-position.
  • A is pyrrolidino.
  • Z is -N(R 16 )-, wherein R 16 is as hereinabove defined.
  • Z is -NH-.
  • R 10 is selected from C ⁇ alkyl, C 2-3 alkenyl, C 2-3 alkynyl, hydroxy, halo, oxo, cyano, trifiuoromethyl and alkoxy.
  • R 10 is selected from C ⁇ alkyl, hydroxy, halo, oxo, cyano, trifiuoromethyl and alkoxy.
  • R 10 is independently selected from C 1 . 3 alk.yl, hydroxy, halo and trifiuoromethyl.
  • R 10 is selected from Ci -3 alkyl and alkoxy.
  • u is 0 or 1.
  • u is 1. In another aspect u is 0.
  • R 13 and R 14 are independently hydrogen or methyl.
  • R 13 and R 14 are hydrogen.
  • s is 0 or 1. In one aspect s is 0.
  • s is 1.
  • a class of compounds of the present invention is of formula (1) wherein: Q is -O-, -S- or -N(R 15 )- wherein R 15 is hydrogen, Ci -3 alkyl or C 2-3 alkanoyl or R 15 and R 1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; R 1 is Ci- ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl,
  • R 5 and R 5 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C ⁇ alkoxy, carboxy and cyano or R 5 and R 5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)]; or
  • R 2 is selected from C 3-7 Cy cloalkyl(CH 2 ) m -, and C 6-12 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from
  • R 3 is selected from hydrogen, C 1-4 alkyl C 3 . 5 cycloalkyl and C 3-5 cycloalkylmethyl; R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R 7 ; R 6 and R 7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R 9 , R 9 O-, R 9 CO-, R 9 C(O)O-, R 9 CON(R 9' )-, (R 9' )(R 9 ")NC(O)-, (R 9> )(R 9 ")N-, R 9 S(O) 3 - wherein a
  • R 9 is independently C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, Ci -4 alkoxy, carboxy and cyano;
  • R 9 , R 9 and R 9 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by io hydroxyl, halo, C 1-4 alkoxy, carboxy or cyano); p is 0; either X is -O-, -S- or -N(R 12 )- wherein R 12 is hydrogen, C 1-3 alkyl or C 1-3 alkanoyl; and
  • Y is:
  • ring A is linked to the pyridine group and is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
  • R 10 is independently selected from C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1-3 alkylS(O) n - (wherein n is 0, 1 , 2 or 3), R 11 CON(R 1 v ),
  • R 11 and R 11 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by hydroxyl, halo, C 1-3 alkoxy, carboxy or cyano) or R 11' and R 11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2;
  • R 13 and R 14 are independently selected from hydrogen and C 1-3 alkyl or R 13 and R 14 may together with the carbon atom to which they are attached form a C 3-7 cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydroly sable ester thereof.
  • Another class of compounds of the present invention is of formula (1) wherein:
  • R 1 is Ci -6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylCi -3 alkyl, [each of which is optionally substituted by
  • substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1 -SaIlCyIS(O) n - (wherein n is 0, 1, 2 or 3); or
  • R 2 is selected from C 3-7 cycloalkyl(CH 2 ) m -, and C 6-12 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or
  • R 3 is selected from hydrogen; R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R 7 ; R 6 and R 7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R 9 , R 9 O-, R 9 CO-, R 9 C(O)O-, R 9 CON(R 9' )-, (R 9' )(R 9 ")NC(O)-, (R 9> )(R 9 ")N-, R 9 S(O) a - wherein a is 0 to 2, R 9 OC(O)-, (R 9' )(R 9 ")NSO 2
  • R 9 is independently C 1-3 alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C 1-4 alkoxy, carboxy and cyano;
  • R 9 , R 9 and R 9 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by io hydroxyl, halo, C 1-4 alkoxy, carboxy or cyano); p is 0; either X is -O-, -S- or -N(R 12 )- wherein R 12 is hydrogen, Ci -3 alkyl or C 1-3 alkanoyl; and
  • Y is :
  • ring A is linked to the pyridine group and -[C(R 13 )(R 14 )] S - is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom 2 5 selected from nitrogen, oxygen and sulphur;
  • R 10 is independently selected from C [-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, Ci -3 alkoxy, C 1-3 alkylS(O) n - (wherein n is 0, 1 5 2 or 3), R 11 CON(R 11' ), (R H' )(R n" )NC(O)-, R 11 OC(O)- and (R H' )(R ⁇ " )NSO 2 - (wherein R 11 is C 1-3 alkyl optionally substituted by hydroxyl, halo or cyano; and R 11' and R 11" are independently selected from hydrogen and C 1-3 alkyl optionally substituted by hydroxyl, halo, C ⁇ alkoxy, carboxy or cyano) or R 11 and R 11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2; R 13 and R
  • Another class of compounds of the present invention is of formula (1) wherein: Q is -S-;
  • R 1 is C 1-6 alkyl, C 3-7 cycloalkyl or C 3-7 cycloalkylC 1-3 alkyl; or
  • R 2 is selected from C 3-7 cycloalkyl(CH 2 ) m -, and C 6-12 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or
  • R 3 is selected from hydrogen; or R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1 or
  • R 6 and R 7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl,
  • R 9 , R 9 and R 9 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by hydroxyl, halo, C 1-4 alkoxy, carboxy or cyano); p is 0; either X is -O-, -S- or -N(R 12 )- wherein R 12 is hydrogen, C 1-3 alkyl or C 1-3 alkanoyl; and
  • Y is:
  • ring A is linked to the pyridine group and -[C(R 13 )(R 14 )] S - is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
  • R 10 is independently selected from C 1-3 alkyl, C 2 . 3 alkenyl, C 2-3 alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C 1-3 alkoxy, C 1-3 alkylS(O) n - (wherein n is 0, 1, 2 or 3), R 11 CON(R 11' ), (R 11 ' XR i r' )NC(O>, R 11 OC(O)- and (R n' )(R ⁇ " )NSO 2 - (wherein R 11 is C 1-3 alkyl optionally substituted by hydroxy 1, halo or cyano; and
  • R 11 and R 11 are independently selected from hydrogen and C 1-3 alkyl optionally substituted by hydroxyl, halo, C 1-3 alkoxy, carboxy or cyano) or R 11 and R 11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, or 1;
  • R 13 and R 14 are independently selected from hydrogen and C 1-3 alkyl or R 13 and R 14 may together with the carbon atom to which they are attached form a C 3-7 cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof. 4.
  • Another class of compounds of the present invention is of formula (1) wherein:
  • R 1 is Ci- ⁇ alkyl
  • R 2 is selected from C 3-7 cycloalkyl(CH 2 ) m -, and C 6-12 polycycloalkyl(CH 2 ) m - (wherein m is 0, 1 or
  • R 3 is selected from hydrogen
  • R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1 or 2 substituents independently selected from R 7 ;
  • R 6 and R 7 are independently selected from hydroxyl, halo and trifluoromethyl; p is 0; either X is -N(R 12 )- wherein R 12 is hydrogen; and Y :
  • ring A is linked to the pyridine group and -[C(R 13 )(R 14 )] S - is linked to the carboxy group;
  • A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
  • R 10 is independently selected from C 1-3 alkyl, hydroxy, halo and trifluoromethyl; u is O, or 1;
  • R 13 and R 14 are independently selected from hydrogen and C 1-3 alkyl or R 13 and R 14 may together with the carbon atom to which they are attached form a C 3-7 cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof. 5.
  • Another class of compounds of the present invention is of formula (1) wherein:
  • R 1 is C 1-6 alkyl
  • R 2 is selected from C 3-7 cycloalkyl, and C 6-12 polycycloalkyl each of which is independently optionally substituted by 1 R 6 ;
  • R 3 is selected from hydrogen;
  • R 6 is selected from hydroxyl, halo and trifluoromethyl; p is O;
  • ring A is linked to the pyridine group and -[C(R 13 )(R l4 )] s - is linked to the carboxy group;
  • A is a 4-7 membered mono- or bi- heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; u is 0; R 13 and R 14 are independently selected from hydrogen and methyl; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
  • suitable compounds of the invention are any one or more of the Examples or a pharmaceutically-acceptable salt thereof.
  • the invention relates to: a compound selected from : 2- [(3R)- 1 - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl] -3 -piperidyl] acetic acid
  • Another aspect of the present invention provides a process for preparing a compound of formula (1) or a pharmaceutically acceptable salt thereof which process [wherein Z is -X-Y-COOH and other variable groups are, unless otherwise specified, as defined in formula (I)] comprises any one of processes a) to e): a) reaction of a compound of Formula (2) with a compound of Formula (3):
  • X'" is a leaving group; and thereafter if necessary or desirable: i) converting a compound of the formula (1) into another compound of the formula (1); ii) removing any protecting groups; iii) resolving enantiomers; iv) forming a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
  • Examples of conversions of a compound of Formula (1) into another compound of Formula (1) include functional group interconversions such as hydrolysis, hydrogenation, hydrogenolysis, oxidation or reduction, and/or further functionalisation by standard reactions such as amide or metal-catalysed coupling, or nucleophilic displacement reactions.
  • Suitable conditions for the above processes a) to e) are as follows.
  • Process a) is typically carried out in a suitable solvent such as dichloromethane or N,N- dimethylformamide for example with either the in situ formation of the acyl halide using a suitable reagent such as oxalyl chloride for example or with the addition of a suitable coupling agent (or combination of agents) to form an active ester such as HOBT and EDAC for example, optionally in the presence of a suitable base such as triethylamine or ⁇ iV-di-wo-propylamine for example.
  • a suitable solvent such as dichloromethane or N,N- dimethylformamide
  • a suitable solvent such as dichloromethane or N,N- dimethylformamide
  • a suitable solvent such as dichloromethane or N,N- dimethylformamide
  • a suitable solvent such as dichloromethane or N,N- dimethylformamide
  • a suitable reagent such as oxalyl chloride
  • a suitable coupling agent or combination of agents
  • Process b) is typically carried out in a suitable solvent such as dichloromethane or THF for example using a strong base (such as sodium hydride or lithium or potassium hexamethyldisilylazides) and a suitable alkylating agent (such as alkyl iodide). Typically the reaction is carried out at ambient or temperature. Suitable examples of leaving groups (X) are chloro, bromo, iodo, mesylate, tosylate or triflate. Others are known to the art. Process c) may be carried out in a suitable solvent such as acetonitrile, butyronitrile or methanol for example, typically with the addition of a suitable base such as potassium carbonate or sodium hydroxide for example.
  • a suitable solvent such as dichloromethane or THF for example using a strong base (such as sodium hydride or lithium or potassium hexamethyldisilylazides) and a suitable alkylating agent (such as alkyl iodide).
  • reaction is carried out at elevated temperature, using Microwave or conventional heating, for example at temperatures between 100-140 0 C. In certain cases the reactions can be carried out at ambient temperature.
  • Suitable examples of leaving groups (X') are chloro, bromo, iodo, mesylate, tosylate or triflate. Others are known to the art.
  • Process d) may be carried out in a suitable solvent such as acetonitrile, butyronitrile, DMF or THF for example, typically with the addition of a suitable base such as potassium carbonate or sodium hexamethyldisilylazide for example.
  • a suitable solvent such as acetonitrile, butyronitrile, DMF or THF
  • a suitable base such as potassium carbonate or sodium hexamethyldisilylazide for example.
  • Suitable examples of leaving groups (X”) are fluoro, and chloro. Others are known to the art.
  • Process e) may be carried out in a suitable solvent such as acetonitrile, butyronitrile, DMF or THF for example, typically with the addition of a suitable base such as potassium carbonate or sodium hexamethyldisilylazide for example.
  • a suitable solvent such as acetonitrile, butyronitrile, DMF or THF
  • a suitable base such as potassium carbonate or sodium hexamethyldisilylazide for example.
  • Suitable examples of leaving groups (X'") are fluoro, and chloro. Others are known to the art. It will be appreciated that the intermediates required to synthesise compounds of formula (1) may be commercially available, may be known to the art or may be prepared by known procedures and/or by the procedures described above a)-e).
  • X 1 and X 2 are leaving groups (typically fluoro or chloro) and W is an amide or alternatively a group that may be converted into an amide by processes known to the art (for example an ester which may be hydrolysed to an acid that may be subsequently transformed into an amide);
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl it will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T. W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991).
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example hydroxylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • cortisone to the active steroid Cortisol by 1 l ⁇ HSDl oxo-reductase activity can be measured using a competitive homogeneous time resolved fluorescence assay (HTRF) (CisBio International, R&D, Administration and Europe Office, In Vitro Technologies — HTRF® / Bioassays BP 84175, 30204 Bagnols/Ceze Cedex, France.
  • HTRF time resolved fluorescence assay
  • the evaluation of compounds described herein was carried out using a baculovirus expressed N terminal 6-His tagged full length human 1 l ⁇ HSDl enzyme(* 1).
  • the enzyme was purified from a detergent solublised cell lysate, using a copper chelate column.
  • Inhibitors of 11 ⁇ HSD 1 reduce the conversion of cortisone to Cortisol, which is identified by an increase in signal, in the above assay.
  • the assay plates were incubated for 25 minutes at 37 0 C after which time the reaction was stopped by the addition of lO ⁇ l of 0.5mM glycerrhetinic acid plus conjugated cortisol(XL665 or D2). lO ⁇ l of anti-cortisol Cryptate was then added and the plates sealed and incubated for 6 hours at room temperature. Fluorescence at 665nm and 620nm was measured and the 665nm:620nm ratio calculated using an Envision plate reader.
  • Compounds of the present invention typically show an IC 5O of less than 30 ⁇ M, and preferably less than 5 ⁇ M.
  • the compound 2-[(3S)-l-[5-(2-adamantylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid achieved 50% inhibition in one assay, but in a subsequent 3 assays did not and hence is also not a preferred aspect of the invention. In one aspect the invention does not relate to 2-[(3S)-I -[5-(2-adamantylcarbamoyl)pyridin-2-yl]-
  • the oral bioavailability of the compounds of the invention may be tested as follows:
  • Compounds are dosed intravenously at 2mg/kg (2ml/kg) and orally at 5mg/kg (5ml/kg) in a 25% HPBCD in sorrensons buffer pH 5.5 formulation.
  • Blood samples (20OuI) are taken Predose,
  • Plasma samples are analysed as below.
  • PK parameters (clearance, volume of distribution, bioavailability, fraction absorbed etc.) are calculated by standard PK methods using suitable PK software (WinNon-Lin).
  • Bioanalvsis of plasma samples The guidelines described are for the manual preparation of plasma samples following single compound or cassette dosing of project compounds to all PK species used within discovery DMPK. Analysis by open access (LC-MS/MS) or manual approaches (LC-MS) is described. Contents 1.
  • Solubilise compound(s) to lmg/ml using DMSO taking into account salt factors if any.
  • DMSO stock(s) may be used to make all calibration & quality control (QC) samples:
  • IV and PO oral dose formulations of expected concentration to lOug/ml in methanol.
  • IV and PO oral dose formulations of expected concentration to lOug/ml in methanol.
  • a formulation made to an expected concentration of 2 mg/ml would be diluted 1:200 to give 10ug/ml solution).
  • High LLOQ is taken as when most of the plasma concentrations lie below the lower limit of quantification or where the LLOQ is greater the 10ng/ml. The following methods should be applied when either of these scenarios is encountered.
  • a pharmaceutical composition which comprises a compound of the Examples, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixir
  • compositions in a form suitable for oral use are preferred.
  • the compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • Suitable pharmaceutically-acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p_-hydroxybenzoate, and anti-oxidants, such as ascorbic acid.
  • Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
  • Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil such as peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
  • the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
  • the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
  • Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening, flavouring and preservative agents.
  • Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
  • compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
  • a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
  • Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
  • Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
  • metabolic syndrome relates to metabolic syndrome as defined in 1) and/or 2) or any other recognised definition of this syndrome.
  • Synonyms for "metabolic syndrome” used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term “metabolic syndrome” is used herein it also refers to Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X.
  • a compound of formula (1), or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use as a medicament there is provided the use of a compound of formula (1), or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 1 l ⁇ HSDl inhibitory effect in a warm-blooded animal, such as man.
  • production of or producing an 1 l ⁇ HSDl inhibitory effect is referred to suitably this refers to the treatment of metabolic syndrome.
  • production of an ⁇ ' 11 ⁇ HSDl inhibitory effect is referred to this refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity.
  • production of an 1 l ⁇ HSDl inhibitory effect is referred to this refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.
  • an 1 l ⁇ HSDl inhibitory effect refers to the treatment of cognitive disorders, such as improving the cognitive ability of an individual, for example by improvement of verbal fluency, verbal memory or logical memory, or for treatment of mild cognitive disorders. See for example WO03/086410 and references contained therein, and Proceedings of National Academy of Sciences (PNAS), 2001, 98(8), 4717-4721.
  • production of an 1 l ⁇ HSDl inhibitory effect is referred to this refers to the treatment of, delaying the onset of and/or reducing the risk of atherosclerosis - see for example J. Experimental Medicine, 2005, 202(4), 517-527.
  • an 1 l ⁇ HSDl inhibitory effect refers to the treatment of Alzheimers and/or neurodegenerative disorders.
  • a method for producing an 1 l ⁇ HSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1), or a pharmaceutically-acceptable salt thereof.
  • the compounds of formula (1), or a pharmaceutically-salt thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of 1 l ⁇ HSDl in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • the inhibition of 1 l ⁇ HSDl described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets.
  • agents than might be co-administered with 1 l ⁇ HSDl inhibitors may include the following main categories of treatment: 1) Insulin and insulin analogues; 2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide), prandial glucose regulators (for example repaglinide, nateglinide), glucagon-like peptide 1 agonist (GLPl agonist) (for example exenatide, liraglutide) and dipeptidyl peptidase IV inhibitors (DPP-IV inhibitors);
  • Insulin and insulin analogues may include the following main categories of treatment: 1) Insulin and insulin analogues; 2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide), prandial glucose regulators (for example repaglinide, nateglinide), glucagon-like peptide 1 agonist (GLPl agonist) (
  • Insulin sensitising agents including PPAR ⁇ agonists (for example pioglitazone and rosiglitazone);
  • Anti-diabetic agents including phosotyrosine phosphatase inhibitors, glucose 6 - phosphatase inhibitors, glucagon receptor antagonists, glucokinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphastase inhibitors, glutamine:fructose -6-phosphate amidotransferase inhibitors 8) Anti-obesity agents (for example sibutramine and orlistat);
  • Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PP ARa agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors); ileal bile acid absorption inhibitors (IBATi), cholesterol ester transfer protein inhibitors and nicotinic acid and analogues (niacin and slow release formulations);
  • Antihypertensive agents such as, ⁇ blockers (eg atenolol, inderal); ACE inhibitors (eg lisinopril); calcium antagonists (eg. nifedipine); angiotensin receptor antagonists (eg candesartan), ⁇ antagonists and diuretic agents (eg. furosemide, benzthiazide);
  • ⁇ blockers eg atenolol, inderal
  • ACE inhibitors eg lisinopril
  • calcium antagonists eg. nifedipine
  • angiotensin receptor antagonists eg candesartan
  • ⁇ antagonists and diuretic agents eg. furosemide, benzthiazide
  • Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors; antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hirudin) and warfarin; 12) Anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone); and
  • NMR data ( 1 H) is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS), determined at 300 or 400
  • 6-chloro-N-cyclohexyl-2-propylsulfanyl-pyridme-3-carboxamide (Intermediate 2, 1.88 g, 6.03 mmol ), Methyl-(R)-3-Pi ⁇ eridine Acetate hydrochloride (1.17 g, 6.03 mmol), K 2 CO 3 (2.50 g, 18.08 mmol) and butyronitrile were mixed in a microwave tube and stirred at 170 0 C for 2 hours. The mixture changed from a poorly soluble white mixture to an orange solution. The reaction was stopped and most of the butyronitrile was evaporated under reduced pressure.
  • Cyclopentanethiol (7.84 niL, 73.22 mmol) was added in one portion to 2,6-dichloro-N- cyclohexylnicotinamide (20 g, 73.22 mmol) and sodium carbonate (23.28 g, 219.65 mmol) in DMF (150 mL). The resulting suspension was stirred at 60 0 C for 3 hours. The mixture was cooled, evaporated, DCM (250 mL) was added and the mixture was washed with water (3x100 mL) and brine (5OmL), dried (MgSO 4 ), filtered and evaporated to a sticky pale yellow solid.
  • Oxalyl chloride (8.72 ml, 100.00 mmol) was added dropwise to 2,6-dichloronicotinic acid (9.60 g, 50 mmol) and N,N-dimethylformamide (0.039 ml, 0.50 mmol) in DCM at 20 0 C over a period of 10 minutes under nitrogen. The resulting suspension was stirred at 20 0 C for 2 hours.
  • reaction mixture was concentrated and diluted with DCM (150 mL), and washed sequentially with water (2x75 mL) and saturated brine (75 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. This was triturated with 4:1 isohexane:EtOAc to give the desired product (5.6g, 82%) as a white powder.
  • reaction mixture was concentrated and diluted with DCM (150 mL), and washed sequentially with water (2x75 mL) and saturated brine (75 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. This was triturated with 4: 1 isohexane:EtOAc to give the desired product (6.5g, 92%) as a white powder.
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 17 and an appropriate aminoester starting material:
  • Lithium hydroxide monohydrate (102 mg, 2.44 mmol) was added to a stirred solution of (lR,5S,6r)-methyl 3-(6-(cyclopentylthio)-5-(3-(pyridin-3-yl)pyrrolidine-l-carbonyl)pyridin-2- yl)-3-azabicyclo[3.1.0]hexane-6-carboxylate (400 mg, 0.81 mmol) in methanol (5 mL)/water (2 rnL). The resulting solution was stirred at ambient temperature for 24 hours. The bulk of thes organic solvent was removed in vacuo and the resulting solution was acidified with IN citric acid. The resulting suspension was extracted with EtOAc (3 x 30ml).
  • Oxalyl chloride (0.274 rnL, 3.15 mmol) was added dropwise to a stirred solution of 2- (cyclopentylthio)-6-((lR,5S,6r)-6-(methoxycarbonyl)-3-azabicyclo[3.1.0]hexan-3-yl)nicotinico acid (380 mg, 1.05 mmol) in DCM (5 mL)/DMF (1 drop) at 0 0 C, under nitrogen. The resulting solution was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was evaporated to dryness and redissolved in DCM (8 mL).
  • the reaction mixture was diluted with EtOAc (75 mL), and washed sequentially with saturated NH4C1 (25 mL), water (50 mL), and saturated brine (50 mL).
  • the organic layer was dried over MgSO4, filtered and evaporated to afford crude product.
  • the crude product was purified by flash silica chromatography, elution gradient 10 to 30% EtOAc in isohexane.
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 27 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 28 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1 , using Intermediate 29 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 31 and an appropriate aminoester starting material:
  • 2,6-dichloro-N-cyclohexylnicotinamide (Intermediate 1, 273 mg, 1 mmol) was stirred in 1,4- dioxane (4 ml). To this solution was added 4-fluorophenethyl alcohol (154 mg, 1.1 mmol) followed by bis-sodium hexamethyldisilylamide 1.0M in THF (1.1 ml, 1.1 mmol). The tube was sealed and subjected to microwave heating 150 °C (Biotage Initiator 300W) for 2 hours. The solvent was evaporated and the residue was diluted with water (15 ml) and extracted with dichloromethane (2x20 ml).
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 32 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 33 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 34 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 37 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 39 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 40 and an appropriate aminoester starting material:
  • Example 4 was prepared in a similar manner to Example 1 , using Intermediate 41 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 42 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 43 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 44 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 45 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 46 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1 , using Intermediate 47 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 48 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 49 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 50 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 51 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 52 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 53 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 54 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 55 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 56 and an appropriate aminoester starting material:
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 57 and an appropriate aminoester starting material:
  • Ethyl 2-butyl-6-oxo-l,6-dihydropyridine-3-carboxylate (450 mg,2.02 mmol) was stirred in phosphorous oxychloride (10 ml, 30.5 mmol) and heated to 120 0 C for 2 hours giving a clear brown solution. The reaction was evaporated and the residue was taken up in EtOAc (25 ml), washed with water (25 ml), saturated brine (25 ml) then dried over MgSO 4 filtered and evaporated.
  • Example 2 The following Example was prepared in a similar manner to Example I 5 using Intermediate 64 and an appropriate aminoester starting material:
  • Example 2 was prepared in a similar manner to Example 1, using Intermediate 65 and an appropriate aminoester starting material:
  • reaction mixture was diluted with DCM (10 mL) and washed sequentially with 2M HCl (10 mL), saturated NaHCC ⁇ (10 mL), and saturated brine (10 mL).
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 66 and an appropriate aminoester starting material: 0
  • Example 2 The following Example was prepared in a similar manner to Example 1, using Intermediate 67 and an appropriate aminoester starting material: Q
  • 6-Chloro-N-cyclohexyl-2-pro ⁇ ylsulfanyl-pyridine-3-carboxamide (Intermediate 2, 1.46 g, 4.66 mmol ), methyl-(R)-3-piperidine acetate hydrochloride (0.90 g, 4.66 mmol), K 2 CO 3 (1.93 g, 13.98 mmol) and butyronitrile were mixed in a microwave tube and stirred at 170 °C for 2 hours. The mixture changed from a poorly soluble white mixture to an orange solution. Most of the butyronitrile was evaporated under reduced pressure.
  • Example 170 f(3S)-l- ⁇ 5-f((2r,5s)-5-Methoxyadamantan-2-yI)(methvI)carbamoyll-6-(propylthio)pyridin-2- yl)piperidin-3-yll acetic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compounds of formula (I) wherein variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are described.

Description

CHEMICAL COMPOUNDS
This invention relates to chemical compounds, or pharmaceutically-acceptable salts thereof. These compounds possess human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (l lβHSDl) inhibitory activity and accordingly have value in the treatment of disease states including metabolic syndrome and are useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit 1 lβHSDl in a warm-blooded animal, such as man. Glucocorticoids (Cortisol in man, corticosterone in rodents) are counter regulatory hormones i.e. they oppose the actions of insulin (Dallman MF, Strack AM, Akana SF et al. 1993; Front Neuroendocrinol 14, 303-347). They regulate the expression of hepatic enzymes involved in gluconeogenesis and increase substrate supply by releasing glycerol from adipose tissue (increased lipolysis) and amino acids from muscle (decreased protein synthesis and increased protein degradation). Glucocorticoids are also important in the differentiation of pre-adipocytes into mature adipocytes which are able to store triglycerides (Bujalska IJ et al. 1999; Endocrinology 140, 3188-3196). This may be critical in disease states where glucocorticoids induced by "stress" are associated with central obesity which itself is a strong risk factor for type 2 diabetes, hypertension and cardiovascular disease (Bjorntorp P & Rosmond R 2000; Int. J. Obesity 24, S80-S85)
It is now well established that glucocorticoid activity is controlled not simply by secretion of Cortisol but also at the tissue level by intracellular interconversion of active Cortisol and inactive cortisone by the 11 -beta hydroxysteroid dehydrogenases, 1 lβHSDl (which activates cortisone) and 1 lβHSD2 (which inactivates Cortisol) (Sandeep TC & Walker BR 2001 Trends in Endocrinol & Metab. 12, 446-453). That this mechanism may be important in man was initially shown using carbenoxolone (an anti-ulcer drug which inhibits both 1 lβHSDl and 2) treatment which (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159) leads to increased insulin sensitivity indicating that 1 lβHSDl may well be regulating the effects of insulin by decreasing tissue levels of active glucocorticoids (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159).
Clinically, Gushing' s syndrome is associated with Cortisol excess which in turn is associated with glucose intolerance, central obesity (caused by stimulation of pre-adipocyte differentiation in this depot), dyslipidaemia and hypertension. Gushing' s syndrome shows a number of clear parallels with metabolic syndrome. Even though the metabolic syndrome is not generally associated with excess circulating Cortisol levels (Jessop DS et al. 2001; J. Clin. Endocrinol. Metab. 86, 4109-4114) abnormally high 1 lβHSDl activity within tissues would be expected to have the same effect. In obese men it was shown that despite having similar or lower plasma Cortisol levels than lean controls, llβHSDl activity in subcutaneous fat was greatly enhanced (Rask E et al. 2001; J. Clin. Endocrinol. Metab. 1418-1421). Furthermore, the central fat, associated with the metabolic syndrome expresses much higher levels of 1 lβHSDl activity than subcutaneous fat (Bujalska IJ et al. 1997; Lancet 349, 1210-1213). Thus there appears to be a link between glucocorticoids, 1 lβHSDl and the metabolic syndrome.
1 lβHSDl knock-out mice show attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting and lower plasma glucose levels in response to stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad. Sci USA 94, 14924-14929) indicating the utility of inhibition of 1 lβHSDl in lowering of plasma glucose and hepatic glucose output in type 2 diabetes. Furthermore, these mice express an anti-atherogenic lipoprotein profile, having low triglycerides, increased HDL cholesterol and increased apo-lipoprotein AI levels. (Morton NM et al. 2001 ; J. Biol. Chem. 276, 41293-41300). This phenotype is due to an increased hepatic expression of enzymes of fat catabolism and PP ARa. Again this indicates the utility of 1 lβHSDl inhibition in treatment of the dyslipidaemia of the metabolic syndrome. The most convincing demonstration of a link between the metabolic syndrome and
1 lβHSDl comes from recent studies of transgenic mice over-expressing 1 lβHSDl (Masuzaki H et al. 2001; Science 294, 2166-2170). When expressed under the control of an adipose specific promoter, 1 lβHSDl transgenic mice have high adipose levels of corticosterone, central obesity, insulin resistant diabetes, hyperlipidaemia and hyperphagia. Most importantly, the increased levels of 1 lβHSDl activity in the fat of these mice are similar to those seen in obese subjects.
Hepatic 1 lβHSDl activity and plasma corticosterone levels were normal, however, hepatic portal vein levels of corticosterone were increased 3 fold and it is thought that this is the cause of the metabolic effects in liver.
Overall it is now clear that the complete metabolic syndrome can be mimicked in mice simply by overexpressing 1 lβHSDl in fat alone at levels similar to those in obese man.
1 lβHSDl tissue distribution is widespread and overlapping with that of the glucocorticoid receptor. Thus, l lβHSDl inhibition could potentially oppose the effects of glucocorticoids in a number of physiological/pathological roles. 1 lβHSDl is present in human skeletal muscle and glucocorticoid opposition to the anabolic effects of insulin on protein turnover and glucose metabolism are well documented (Whorwood CB et al. 2001; J. Clin. Endocrinol. Metab. 86, 2296-2308). Skeletal muscle must therefore be an important target for 11 βHSD 1 based therapy.
Glucocorticoids also decrease insulin secretion and this could exacerbate the effects of glucocorticoid induced insulin resistance. Pancreatic islets express 1 lβHSDl and carbenoxolone can inhibit the effects of 11-dehydocorticosterone on insulin release (Davani B et al. 2000; J. Biol. Chem. 275, 34841-34844). Thus in treatment of diabetes 1 lβHSDl inhibitors may not only act at the tissue level on insulin resistance but also increase insulin secretion itself.
Skeletal development and bone function is also regulated by glucocorticoid action. 1 lβHSDl is present in human bone osteoclasts and osteoblasts and treatment of healthy volunteers with carbenoxolone showed a decrease in bone resorption markers with no change in bone formation markers (Cooper MS et al 2000; Bone 27, 375-381). Inhibition of 1 lβHSDl activity in bone could be used as a protective mechanism in treatment of osteoporosis.
Glucocorticoids may also be involved in diseases of the eye such as glaucoma. 1 lβHSDl has been shown to affect intraocular pressure in man and inhibition of 11 βHSD 1 may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Opthalmology & Visual Science 42, 2037-2042). There appears to be a convincing link between 11 βHSDl and the metabolic syndrome both in rodents and in humans. Evidence suggests that a drug which specifically inhibits 1 lβHSDl in type 2 obese diabetic patients will lower blood glucose by reducing hepatic gluconeogenesis, reduce central obesity, improve the atherogenic lipoprotein phenotype, lower blood pressure and reduce insulin resistance. Insulin effects in muscle will be enhanced and insulin secretion from the beta cells of the islet may also be increased.
Currently there are two main recognised definitions of metabolic syndrome. 1) The Adult Treatment Panel (ATP III 2001 JMA) definition of metabolic syndrome indicates that it is present if the patient has three or more of the following symptoms: Waist measuring at least 40 inches (102 cm) for men, 35 inches (88 cm) for women; Serum triglyceride levels of at least 150 mg/dl (1.69 mmol/1);
HDL cholesterol levels of less than 40 mg/dl (1.04 mmol/1) in men, less than 50 mg/dl (1.29 mmol/1) in women; Blood pressure of at least 135/80 mm Hg; and / or
Blood sugar (serum glucose) of at least 110 mg/dl (6.1 mmol/1).
2) The WHO consultation has recommended the following definition which does not imply causal relationships and is suggested as a working definition to be improved upon in due course: The patient has at least one of the following conditions: glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance; together with two or more of the following:
Raised Arterial Pressure; Raised plasma triglycerides Central Obesity Microalbuminuria
We have found that the compounds defined in the present invention, or a pharmaceutically-acceptable salt thereof, are effective llβHSDl inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome. We have also found that the compounds of the invention have improved properties, which would make them better candidates for use as pharmaceuticals. For example, in general the compounds of the invention have good oral bioavailability whilst retaining potency. Therefore this group of compounds would be expected to provide superior oral exposure at a lower dose and thereby be particularly suitable for use in the treatment or prevention of a disease or medical condition treatable by inhibiting 11 βHSD 1. The compounds of the invention may also have superior potency and/or advantageous physical properties and/or favourable toxicity profiles and/or favourable metabolic profiles in comparison with other 1 lβHSDl inhibitors known in the art. Accordingly there is provided a compound of formula (1):
Figure imgf000005_0001
(1) wherein:
Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, C1-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl,
C3-7cycloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, phenyl, phenylC1-3alkyl, heteroaryl, heteroarylC1-3alkyl, heterocyclyl, or heterocyclylC1-3alkyl [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl, Ci-3alkoxy, carboxyC1-3alkyl, Ci-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O)-, R5 C(O)-, R5 OC(O)- and (R5')(R5")NSO2- (wherein R5 is Ci-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo and cyano; and
R5 and R5 are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-3alkoxy, carboxy and cyano or R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)] and optional substituents for heterocyclyl and the heterocyclyl group in heterocyclylC1-3alkyl are additionally selected from R21, R21CO- R2IS(O)k (wherein k is 0, 1 or 2) and R21CH2OC(O)- wherein R21 is phenyl optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, cyano and trifluoromethyl; or when Q is a bond R1 may also be hydrogen;
R2 is selected from C3-7cycloalkyl(CH2)m-, and C6-i2polycycloalkyl(CH2)m- (wherein the cycloalkyl and polycycloalkyl rings optionally contain 1 or 2 ring atoms independently selected from nitrogen, oxygen and sulphur; m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from R6); R3 is selected from hydrogen, C1-4alkyl C3-5cycloalkyl and C3-5cycloalkylmethyl;
R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7;
R4 is independently selected from halo, C1-2alkyl, cyano, Ci-2alkoxy, and trifluoromethyl;
R6 and R7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl,
R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9')(R9")N-, R9S(O)a- wherein a is 0 to 2, R9 OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9'")-, phenyl and heteroaryl [wherein the phenyl and heteroaryl groups are optionally fused to a phenyl, heteroaryl or a saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur and the resulting ring
5 system is optionally substituted by 1, 2 or 3 substituents independently selected from C1-4alkyl, hydroxyl, cyano, trifluoromethyl, trifluoromoxy, halo, C1-4alkoxy,
Figure imgf000007_0001
C1-4alkoxyC1-4alkyl, amino, N-C1-4alkylamino, di-N,N-(C1-4alkyl)amino, N-C1-4alkylcarbamoyl, di-N,N-(C1-4alkyl)carbamoyl, Ci-4alkylS(O)r, C1-4alkylS(O)rCi-4alkyl (wherein r is 0, 1 and 2)]; R9 is independently C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently io selected from hydroxyl, halo, C1-4alkoxy, carboxy and cyano;
R9 , R9 and R9 are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-4alkoxy, carboxy or cyano); p is 0, 1 or 2; either X is -O(CH2)q-, -S(CH2) q- or -N(R12)(CH2) q- wherein R12 is hydrogen, C1-3alkyl or Ci- i5 3alkanoyl and q is 0 or 1; and Y is:
1) a C3-7cycloalkdiyl ring, a phenylene ring, an adamantdiyl group, a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur, or - [C(Rx)(Ry)] v- (wherein Rx and Ry are
20 independently selected from hydrogen, C1-3alkyl, C1-3alkoxy and hydroxyl or Rx and Ry together with the carbon atom to which they are attached form a C3-7cycloalkdiyl ring and v is 1, 2, 3, 4 or 5) and when v is more than 1 the -[C(Rx)(Ry)]v- group may optionally be interrupted by a -O-, - S- or -N(R20)- group wherein R20 is hydrogen or C1-3alkyl; or
2) -X-Y- together represents a group of the formula: is
Figure imgf000007_0002
(Z)t[C(Ri3)(Ri4)]s-
wherein: ring A is linked to the pyridine group and -(Z)t[C(R13)(RI4)]s- is linked to the carboxy group; and
A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; Z is -O-, -S- or -N(R16)- wherein R16 is hydrogen, C1-3alkyl or C^alkanoyl; t is 0 or 1 provided that when s is 0 then t is 0;
R10 is independently selected from C1-3alkyl, C2-3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, Ci-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R11CON(R11'),
(R11 XR11^NC(O)-, R11 OC(O)- and (Rl r)(Rn")NSO2- (wherein R11 is C1-3alkyl optionally substituted by hydroxyl, halo or cyano; and
R11 and R11 are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-3alkoxy, carboxy or cyano) or R11 and R11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2; R13 and R14 are independently selected from hydrogen and C1-3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof. provided the compound is not: {(35)-l-[5-(adamantan-l-ylcarbamoyl)pyridin-2-yl]piperidin-3-yl}acetic acid; or
{(35)-l-[5-(cyclohexylcarbamoyl)-6-(piperazin-l-yl)pyridin-2-yl]piperidin-3-yl}acetic acid; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
In another aspect there is provided a compound of the formula (1) as herein above defined or a pharmaceutically-acceptable salt thereof. In another aspect there is provided a compound of formula (1): wherein:
Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, Ci-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl,
C3-7cycloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, phenyl, phenylCi_3alkyl, heteroaryl, heteroarylC1-3alkyl, heterocyclyl, or heterocyclylC1-3alkyl [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O)-,
R5OC(O)- and (R5 ')(R5")NSO2- (wherein R5 is C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo and cyano; and
R5 and R5 are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-3alkoxy, carboxy and cyano or
R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)]; or when Q is a bond R1 may also be hydrogen;
R2 is selected from C3.7cycloalkyl(CH2)m-, and C6-i2polycycloalkyl(CH2)m- (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from
R6);
R3 is selected from hydrogen, C1-4alkyl C3-5Cy cloalkyl and C3-5cycloalkylmethyl;
R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7;
R4 is independently selected from halo, C1-2alkyl, cyano, C1-2alkoxy, and trifluoromethyl; R6 and R7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9')(R9")N-, R9S(O)3- wherein a is O to 2, R9 OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9'")-, phenyl and heteroaryl [wherein the phenyl and heteroaryl groups are optionally fused to a phenyl, heteroaryl or a saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur and the resulting ring system is optionally substituted by 1, 2 or 3 substituents independently selected from C^alkyl, hydroxyl, cyano, trifluoromethyl, trifluoromoxy, halo, C1-4alkoxy, C1-4alkoxyC1-4alkyl, C1-4alkoxyC1-4alkyl, amino, N-C1-4alkylamino, di-N,N-(C1-4alkyl)amino, N-C1-4alkylcarbamoyl, di-N,N-(C1-4alkyl)carbamoyl, C1-4alkylS(O)r, Ci-4alkylS(O)rCMalkyl (wherein r is 0, 1 and 2)]; R9 is independently C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, Ci-4alkoxy, carboxy and cyano;
R9 , R9 and R9 ' are independently selected from hydrogen and Ci-3alkyl optionally substituted by hydroxyl, halo, C1-4alkoxy, carboxy or cyano); p is O, 1 or 2; X is -O-, -S- or-N(R12)- wherein R12 is hydrogen, C1-3alkyl or C1-3alkanoyl;
Y is either:
1) a C3-7cycloalkdiyl ring, a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur, or
5 - [C(Rx)(Ry )]v- (wherein Rx and Ry are independently selected from hydrogen, C1-3alkyl, C1- 3alkoxy and hydroxyl or Rx and Ry together with the carbon atom to which they are attached form a C3-7Cy cloalkdiyl ring and v is 1, 2, 3, 4 or 5) and when v is more than 1 the - [C(Rx)(Ry )]v- group may optionally be interrupted by a -O-, -S- or -N(R20)- group wherein R20 is hydrogen or C1-3alkyl; or io 2) -X-Y- together represents a group of the formula:
Figure imgf000010_0001
i5 wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
20 R10 is independently selected from Ci-3alkyl, C2-3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R11CON(R11'), (RU ')(RU")NC(O)-, R11 OC(O)- and (Ri r)(Rπ")NSO2- (wherein R11 is Ci-3alkyl optionally substituted by hydroxyl, halo or cyano; and R11 and R11 are independently selected from hydrogen and C1-3alkyl optionally substituted by
25 hydroxyl, halo, Ci-3alkoxy, carboxy or cyano) or R11' and R11" together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2;
R13 and R14 are independently selected from hydrogen and Ci-3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt thereof.
In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C1-4alkyl" includes propyl, isopropyl and t-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chain version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals therefore "C1-4alkoxyC1-4alkyl" would include l-(C1-4alkoxy)propyl, 2-(C1-4alkoxy)ethyl and 3-(C1-4alkoxy)butyl. The term "halo" refers to fluoro, chloro, bromo and iodo.
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
A 4-7 membered saturated ring (for example formed between R1 and R15 or R5 and R5 and the nitrogen atom to which they are attached) is a monocyclic ring containing the nitrogen atom as the only ring atom.
"Heteroaryl", unless otherwise specified, is a totally unsaturated, monocyclic ring containing 5 or 6 atoms of which at least 1, 2 or 3 ring atoms are independently chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon-linked. A ring nitrogen atom may be optionally oxidised to form the corresponding N-oxide. Examples and suitable values of the term "heteroaryl" are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyrimidyl, pyrazinyl, pyridazinyl and pyridyl. Particularly "heteroaryl" refers to thienyl, furyl, thiazolyl, pyridyl, imidazolyl or pyrazolyl. "Heterocyclyl" is a 4-7 saturated, monocyclic ring having 1-3 ring heteroatoms selected from nitrogen, oxygen and sulphur. Examples of heterocyclyl include piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl
A polycycloalkyl ring is a ring system in which either at least 2 rings are fused together or in which 2 rings have one ring atom in common (spiro). In particular the polycycloalkyl ring has 2, 3 or 4 rings. An example of a polycycloalkyl ring is adamantyl.
A "saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur", unless otherwise specified contains 4-14 ring atoms. Particularly a mono ring contains 4 -7 ring atoms, a bicyclic ring 6-14 ring atoms and a bridged ring system 6-14 ring atoms. Examples of mono rings include piperidinyl, piperazinyl and morpholinyl. Examples of bicyclic rings include decalin and 2,3,3a,4,5,6,7,7a-octahydro-lH-indene.
Bridged ring systems are ring systems in which there are two or more bonds common to two or more constituent rings. Examples of bridged ring systems include l,3,3-trimethyl-6- azabicyclo[3.2.1]octane, 2-aza-bicyclo[2.2.1]heptane and 7-azabicyclo(2,2,l)heptane, 1- and 2- adamantanyl.
A "saturated, partially saturated or unsaturated monocyclic ring" is, unless otherwise specified, a 4-7 membered ring. Examples include, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and phenyl.
A "C3-7cycloalkdiyl ring" is a saturated monocyclic carbocyclic ring. It is the di-radical of the cycloalkane ring. Adamantdiyl is the di-radical of an adamantane ring system. Phenylene is the diradical of the benzene ring. In a particular aspect the radicals are on different ring atoms.
Examples of "5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur" include piperazinyl, piperidinyl and morpholinyl.
A "4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur" is a saturated ring system being monocyclic, bicyclic or a spiro ring system having 4 to 7 ring atoms.
Examples of the "4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur" include piperidinyl, piperazinyl and morpholinyl. Examples of a "saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur" include piperidinyl, piperazinyl and morpholinyl.
Examples of "Ci-4alkoxy" include methoxy, ethoxy and propoxy. Examples of "Ci-4alkoxyC1-4alkyl" include methoxymethyl, ethoxymethyl, propoxymethyl, 2-methoxyethyl, 2- ethoxyethyl and 2-propoxyethyl. Examples of "Ci-4alkylS(O)n wherein n is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C1.4alkylS(O)qCi.4alkyl" wherein q is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methylthiomethyl, ethylthiomethyl, methylsulphinylmethyl, ethylsulphinylmethyl, mesylmethyl and ethylsulphonylmethyl. Examples of "C1-4alkanoyl" include propionyl and acetyl. Examples of "iV-(C1-4alkyl)amino" include methylamino and ethylamino. Examples of "ΛζN-(C1-4alkyl)2amino" include ΛζiV-dimethylamino, N,N-diethylamino and N-ethyl-JV-methylamino. Examples of "C2-4alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-4alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "N-(C1-4alkyl)carbamoyl" are methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,iV-(C1-4alkyl)2carbamoyl" are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C3-7cycloalkylC1-3alkalkyl" include cyclopropymethyl, 2-cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl. Examples of "C3-7cycloalkylC2- 3alkalkenyl" include 2-cyclopropylethenyl, 2-cyclopentylethenyl and 2-cyclohexylethenyl.
Examples of "C3-7cycloalkylC2-3alkalkynyl" include 2-cyclopropylethynyl, 2-cyclopentylethynyl and 2-cyclohexylethynyl.
Examples of "C3-7cycloalkyl(CH2)m-" include cyclopropymethyl, 2-cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl. Examples of C6-i2polycycloalkyl(CH2)m- include norbornyl bicyclo[2.2.2]octane(CH2)m-, bicyclo[3.2.1]octane(CH2)m-and 1- and 2-adamantanyl(CH2)m-.
A suitable pharmaceutically-acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, tert-butylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
An in- vivo hydroly sable ester of a compound of the invention containing a carboxy or a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically- acceptable esters for carboxy include C1 to C6alkoxymethyl esters for example methoxymethyl, Ci to 6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3 to 8cycloalkoxycarbonyloxyCi to 6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters, for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C1- 6alkoxycarbonyloxyethyl esters.
An in- vivo hydrolysable ester of a compound of the invention containing a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α-acyloxyalkyl ethers and related compounds which as a result of the in- vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
Some compounds of the formula (1) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess 1 lβHSDl inhibitory activity. The invention relates to any and all tautomeric forms of the compounds of the formula (1) that possess l lβHSDl inhibitory activity.
It is also to be understood that certain compounds of the formula (1) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms, which possess 1 lβHSDl inhibitory activity. In one embodiment of the invention are provided compounds of formula (1). In an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula
(I)-
When a general reference is made to the positions on the pyridine ring, the 2-position refers to the position which is substituted by the -Q-R1 group and the other positions are numbered accordingly.
Particular values of variable groups are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter, for compounds of formula (1):
In one aspect Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, Ci-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring and R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3- 7cycloalkylC1-3alkyl, C3-7cycloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, phenyl, phenylC1-3alkyl, heteroaryl, heteroarylCi-3alkyl, heterocyclyl, or
Figure imgf000015_0001
[each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyL C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O)-, R5 OC(O)- and (R5 ')(R5")NSO2- (wherein R5 is C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo and cyano; and
R5 and R5 are independently selected from hydrogen and C^alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-3alkoxy, carboxy and cyano or R and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)].
In one aspect Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, C1-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring and R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3- 7cycloalkylC1-3alkyl, C3-7Cy cloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, phenyl, heteroaryl, heterocyclyl, or heterocyclylC1-3alkyl [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O)-, R5 OC(O)- and (R5')(R5")NSO2- (wherein R5 is C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo and cyano; and R5 and R5 are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-3alkoxy, carboxy and cyano or R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)].
In one aspect, Q is O, S or a single bond and R1 is Cμβalkyl, C2-6alkenyl, C2-6alkynyl, C3- 7cycloalkyl, C3-7cycloalkylC1-3alkyl, C3-7cycloalkylC2-3alkenyl or C3-7cycloalkylC2-3alkynyl, [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3 alky IS (O)n- (wherein n is O, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O)-, R5 OC(O)- and (R5')(R5")NSO2- (wherein R5 is Ci-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo and cyano; and R5 and R5 are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently hydroxyl, halo, Ci-3alkoxy, carboxy and cyano or R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)]. In another aspect, the invention relates to a compound of the formula (I) as hereinabove defined wherein Q is a single bond. . In another aspect Q is -N(R15)-. In one aspect R15 is hydrogen. In another aspect R15 is C1-3alkyl.
In one aspect R15 is methyl. In one aspect Q is O. In another aspect Q is S.
In one aspect R1 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl, [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3).
In another aspect R1 is C1-6alkyl, C3-7cycloalkyl or C3-7cycloalkylCi-3alkyl. In another aspect R1 is C3-4Cy cloalkyl optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and C1-3alkoxy. In another aspect R1 is C3-4cycloalkyl.
In another aspect R1 is C3-4cycloalkylC1-2alkyl optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and Ci-3alkoxy.
In another aspect R1 is C3-4cycloalkylC1-2alkyl. In another aspect R1 is C1-4alkyl optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and C1-3alkoxy. In another aspect R1 is C1-4alkyl.
In another aspect R1 is propyl optionally substituted by 1 or 2 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl and C1-3alkoxy. In another aspect R1 is propyl.
In another aspect R1 is phenylC1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl and C1-3alkoxyln another aspect R1 is phenylCi-3alkyl.
In another aspect R1 is heteroarylC1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl and Cj-3alkoxy. In another aspect R1 is heteroarylC1-3alkyl.
In another aspect R1 is phenyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl and C1-3alkoxy. In another aspect R1 is phenyl.
In another aspect R1 is heteroaryl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxό, cyano, trifluoromethyl and C1-3alkoxy.
In another aspect R1 is heteroaryl. In another aspect -Q-R1 is hydrogen.
In one aspect, R3 is C1-4alkyl.
In another aspect, R3 is hydrogen, methyl or ethyl.
In another aspect, R3 is hydrogen.
In another aspect, R3 is methyl. In another aspect, R3 is ethyl.
In one aspect, R4 is methyl.
In one aspect p is 0.
In one aspect, p is 1 or 2.
In another aspect, p is 0 or 1. In another aspect, p is 1.
In another aspect, p is 2.
In one aspect p is 1 and R4 is in the 5-position.
In one aspect R2 is selected from C3-7cycloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1 , 2 or 3 substituents independently selected from R6 as hereinabove defined).
In another aspect R2 is selected from C3.7cycloalkyl(CH2)m-, and C6-
12polycycloalkyl(CH2)m- (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1 or 2 substituents independently selected from R6, wherein R6 is independently selected from hydroxyl, halo and trifluoromethyl). In another aspect, R2 is selected from C3-7cycloalkyl, and C6-12polycycloalkyl each of which is independently optionally substituted by 1 R6, wherein R6 is selected from hydroxyl, halo and trifluoromethyl).
In one aspect, R2 is selected from C5-7Cy cloalkyl(CH2)m- and Cg.i2polycycloalkyl(CH2)m- (wherein the rings are optionally substituted by 1, 2 or 3 substituents independently selected from R6) and wherein m is 0, 1 or 2.
In another aspect, R2 is selected from C5-7cycloalkyl(CH2)m-, C7-i0bicycloalkyl(CH2)m- and Ciotricycloalkyl(CH2)m- (wherein the cycloalkyl, bicycloalkyl and tricycloalkyl rings are optionally substituted by 1, 2 or 3 substituents independently selected from R6) and wherein m is 0, 1 or 2.
In yet another aspect, R2 is selected from C5-7cycloalkyl(CH2)m-, C7-10bicycloalkyl(CH2)m- and adamantyl (wherein the cycloalkyl, bicycloalkyl and tricycloalkyl rings are optionally substituted by 1, 2 or 3 substituents independently selected from R6) and wherein m is 0, 1 or 2.
In one aspect, m is 0 or 1.
In another aspect, R2 and R3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, 6-12 membered bicyclic or 6-12 membered bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially-saturated or aryl monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7.
In another aspect, R2 and R3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially-saturated or aryl monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7.
In another aspect, R2 and R3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, ring system optionally containing 1 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and is optionally substituted by 1 or 2 substituents independently selected from R7.
In one aspect, R6 is independently selected from hydroxyl, R9O-, R9CO- and R9C(O)O- wherein R9 is as hereinabove defined.
In one aspect, R6 is independently selected from hydroxyl, R9O-, R9CO- and R9C(O)O- wherein R9 is C1-3alkyl optionally substituted by C1-4alkoxy or carboxy.
In another aspect, R6 is independently selected from R9CON(R9')-, R9SO2N(R9")- and (R9')(R9")NC(O)N(R9'")-; wherein R9 is as hereinabove defined.
In another aspect, R6 is independently selected from R9CON(R9')-, R9SO2N(R9")- and (R9')(R9")NC(O)N(R9'")-;
R9 is Ci-3alkyl optionally substituted by C1-4alkoxy or carboxy;
R9 , R9 and R9 are independently selected from hydrogen and d^alkyl optionally substituted by
Ci-4alkoxy or carboxy). In another aspect, R6 is independently selected from (R9')(R9")NC(O)- and (R9')(R9")N-; wherein R9 and-R9 are as hereinabove defined.
In another aspect, R6 is independently selected from (R9')(R9")NC(O)- and (R9')(R9")N-; wherein R9 and R9 are independently selected from hydrogen and C1-3alkyl optionally substituted by Q^alkoxy or carboxy.
In one aspect R6 is selected from methyl, trifluoromethyl, chloro, fmoro, bromo, methoxy, ethoxy, trifluormethoxy, methanesulfonyl, ethanesulfonyl, methylthio, ethylthio, amino, N- methylamino, N-ethylamino, N-propylamino, N,N-dimethylamino, N,N-methylethylamino or N,N-diethy lamino . In one aspect R6 is selected from hydroxy, halo and trifluoromethyl.
In another aspect, R6 is optionally substituted phenyl, pyridyl or pyrimidyl.
In another aspect, R6 is optionally substituted pyrid-2-yl, pyrid-3-yl or pyrid-4-yl.
In another aspect, R6 is carboxy.
In one aspect R7 is selected from hydroxy, halo and trifluoromethyl. In one aspect X is -O-, -S- or -N(R12)- wherein R12 is hydrogen, C1-3alkyl or C1-3alkanoyl.
In one aspect X is -O- .
In another aspect X is -N(R12)-, wherein R12 is as hereinabove defined.
In another aspect X is -N(R12)-, wherein R12 is hydrogen.
In another aspect X is -S-. In one aspect Y is a C3-7cycloalkdiyl ring, a 5-7 membered saturated heterocyclic ring
(linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur, or -[C(Rx)(Ry)]v- (wherein Rx and Ry are independently selected from hydrogen and methyl or Rx and Ry together with the carbon atom to which they are attached form a C3- 7cycloalkdiyl ring and v is 1, 2, 3, 4 or 5). In another aspect Y is a C3-7cycloalkdiyl ring or a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur.
In another aspect Y is a C3-7cycloalkdiyl ring.
In another aspect Y is a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur.
In another aspect Y is of the formula -[C(Rx)(Ry)]v- (wherein Rx and Ry are independently selected from hydrogen and methyl and v is 1, 2, 3, 4 or 5) and when v is more than 1 the - [C(Rx)(Ry)] v- group may optionally be interrupted by a-O-, -S- or -N(R20)- group wherein R20 is hydrogen or C1-3alkyl.
In another aspect Y is of the formula -[C(Rx)(Ry)]v- (wherein Rx and Ry are independently selected from hydrogen and methyl and v is 1, 2, 3, 4 or 5). In one aspect -X-Y- together represents a group of the formula:
wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; R10 is independently selected from C^alkyl, hydroxy, halo and trifluoromethyl; u is 0, or 1 ;
R13 and R14 are independently selected from hydrogen and C^alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2. In another aspect -X-Y- together represents a group of the formula:
Figure imgf000020_0002
wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and A is a 4-7 membered mono- or bi- heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; u is O; R13 and R14 are independently selected from hydrogen and methyl; and s is 0, 1 or 2.
In another aspect Rx and Ry are hydrogen.
In another aspect v is 3, 4 or 5. In one aspect A is a 5 or 6 membered mono-heterocyclic ring containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur.
In another aspect A is piperidino, pyrrolidino, azabicyclo[3.1.0]hexane, morpholino or thiomorpholino. In another aspect A is piperidino, morpholino or thiomorpholino.
In another aspect A is piperidino.
In another aspect A is piperidino in which the ~(Z)t[C(R13)(R14)]s-COOH group is in the 3-position.
In another aspect A is piperidino in which the -(Z)t[C(RI3)(R14)]s-COOH group is in the 4-position.
In another aspect A is pyrrolidino.
In one aspect Z is -N(R16)-, wherein R16 is as hereinabove defined.
In another aspect Z is -NH-.
In one aspect t is 0. In one aspect R10 is selected from C^alkyl, C2-3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifiuoromethyl and alkoxy.
In another aspect R10 is selected from C^alkyl, hydroxy, halo, oxo, cyano, trifiuoromethyl and alkoxy.
In another aspect R10 is independently selected from C1.3alk.yl, hydroxy, halo and trifiuoromethyl.
In another aspect R10 is selected from Ci-3alkyl and alkoxy.
In one aspect u is 0 or 1.
In another aspect u is 1. In another aspect u is 0.
In one aspect R13 and R14 are independently hydrogen or methyl.
In another aspect R13 and R14 are hydrogen.
In one aspect s is 0 or 1. In one aspect s is 0.
In another aspect s is 1.
1. A class of compounds of the present invention is of formula (1) wherein: Q is -O-, -S- or -N(R15)- wherein R15 is hydrogen, Ci-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; R1 is Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl,
C3-7cycloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, phenyl, heteroaryl, heterocyclyl, or heterocyclylC1-3alkyl [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, Ci-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O>, R5 OC(O)- and (R5')(R5")NSO2- (wherein R5 is C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy 1, halo and cyano; and
R5 and R5 are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C^alkoxy, carboxy and cyano or R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)]; or
R2 is selected from C3-7Cy cloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from
R6);
R3 is selected from hydrogen, C1-4alkyl C3.5cycloalkyl and C3-5cycloalkylmethyl; R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7; R6 and R7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9>)(R9")N-, R9S(O)3- wherein a is 0 to 2, R9 OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9>>, phenyl and heteroaryl [wherein the phenyl and heteroaryl groups are optionally fused to a phenyl, heteroaryl or a saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur and the resulting ring system is optionally substituted by 1, 2 or 3 substituents independently selected from C^alkyl, hydroxyl, cyano, trifluoromethyl, trifluoromoxy, halo, C1-4alkoxy, C1-4alkoxyC1-4alkyl, 5 C1-4alkoxyC1-4alkyl, amino, N-C^alkylamino, di-N,N-(C1-4alkyl)amino, N-C1-4alkylcarbamoyl, di-N,N-(C1-4alkyl)carbamoyl, C1-4alkylS(O)r-, C1-4alkylS(O)rC1-4alkyl (wherein r is 0, 1 and 2)];
R9 is independently C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, Ci-4alkoxy, carboxy and cyano;
R9 , R9 and R9 are independently selected from hydrogen and C1-3alkyl optionally substituted by io hydroxyl, halo, C1-4alkoxy, carboxy or cyano); p is 0; either X is -O-, -S- or -N(R12)- wherein R12 is hydrogen, C1-3alkyl or C1-3alkanoyl; and
Y is:
1) a C3-7cycloalkdiyl ring, a 5-7 membered saturated heterocyclic ring (linked by a ring i5 carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur, or -[C(Rx)(Ry)]v- (wherein Rx and Ry are independently selected from hydrogen, C1-3alkyl, C1- 3alkoxy and hydroxyl or Rx and Ry together with the carbon atom to which they are attached form a C3-7cycloalkdiyl ring and v is 1, 2, 3, 4 or 5) and when v is more than 1 the - [C(Rx)(Ry )]v- group may optionally be interrupted by a -O-, -S- or -N(R20)- group wherein R20 is hydrogen or
20 C1-3alkyl; or
2) -X-Y- together represents a group of the formula:
Figure imgf000023_0001
25 wherein: ring A is linked to the pyridine group and
Figure imgf000023_0002
is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
R10 is independently selected from C1-3alkyl, C2-3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1 , 2 or 3), R11CON(R1 v),
(Ri r)(Rπ")NC(O)-, R11 OC(O)- and (R11 XR11^NSO2- (wherein R11 is C1-3alkyl optionally substituted by hydroxyl, halo or cyano; and
R11 and R11 are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-3alkoxy, carboxy or cyano) or R11' and R11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2;
R13 and R14 are independently selected from hydrogen and C1-3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydroly sable ester thereof.
2. Another class of compounds of the present invention is of formula (1) wherein:
Q is -S-;
R1 is Ci-6alkyl, C3-7cycloalkyl, C3-7cycloalkylCi-3alkyl, [each of which is optionally substituted by
1, 2 or 3 substituents independently selected from hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-SaIlCyIS(O)n- (wherein n is 0, 1, 2 or 3); or
R2 is selected from C3-7cycloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein m is 0, 1 or
2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from
R6);
R3 is selected from hydrogen; R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7; R6 and R7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9>)(R9")N-, R9S(O)a- wherein a is 0 to 2, R9 OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9 XR9")NC(O)N(R9'")-, phenyl and heteroaryl [wherein the phenyl and heteroaryl groups are optionally fused to a phenyl, heteroaryl or a saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur and the resulting ring system is optionally substituted by 1, 2 or 3 substituents independently selected from Chalky 1, hydroxyl, cyano, trifluoromethyl, trifluoromoxy, halo, C1-4alkoxy, C1-4alkoxyC1-4alkyl, 5 C1-4alkoxyC1-4alkyl, amino, N-C1-4alkylamino, di-N,N-(C1-4alkyl)amino, N-C1-4alkylcarbamoyl, di-N,N-(C1-4alkyl)carbamoyl, C1-4alkylS(O)r-, C1-4alkylS(O)rC1.4alkyl (wherein r is O5 1 and 2)];
R9 is independently C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-4alkoxy, carboxy and cyano;
R9 , R9 and R9 are independently selected from hydrogen and C1-3alkyl optionally substituted by io hydroxyl, halo, C1-4alkoxy, carboxy or cyano); p is 0; either X is -O-, -S- or -N(R12)- wherein R12 is hydrogen, Ci-3alkyl or C1-3alkanoyl; and
Y is :
1) a C3-7cy cloalkdiyl ring, a 5-7 membered saturated heterocyclic ring (linked by a ring i5 carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur; or
2) -X-Y- together represents a group of the formula:
Figure imgf000025_0001
20 wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom 25 selected from nitrogen, oxygen and sulphur;
R10 is independently selected from C[-3alkyl, C2-3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, Ci-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 15 2 or 3), R11CON(R11'), (RH')(Rn")NC(O)-, R11OC(O)- and (RH')(Rπ")NSO2- (wherein R11 is C1-3alkyl optionally substituted by hydroxyl, halo or cyano; and R11' and R11" are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C^alkoxy, carboxy or cyano) or R11 and R11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2; R13 and R14 are independently selected from hydrogen and C^alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
3. Another class of compounds of the present invention is of formula (1) wherein: Q is -S-;
R1 is C1-6alkyl, C3-7cycloalkyl or C3-7cycloalkylC1-3alkyl; or
R2 is selected from C3-7cycloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein m is 0, 1 or
2 and the rings are optionally substituted by 1 or 2 substituents independently selected from R6);
R3 is selected from hydrogen; or R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1 or
2 substituents independently selected from R7; R6 and R7 are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl,
R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9")NC(O)-, (R9>)(R9")N-, R9S(O)8- wherein a is 0 to 2, R9 OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9'")-;
R9 , R9 and R9 are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-4alkoxy, carboxy or cyano); p is 0; either X is -O-, -S- or -N(R12)- wherein R12 is hydrogen, C1-3alkyl or C1-3alkanoyl; and
Y is:
1) a C3-7Cy cloalkdiyl ring or a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur; or 2) -X-Y- together represents a group of the formula:
Figure imgf000027_0001
wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
R10 is independently selected from C1-3alkyl, C2.3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R11CON(R11'), (R11 'XRi r')NC(O>, R11OC(O)- and (Rn')(Rπ")NSO2- (wherein R11 is C1-3alkyl optionally substituted by hydroxy 1, halo or cyano; and
R11 and R11 are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-3alkoxy, carboxy or cyano) or R11 and R11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, or 1;
R13 and R14 are independently selected from hydrogen and C1-3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof. 4. Another class of compounds of the present invention is of formula (1) wherein:
Q is -S-;
R1 is Ci-βalkyl;
R2 is selected from C3-7cycloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein m is 0, 1 or
2 and the rings are optionally substituted by 1 or 2 substituents independently selected from R6); R3 is selected from hydrogen; or
R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1 or 2 substituents independently selected from R7;
R6 and R7 are independently selected from hydroxyl, halo and trifluoromethyl; p is 0; either X is -N(R12)- wherein R12 is hydrogen; and Y :
1) a C3-7cycloalkdiyl ring or a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur; or
2) -X-Y- together represents a group of the formula:
Figure imgf000028_0001
wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and
A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
R10 is independently selected from C1-3alkyl, hydroxy, halo and trifluoromethyl; u is O, or 1;
R13 and R14 are independently selected from hydrogen and C1-3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof. 5. Another class of compounds of the present invention is of formula (1) wherein:
Q is -S-;
R1 is C1-6alkyl;
R2 is selected from C3-7cycloalkyl, and C6-12polycycloalkyl each of which is independently optionally substituted by 1 R6; R3 is selected from hydrogen;
R6 is selected from hydroxyl, halo and trifluoromethyl; p is O;
-X-Y- together represents a group of the formula:
Figure imgf000029_0001
wherein: ring A is linked to the pyridine group and -[C(R13)(Rl4)]s- is linked to the carboxy group; and
A is a 4-7 membered mono- or bi- heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; u is 0; R13 and R14 are independently selected from hydrogen and methyl; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
6. In another aspect a class of compounds according to the present invention is of the formula (IB):
Figure imgf000029_0002
wherein R1, R2, X and Y have any of the definitions given above. In another aspect of the invention, suitable compounds of the invention are any one or more of the Examples or a pharmaceutically-acceptable salt thereof. In another aspect the invention relates to: a compound selected from : 2- [(3R)- 1 - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl] -3 -piperidyl] acetic acid
1 - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperidine-3 -carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperidine-4-carboxy lie acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]acetic acid
2- [ 1 - [5 -(cy clohexy lcarbamoyl)-6-propy lsulfanyl-pyridin-2-yl] -3 -piperidyl] acetic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxy lie acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperazin-l-yl]acetic acid
(3R,5S)-4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-ρyridin-2-yl]amino]adamantane-l- carboxylic acid
(3R,5S)-4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]amino]adamantane-l- carboxylic acid
4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-metb.yl-amino]cyclohexane-l- carboxylic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxybenzoic acid
3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylbenzoic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylbenzoic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxybenzoic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]acetic acid
3-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxypb.enyl]propanoic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylphenoxy]acetic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenoxy]acetic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]propanoic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylphenyl]acetic acid
2-[3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]acetic acid
2-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylbenzoic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxycyclohexane-l-carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperidine-2-carboxylic acid
(2S)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-2-carboxylic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]propanoic acid 4-[[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-ρyridin-2-yl]amino]methyl]cyclohexane-l- carboxylic acid
3 - [ [5 -(cy clohexy lcarbamoy l)-6-propylsulfanyl-pyridin-2-y 1] amino]propanoic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]azepane-4-carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-methyl-piperidine-4-carboxylic acid
(lS,5R)-3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridm-2-yl]-3-azabicyclo[3.1.0]hexane-
6-carboxylic acid
4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]amino]cyclohexane-l-carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-propan-2-yl-piperidine-4- carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-metliyl-piperidine-4-carboxylic acid
2-[l-[5-(cycloliexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]-2-methyl-propanoic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
3-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]propanoic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]azetidin-3-yl]oxyacetic acid
1 -[I -[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]cyclobutane-l - carboxylic acid
1 - [ 1 - [5 -(cy clohexy lcarbamoy l)-6-propy lsulfanyl-pyridin-2-y 1] -3 -piperidyl] cyclopropane- 1 - carboxylic acid
2-[l-[5-(cycloliexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid
2-[[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]oxy]propanoic acid
2- [[I - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl] -3 -piperidyl] oxy] -2-methyl- propanoic acid
2-[[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]oxy]acetic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-methyl-piperidine-3-carboxylic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]-2-methyl-propanoic acid 1 - [ 1 - [5 -(cyclohexy lcarbamoyl)-6-propy lsulfanyl-pyridin-2-yl] -4-piperidyl] cyclobutane- 1 - carboxylic acid
1 -[I -[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]cyclopropane- 1 - carboxylic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]morpholine-2-carboxylic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclohexylsulfanyl-pyridm-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclohexylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid l-[l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]-3-piperidyl]cyclopropane-l- carboxylic acid
2-[(3S)-I- [5 -(2-adamanty lcarbamoy l)-6-propy lsulfanyl-pyridin-2-yl] -3 -piperidy 1] acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid
2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]oxy acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[5-(2-adamantylcarbanioyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxy lie acid
2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(2S)- 1 -[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-2-carboxylic acid
(lS,5R)-3-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-
6-carboxylic acid
(3 S)- 1 -[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]ρyrrolidine-3-carboxylic acid
4-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]morpholine-2-carboxylic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3- yl]oxyacetic acid 2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3- yl]oxy acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-cyclohexylsulfanyl-pyridin-2-yl]pyrrolidin-3- yl]oxy acetic acid
2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-cyclohexylsulfanyl-pyridin-2-yl]pyrrolidin-3- yl]oxy acetic acid
2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxylic acid
(3S)-l-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxy lie acid
(1 S,5R)-3-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]-3-azabicyclo[3.1.OJhexane-
6-carboxylic acid
2-[(3R)- 1 -[5-(2-adamantylcarbamoyl)-6-methylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[5-(2-adamantylcarbamoyl)-6-methylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxy lie acid
(lS,5R)-3-[5 -(2-adamantylcarbamoyl)-6-methy lsulfanyl-pyridin-2-yl] -3 - azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbanioyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl] acetic acid
4- [[[5 - [((2r, 5 s)-5 -hy droxy-2-adamantyl)carbamoyl] -6-propy lsulfany l-pyridin-2- yl]amino]methyl]cyclohexane- 1 -carboxylic acid
4-[[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2- yl]amino]cyclohexane- 1 -carboxylic acid
4-[[5-[((2r,5s)-5-hydroxy-2-adaniantyl)carbamoyl]-6-propylsulfanyl-pyridin-2- yl]amino]cyclohexane- 1 -carboxylic acid
2-[(3S)-l-[5-[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]piperidine-4- carboxylic acid
2-[(3R)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-4- piperidyl] acetic acid (lR,5S)-3-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxylic acid l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-4-methyl- piperidine-4-carboxylic acid l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-3- carboxylic acid
2-[(3R)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-piOpylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl]acetic acid
3-[l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- piperidyljpropanoic acid
2-[l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]-
2-methyl-propanoic acid
2-[(3S)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3-yl] acetic acid
2-[(3S)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3R)-l-[6-cyclopentylsulfanyl-5τ[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3-yl] acetic acid
(3R)-I- [6-cy clopenty lsulfany 1-5 - [((2r, 5 s)-5 -hy droxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-3 -carboxylic acid
(2S)- 1 - [6-cy clopentylsulfany 1-5 - [((2r, 5 s)-5 -hy droxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-2-carboxylic acid
(lR,5S)-3-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxylic acid l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]piperidine-
4-carboxylic acid
2-[(3R)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3-yl]acetic acid
(2S)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-2-carboxylic acid
(3R)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-3-cafboxylic acid 2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-hydroxy-2-adaniantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-(3-methylbutylsulfanyl)pyridin-2- yl] -3 -piperidyl] acetic acid
(3R)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-(3-methylbutylsulfanyl)pyridin-2- yl]pyrrolidine-3-carboxylic acid
( 1 R,5 S)-3 - [5- [((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-(3 -methylbutylsulfanyl)pyridin-2- yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[6-benzylsulfanyl-5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-[ [(2r, 5 s)-5 -hy droxy-2-adamantyl] carbamoyl] -6-phenethylsulfany l-pyridin-2-yl] -3 - piperidyl] acetic acid
2- [(3 S)- 1 - [5 - [[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl] -6-propoxy-pyridin-2-yl] -3 - piperidyl] acetic acid
2-[l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propoxy-pyridin-2-yl]-3-piperidyl]-2- methyl-propanoic acid
( 1 R,5 S,6r)-3 -(6-(cyclopentylthio)-5-(3 -(pyridin-3-yl)pyrrolidine- 1 -carbonyl)pyridin-2-yl)-3 - azabicyclo[3.1.0]hexane-6-carboxylic acid
(1 S,5R)-3-[6-cyclohexylsulfanyl-5-(3-pyridin-3-ylpyrrolidine- 1 -carbonyl)pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxy lie acid
2-[(3S)-l-[6-propylsulfanyl-5-(3-pyridin-3-ylpyrrolidine-l-carbonyl)pyridin-2-yl]-3- piperidyl] acetic acid
2- [(3 S)-I- [6-propylsulfanyl-5-(3 -pyridin-2-ylpyrrolidine- 1 -carbonyl)pyridin-2-yl]-3 - piperidyl] acetic acid
2-[(3S)-l-[5-(piperidine-l-carbonyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)-I- [6-propylsulfanyl-5-(3-pyrazin-2-ylpyrrolidine- 1 -carbonyl)pyridin-2-yl]-3 - piperidyl] acetic acid
2-[(3S)-l-[5-(4,4-difluoropiρeridine-l-carbonyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[6-propylsulfanyl-5-[3-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-yl]-3- piperidyl] acetic acid 2-[(3S)-l-[6-propylsulfanyl-5-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-I- [5-(4-carbamoy lpiperidine- 1 -carbonyl)-6-propylsulfanyl-pyridin-2-yl] -3 - piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexyl-cyclopropyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexyl-(cyclopropylmethyl)carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexyl-ethyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-propan-2-yl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-[(4-hydroxycyclohexyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3 S)-I- [6-propylsulfanyl-5- [3 - [2-(trifluoromethyl)phenyl]pyrrolidine- 1 -carbonyl]pyridin-2- yl] -3 -piperidyl] acetic acid
2-[(3S)-l-[5-[((2r,5s)-5-methylsulfonyl-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-
3-piperidyl]acetic acid
2-[(3 S)- 1 -[6-cyclopentylsulfanyl-5-(3-pyridin-3-ylpyrrolidine- 1 -carbonyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-phenethylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid2-
[(3S)-l-[5-(cyclohexylcarbamoyl)-6-phenethylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(2-pyridin-3-ylethylsulfanyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(2-pyrazin-2-ylethylsulfanyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-I- [5 -(cyclohexylcarbamoyl)pyridin-2-yl] -3 -piperidyl] acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-[2-(4-fluorophenyl)ethoxy]pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)-I- [5-(cyclohexylcarbamoyl)-6-(3 -methylbutoxy)pyridin-2-yl]-3 -piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(3-phenylpropoxy)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(2-pyridin-3-ylethoxy)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-methoxy-pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-propoxy-pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)- 1 - [5 -(cyclohexy lcarbamoyl)-6-( 1 -piperidyl)pyridin-2-yl] -3 -piperidyl] acetic acid
2-[(3S)-l-[6-[2-(4-chlorophenyl)ethylamino]-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-[3-(4-fluorophenyl)pyrrolidin-l-yl]pyridin-2-yl]-3- piperidyl]acetic acid 2- [(3 S)-I- [5-(cyclohexylcarbamoyl)-6-(3 ,4-dihydro- 1 H-isoquinolin-2-yl)pyridin-2-yl]-3 - piperidyl] acetic acid
2-[(3 S)- 1 -[5-(cyclohexylcarbamoyl)-6-(3 ,4-dihydro- 1 H-isoquinolin-2-yl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(4-phenylpiperazin-l-yl)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-[4-(4-fluorobenzoyl)piperazin-l-yl]pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[6-(4-acetylpiperazin-l-yl)-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(4-ethylsulfonylpiperazin-l-yl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[6-[4-(benzenesulfonyl)piperazin-l-yl]-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(4-phenylmethoxycarbonylpiperazin-l-yl)pyridin-2-yl]-3- piperidyl]acetic acid
2- [(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6-propylamino-pyridin-2-yl]-3 -piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(phenethylamino)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(methyl-phenethyl-amino)pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(methyl-propyl-amino)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-pyrrolidin-l-yl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-morpholin-4-yl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-propylamino-pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-(methyl-propyl-amino)pyridin-2-yl]-3- piperidyl] acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-methyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(l-adamantylcarbamoyl)-6-methyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-methyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-butyl-pyridin-2-yl]-3-piperidyl]acetic acid
3-[5-(2-adamantylcarbamoyl)-6-butyl-pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[6-butyl-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-cyclopropyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-cyclopropyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[6-cyclopropyl-5-[[(2r,5s)-5-hydiOxy-2-adamantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3R)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
[(35)-l-{5-[((2r,5s)-5-methoxyadamantan-2-yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2- yl}piperidin-3-yl] acetic acid [(35)-l-{5-[((2r,5s)-5-hydroxyadamantan-2-yl)(methyl)carbamoyl]-6-(propyltliio)pyridin-2- yl}piperidin-3-yl]acetic acid
{ (3S)- 1 - [5 -(adamantan- 1 -ylcarbamoyl)-6-(propy lthio)pyridin-2-y l]piperidin-3 -yl } acetic acid
{(35)-l-[6-(propylthio)-5-(tetrahydro-2i7-pyran-4-ylcarbamoyl)pyridin-2-yl]piperidin-3-yl}acetic acid [(3S)-l-{5-[methyl(tetrahydro-2H-pyran-4-yl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3- yl] acetic acid
2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[6-cycloρentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3S)-l-[6-cycloρentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl] carbamoyl]pyridin-2-yl] -3 -piperidy 1] acetic acid 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2- yl] -3 -piperidyl] acetic acid
2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl] acetic acid 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propoxy-pyridin-2-yl]-3- piperidyljacetic acid
(3R)-l-[6-cycloρentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidine-3-carboxylic acid
(lR,5S)-3-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3R)-l-[5 - [[(2r,5 s) -5 -(difluoromethoxy)-2-adamanty 1] carbamoyl] -6-propy lsulfany 1- pyridin-2-y l]pyrrolidin-3 -y l]acetic acid l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidine-3-carboxylic acid
(S)-2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid and (R)-2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid and pharmaceutically-acceptable salts thereof. Another aspect of the present invention provides a process for preparing a compound of formula (1) or a pharmaceutically acceptable salt thereof which process [wherein Z is -X-Y-COOH and other variable groups are, unless otherwise specified, as defined in formula (I)] comprises any one of processes a) to e): a) reaction of a compound of Formula (2) with a compound of Formula (3):
Figure imgf000039_0001
(2) (3) b) reaction of a compound of Formula (4) with a compound of Formula (5):
Figure imgf000040_0001
(4) (5) wherein X is a leaving group; or c) reaction of a compound of Formula (6) with a compound of Formula (7):
Figure imgf000040_0002
(6) (7)
wherein X' is a leaving group; or d) reaction of a compound of Formula (8) with a compound of Formula (9):
Figure imgf000040_0003
wherein X" is a leaving group; or e) reaction of a compound of Formula (10) with a compound of Formula (11):
Figure imgf000040_0004
(10) (11)
wherein X'" is a leaving group; and thereafter if necessary or desirable: i) converting a compound of the formula (1) into another compound of the formula (1); ii) removing any protecting groups; iii) resolving enantiomers; iv) forming a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
Examples of conversions of a compound of Formula (1) into another compound of Formula (1), well known to those skilled in the art, include functional group interconversions such as hydrolysis, hydrogenation, hydrogenolysis, oxidation or reduction, and/or further functionalisation by standard reactions such as amide or metal-catalysed coupling, or nucleophilic displacement reactions. Suitable conditions for the above processes a) to e) are as follows. Process a) is typically carried out in a suitable solvent such as dichloromethane or N,N- dimethylformamide for example with either the in situ formation of the acyl halide using a suitable reagent such as oxalyl chloride for example or with the addition of a suitable coupling agent (or combination of agents) to form an active ester such as HOBT and EDAC for example, optionally in the presence of a suitable base such as triethylamine or ΛζiV-di-wo-propylamine for example. Typically the reaction is carried out at ambient or elevated temperature between 0-60 0C. Process b) is typically carried out in a suitable solvent such as dichloromethane or THF for example using a strong base (such as sodium hydride or lithium or potassium hexamethyldisilylazides) and a suitable alkylating agent (such as alkyl iodide). Typically the reaction is carried out at ambient or temperature. Suitable examples of leaving groups (X) are chloro, bromo, iodo, mesylate, tosylate or triflate. Others are known to the art. Process c) may be carried out in a suitable solvent such as acetonitrile, butyronitrile or methanol for example, typically with the addition of a suitable base such as potassium carbonate or sodium hydroxide for example. Typically the reaction is carried out at elevated temperature, using Microwave or conventional heating, for example at temperatures between 100-140 0C. In certain cases the reactions can be carried out at ambient temperature. Suitable examples of leaving groups (X') are chloro, bromo, iodo, mesylate, tosylate or triflate. Others are known to the art.
Process d) may be carried out in a suitable solvent such as acetonitrile, butyronitrile, DMF or THF for example, typically with the addition of a suitable base such as potassium carbonate or sodium hexamethyldisilylazide for example. Typically the reaction is carried out at ambient or elevated temperature between 30-180 0C (achieved using conventional heating or microwave irradiation). Suitable examples of leaving groups (X") are fluoro, and chloro. Others are known to the art.
Process e) may be carried out in a suitable solvent such as acetonitrile, butyronitrile, DMF or THF for example, typically with the addition of a suitable base such as potassium carbonate or sodium hexamethyldisilylazide for example. Typically the reaction is carried out at ambient or elevated temperature between 30-180 0C (achieved using conventional heating or microwave irradiation). Suitable examples of leaving groups (X'") are fluoro, and chloro. Others are known to the art. It will be appreciated that the intermediates required to synthesise compounds of formula (1) may be commercially available, may be known to the art or may be prepared by known procedures and/or by the procedures described above a)-e). It will be appreciated that the sequence in which these processes are carried out, will be determined by the type of compound of formula (1) being synthesised. For example, reaction of a compound of Formula (12) with appropriate nucleophilic reagents (Nu) resulting in displacement of leaving groups (X1 and X2) to generate compounds of types (13) or (14) which would be potentially useful intermediates in the synthesis of compounds of formula (1)
Figure imgf000042_0001
(12) (13) (14) wherein X1 and X2 are leaving groups (typically fluoro or chloro) and W is an amide or alternatively a group that may be converted into an amide by processes known to the art (for example an ester which may be hydrolysed to an acid that may be subsequently transformed into an amide);
It will be appreciated to those skilled in the art that the nature of X1 and X2, the nature of W, the nature and position of any R4 substituents and reaction conditions such as solvent and temperature and any additional catalysts (for example palladium & copper ligands) may affect the order in which the groups are X1 and X2 are displaced and in turn the order in which the reactions are required to be carried out in order to deliver the required compounds. It will be appreciated that examples of pyridines with appropriate substitution in the 4 and 6-positions are known to the art and that they may also be used as starting points for the synthesis of compounds of type (1). It will be appreciated that when Q is H, the required compounds may be accessed from intermediates of type (15) according to the processes described above.
Figure imgf000043_0001
It will be appreciated that certain of the various substituents in the compounds of the present invention, and in intermediates in their preparation, may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, oxidation of substituents and alkylation of substituents, for example, alkylation reactions such as conversion of a secondary amide to a primary amide typically carried out using strong base (such as sodium hydride or lithium or potassium hexamethyldisilylazides) and a suitable alkylating agent (such as methyl iodide). The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T. W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example hydroxylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
As stated hereinbefore the compounds defined in the present invention possess 1 lβHSDl inhibitory activity. These properties may be assessed using the following assay. Assays
The conversion of cortisone to the active steroid Cortisol by 1 lβHSDl oxo-reductase activity, can be measured using a competitive homogeneous time resolved fluorescence assay (HTRF) (CisBio International, R&D, Administration and Europe Office, In Vitro Technologies — HTRF® / Bioassays BP 84175, 30204 Bagnols/Ceze Cedex, France. Cortisol bulk HTRF kit: CatNo. 62CORPEC).
The evaluation of compounds described herein was carried out using a baculovirus expressed N terminal 6-His tagged full length human 1 lβHSDl enzyme(* 1). The enzyme was purified from a detergent solublised cell lysate, using a copper chelate column. Inhibitors of 11 βHSD 1 reduce the conversion of cortisone to Cortisol, which is identified by an increase in signal, in the above assay.
Compounds to be tested were dissolved in dimethyl sulphoxide (DMSO) to 1OmM and diluted further in assay buffer containing 1% DMSO to 10 fold the final assay concentration. Diluted compounds were then plated into black 384 well plates (Matrix, Hudson NH, USA). The assay was carried out in a total volume of 20μl consisting of cortisone (Sigma, Poole,
Dorset, UK, 16OnM), glucose-6-phosphate (Roche Diagnostics, ImM), NADPH (Sigma, Poole, Dorset, lOOμM), glucose-6-phosphate dehydrogenase (Roche Diagnostics, 12.5μg/ml), EDTA (Sigma, Poole, Dorset, UK, ImM), assay buffer (K2HPO4/KH2PO4, 10OmM) pH 7.5, recombinant 11 βHSD 1 [using an appropriate dilution to give a viable assay window - an example of a suitable dilution may be 1 in 1000 dilution of stock enzyme] plus test compound. The assay plates were incubated for 25 minutes at 370C after which time the reaction was stopped by the addition of lOμl of 0.5mM glycerrhetinic acid plus conjugated cortisol(XL665 or D2). lOμl of anti-cortisol Cryptate was then added and the plates sealed and incubated for 6 hours at room temperature. Fluorescence at 665nm and 620nm was measured and the 665nm:620nm ratio calculated using an Envision plate reader.
These data was then used to calculate IC50 values for each compound (Origin 7.5, Microcal software, Northampton MA, USA) and/or the % inhibition at 30μM of compound. * 1 The Journal of Biological Chemistry, Vol. 26, No 25, ρpl6653 - 16658
Compounds of the present invention typically show an IC5O of less than 30μM, and preferably less than 5 μM.
The following table displays IC50 values for selected compounds:
Figure imgf000046_0001
The following table displays %inhibition of human 11-βHSD at a test concentration of 30μM of compound:
Figure imgf000046_0002
Figure imgf000047_0001
The compounds:
{(35)-l-[5-(adamantan-l-ylcarbamoyl)pyridin-2-yl]piperidin-3-yl}acetic acid; and
{ (3S)- 1 -[5-(cyclohexylcarbamoyl)-6-(piperazin- 1 -yl)pyridin-2-yl]piperidin-3 -yl} acetic acid did not achieve 50% inhibition of the enzyme at less than or equal to 30 micromolar and hence are not preferred compounds of the invention.
The compound 2-[(3S)-l-[5-(2-adamantylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid achieved 50% inhibition in one assay, but in a subsequent 3 assays did not and hence is also not a preferred aspect of the invention. In one aspect the invention does not relate to 2-[(3S)-I -[5-(2-adamantylcarbamoyl)pyridin-2-yl]-
3-piperidyl]acetic acid.
The oral bioavailability of the compounds of the invention may be tested as follows:
Determination of Bioavailability in PK Studies
Compounds are dosed intravenously at 2mg/kg (2ml/kg) and orally at 5mg/kg (5ml/kg) in a 25% HPBCD in sorrensons buffer pH 5.5 formulation. Blood samples (20OuI) are taken Predose,
0.25, 0.5, 1, 2, 3, 4, 5, 6, 8 and 24 h post dose for both routes and plasma prepared by centrifugation. Plasma samples are analysed as below. PK parameters (clearance, volume of distribution, bioavailability, fraction absorbed etc.) are calculated by standard PK methods using suitable PK software (WinNon-Lin). Bioanalvsis of plasma samples The guidelines described are for the manual preparation of plasma samples following single compound or cassette dosing of project compounds to all PK species used within discovery DMPK. Analysis by open access (LC-MS/MS) or manual approaches (LC-MS) is described. Contents 1. Materials
2. Generic Extraction Method
3. Example Sample List Using Generic Plate Layout
4. Open Access Batch Submission and System Checks
5. Acceptance Criteria for Batch Pass 1. Materials
Solvents: Methanol, acetonitrile and DMSO
Water: Purified or HPLC grade
ImI shallow 96-well plates OR eppendorf tubes
2ml deep well 96-well plates plus lids Blank (control) plasma
2. Generic Extraction Method
Solubilise compound(s) to lmg/ml using DMSO taking into account salt factors if any. The
DMSO stock(s) may be used to make all calibration & quality control (QC) samples:
2.i Single compound analysis 2.i.a Preparation of calibration and QC samples: 1. Prepare standard solutions as follows:
Figure imgf000048_0001
100 0.5 0.5 50 5
50 0.5 0.5 10 1
2. Transfer 50ul blank plasma to a well of a ImI 96- well plate (shallow well)
3. Transfer 5ul of each of the standard solutions to further wells of the plate
4. Add 50ul blank plasma to each of these wells. 5. To generate the QC samples, add three aliquots of 5ul of the 100ng/ml, 1000ng/ml and
10,000ng/ml standard solutions to the plate (3 QCs at each concentration).
6. Add 50ul blank plasma to each of these.
7. Transfer 50ul of each PK sample to the ImI 96- well plate
8. Add 5ul methanol (- compound) to each of the PK samples 9. Ensure all dose formulations are well mixed by vortex mixing.
10. Dilute intravenous (IV) and oral dose (PO) formulations of expected concentration to lOug/ml in methanol. (For example, a formulation made to an expected concentration of 2 mg/ml would be diluted 1:200 to give 10ug/ml solution).
11. Add 6x 50 ul aliquots of plasma to the plate. Add 5 ul of diluted IV formulation to three of the wells, repeat with PO formulation and remaining 3 wells.
12. Precipitate proteins by adding lOOul acetonitrile containing a project related internal standard (at lug/ml) to all calibration, QC, PK and formulation samples.
13. Vortex mix the plate before centrifugation at 4,00Og for 10 minutes.
14. Transfer lOOul of the supernatant to the wells of a 2ml 96-well plate (see following plate map). Care should be taken not to disturb the pellet.
15. Add ~1.5ml of 50:50 Methanol: Water into the last well.
16. For analysis on triple quad systems: add 400ul water (HPLC grade) to each sample. Gently mix.
17. Add lOOul of the 100,000ng/ml stock of each of the standard solutions to the 2ml plate and add 900ul water. Add a sample of internal standard to a further well (see plate map).
These are for compound tuning (denoted on the plate map as tune solutions)
18. For analysis on platform systems: add lOOul water (HPLC grade) to each sample. Gently mix.
19. Manually tune all compounds using compound solutions prepared to 5,000ng/ml (add 1 OOul of the 50,000ng/ml standard solutions to 900ul water) 2.ii Cassette dose analysis 2.iia Preparation of calibration and QC samples:
Note: For cassette dosing, the amount of methanol required to dilute the lmg/ml stock will be adjusted according to the number of compounds present. 1. Add 1 OOul of each lmg/ml stock required to a vial.
2. Add the required volume of methanol to yield a total volume of ImI.
3. Perform all further steps as for single compound analysis (steps 2 -16 above). 2.iii In cases where PK samples exceed the Upper limit of Quantification (ULOQ).
1. Prepare a further calibration curve and QC samples as above (steps 1 - 6). 2. Transfer <50ul (e.g. 25ul) of the PK samples that exceed the ULOQ.
3. Add enough control plasma to these samples to yield a final plasma volume of 50ul. Make a note of the dilution made.
4. Transfer 50ul of all remaining PK samples.
5. Prepare all formulation samples and extract all samples as described above, (steps 8 - 16) Note: Upper concentrations used to generate the calibration curve may be reviewed, however, care must be taken to avoid saturation of the HPLC column or MS equipment. It is for this reason that dilution of PK samples is recommended.
2.iv In cases of poor sensitivity (high Lower Limit of Quantification).
Note: High LLOQ is taken as when most of the plasma concentrations lie below the lower limit of quantification or where the LLOQ is greater the 10ng/ml. The following methods should be applied when either of these scenarios is encountered.
According to a further aspect of the invention there is provided a pharmaceutical composition, which comprises a compound of the Examples, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing). In general, compositions in a form suitable for oral use are preferred. The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents. Suitable pharmaceutically-acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p_-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl |>-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame). Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol. Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990. We have found that the compounds defined in the present invention, or a pharmaceutically-acceptable salt thereof, are effective l lβHSDl inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome.
It is to be understood that where the term "metabolic syndrome" is used herein, this relates to metabolic syndrome as defined in 1) and/or 2) or any other recognised definition of this syndrome. Synonyms for "metabolic syndrome" used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term "metabolic syndrome" is used herein it also refers to Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X.
According to a further aspect of the present invention there is provided a compound of formula (1), or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
Thus according to this aspect of the invention there is provided a compound of formula (1), or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use as a medicament. According to another feature of the invention there is provided the use of a compound of formula (1), or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man.
Where production of or producing an 1 lβHSDl inhibitory effect is referred to suitably this refers to the treatment of metabolic syndrome. Alternatively, where production of an ■' 11 βHSDl inhibitory effect is referred to this refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity. Alternatively, where production of an 1 lβHSDl inhibitory effect is referred to this refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression. Alternatively, where production of an 1 lβHSDl inhibitory effect is referred to this refers to the treatment of cognitive disorders, such as improving the cognitive ability of an individual, for example by improvement of verbal fluency, verbal memory or logical memory, or for treatment of mild cognitive disorders. See for example WO03/086410 and references contained therein, and Proceedings of National Academy of Sciences (PNAS), 2001, 98(8), 4717-4721. Alternatively, where production of an 1 lβHSDl inhibitory effect is referred to this refers to the treatment of, delaying the onset of and/or reducing the risk of atherosclerosis - see for example J. Experimental Medicine, 2005, 202(4), 517-527.
Alternatively, where production of an 1 lβHSDl inhibitory effect is referred to this refers to the treatment of Alzheimers and/or neurodegenerative disorders. According to a further feature of this aspect of the invention there is provided a method for producing an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1), or a pharmaceutically-acceptable salt thereof.
In addition to their use in therapeutic medicine, the compounds of formula (1), or a pharmaceutically-salt thereof, are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of 1 lβHSDl in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
The inhibition of 1 lβHSDl described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets. For example agents than might be co-administered with 1 lβHSDl inhibitors, particularly those of the present invention, may include the following main categories of treatment: 1) Insulin and insulin analogues; 2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide), prandial glucose regulators (for example repaglinide, nateglinide), glucagon-like peptide 1 agonist (GLPl agonist) (for example exenatide, liraglutide) and dipeptidyl peptidase IV inhibitors (DPP-IV inhibitors);
3) Insulin sensitising agents including PPARγ agonists (for example pioglitazone and rosiglitazone);
4) Agents that suppress hepatic glucose output (for example metformin);
5) Agents designed to reduce the absorption of glucose from the intestine (for example acarbose);
6) Agents designed to treat the complications of prolonged hyperglycaemia; e.g. aldose reductase inhibitors
7) Other anti-diabetic agents including phosotyrosine phosphatase inhibitors, glucose 6 - phosphatase inhibitors, glucagon receptor antagonists, glucokinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphastase inhibitors, glutamine:fructose -6-phosphate amidotransferase inhibitors 8) Anti-obesity agents (for example sibutramine and orlistat);
9) Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PP ARa agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors); ileal bile acid absorption inhibitors (IBATi), cholesterol ester transfer protein inhibitors and nicotinic acid and analogues (niacin and slow release formulations);
10) Antihypertensive agents such as, β blockers (eg atenolol, inderal); ACE inhibitors (eg lisinopril); calcium antagonists (eg. nifedipine); angiotensin receptor antagonists (eg candesartan), α antagonists and diuretic agents (eg. furosemide, benzthiazide);
11) Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor Vila inhibitors; antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hirudin) and warfarin; 12) Anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone); and
13) Agents that prevent the reabsorption of glucose by the kidney (SGLT inhibitors). In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.
Examples
The invention will now be illustrated by the following Examples in which, unless stated otherwise: (i) temperatures are given in degrees Celsius (0C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 °C and under an atmosphere of an inert gas such as argon;
(ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure
(600-4000 Pa; 4.5-30 mniHg) with a bath temperature of up to 60 0C; (iii) chromatography means flash chromatography on silica gel;
(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
(v) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; (vi) where given, NMR data (1H) is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS), determined at 300 or 400
MHz (unless otherwise stated) using perdeuterio dimethyl sulfoxide (DMSO-J6) as solvent, unless otherwise stated; peak multiplicities are shown thus: s, singlet; d, doublet; dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; (vii) chemical symbols have their usual meanings; SI units and symbols are used;
(viii) solvent ratios are given in volume : volume (v/v) terms;
(ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported;
(x) The following abbreviations may be used below or in the process section hereinbefore: Et2O diethyl ether
DMF dimethylformamide DCM dichloromethane
DME 1 ,2-dimethoxyethane
MeOH methanol
EtOH ethanol
H2O water
TFA trifluoroacetic acid
THF tetrahydrofuran
DMSO dimethylsulfoxide
HOBt 1 -hydroxybenzotriazole
EDCI (EDAC) l-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride
DIPEA diisopropylethylamine
DEAD diethyl azodicarboxylate
EtOAc ethyl acetate
NaHCO3 sodium bicarbonate
K3PO4 potassium phosphate
MgSO4 magnesium sulfate
PS polymer supported
BINAP 2,2'-bis(diphenylphosphino)- 1 , 1 'binaphthyl
Dppf 1 , 1 ' -bis(diphenylphosphino)ferrocene dba dibenzylidineacetone
PS-CDI polymer supported carbonyldiimidazole
Example 1
2-f(3RVl-f5-(CvclohexvIcarbamovπ-6-proDVlsulfanvl-ϋvridin-2-vll-3-piperidvllacetic acid
Figure imgf000057_0001
6-chloro-N-cyclohexyl-2-propylsulfanyl-pyridme-3-carboxamide (Intermediate 2, 1.88 g, 6.03 mmol ), Methyl-(R)-3-Piρeridine Acetate hydrochloride (1.17 g, 6.03 mmol), K2CO3 (2.50 g, 18.08 mmol) and butyronitrile were mixed in a microwave tube and stirred at 170 0C for 2 hours. The mixture changed from a poorly soluble white mixture to an orange solution. The reaction was stopped and most of the butyronitrile was evaporated under reduced pressure. Water (20 niL) was added and the product was extracted with EtOAc (2 x 40 mL), washed with brine (10 mL), dried over MgSO4, filtered and evaporated under reduced pressure to give an orange oil. It was preloaded on Celite and purification by flash column chromatography (SiO2, eluent gradient: 0% to 50%, hexane:EtOAc) afforded the title compound as a slightly yellow oil which crystallised to give a white solid (1.44 g, 55%). The solid was taken in THF (20 mL), water was added (10 mL) followed by LiOH (281 mg). The reaction was stirred at room temperature for three hours. The solution was acidified with 2 N HCl between pH 4 and pH 5 and the product extracted in EtOAc (2 x 40 mL). The solution was washed with brine (10 mL), dried over MgSO4 and the organic phase evaporated under reduced pressure to give a white solid (1.38g, 99%).
1H NMR (400.13 MHz, DMSO-d6) δθ.95 (3H, t), 1.11 (IH, m), 1.26 (3H, m), 1.30 (IH, m), 1.43 (IH, m), 1.59 (2H, t), 1.65 - 1.72 (2H, m), 1.69 - 1.73 (IH, m), 1.77 (3H, m), 1.83 - 1.85 (IH5 m), 2.12 - 2.25 (2H, m), 2.71 - 2.77 (IH, m), 2.86 - 3.02 (3H, m), 3.63 - 3.67 (IH, m), 4.20 (IH, d), 4.29 (IH, d), 6.47 (IH, d), 7.61 (IH, d), 7.79 (IH, d) MS m/e MH+420 The following Examples were prepared in a similar manner to Example 1, using
Intermediate 2 and an appropriate aminoester starting material:
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0002
Intermediate 1
2,6-dichloro-N-cyclohexyl-pyridine-3-carboxamide
Figure imgf000067_0001
To a solution of 2,6-dichloronicotinic acid (5.005 g, 26.18 mmol) in DCM (60 ML) was added a few drops of DMF followed by the addition dropwise of oxalyl chloride (2.27 niL, 26.18 mmol). The reaction was stirred at room temperature for two hours until gas bubbling had stopped. The solvent was evaporated under reduced pressure to give an oil. DCM (60 mL) was added and the reaction mixture was cooled in an ice bath. Cyclohexylamine (5.98 mL, 52.36 mmol) was added slowly keeping the temperature below 15°C. The reaction was stirred at room temperature overnight.
The reaction mixture was extracted in DCM and washed with sat bicarb (30 mL), water (30 mL) and brine. The solvent was evaporated under reduced pressure to give a brown/red solid. It was recrystalised in hexane/ethyl acetate and filtered to give a white solid (6.986 g, 25.6 mmol,
98%) i
1H NMR (400.13 MHz, DMSOd6) δl.12 - 1.18 (IH, m), 1.21 - 1.25 (IH, m), 1.29 (2H, m), 1.30 s - 1.34 (IH, m), 1.55 - 1.59 (IH, m), 1.70 - 1.73 (2H, m), 1.84 (2H, m, 3.69 - 3.77 (IH, m), 7.62 - 7.64 (IH, d), 7.93 (IH, d), 8.46 (IH, d)
MS m/e MH+ 273
Intermediate 2 o ό-chloro-N-cyclohexyl-l-propylsulfanyl-pyridine-S-carboxamide
Figure imgf000068_0001
To a solution of propane thiol (2.975 niL, 32.89 mmol)l in DMF (25 rnL) was added slowly a solution of IN NaHMDS in THF (33 ml, 33.00mmol). The mixture was stirred for tens minutes at room temperature and then added slowly to a solution of 2,6-dichloro-N-cyclohexyl- pyridine-3-carboxamide (Intermediate 1, 8.95 g, 32.89 mmol) in DMF (50 mL). The reaction was stirred at room temperature for two hours. The reaction was stopped and most of the THF and DMF was evaporated. The product was extracted with DCM (150 mL), washed with water (2 x 25 ml) and brine (25 mL). The solution was dried over MgSO4 and evaporated under reduced0 pressure to give a slightly pink solid. The solid was triturated in hexane and filtered; all of the coloured impurity went into solution to leave a white solid (7.84 g, 76%).
1H NMR (300.072 MHz, DMSOd6) δ 0.98 (3H, t), 1.21 - 1.25 (IH, m), 1.28 (3H, d), 1.59 - 1.68 (3H, m), 1.71 (IH, d), 1.73 - 1.74 (IH, m), 1.83 (2H, d), 3.04 (2H, t), 3.61-3.74 (IH, m), 7.265 (IH, d), 7.73 (IH, d), 8.30 (IH, d) MS nVe MH+ Sn
The following Examples were prepared in a similar manner to Example 1, using Intermediate 3 and an appropriate aminoester starting material:
Figure imgf000069_0001
Intermediate 3
6-chloro-N-cyclohexyl-2-(cyclopentylthio)nicotinamide
Figure imgf000070_0001
Cyclopentanethiol (7.84 niL, 73.22 mmol) was added in one portion to 2,6-dichloro-N- cyclohexylnicotinamide (20 g, 73.22 mmol) and sodium carbonate (23.28 g, 219.65 mmol) in DMF (150 mL). The resulting suspension was stirred at 60 0C for 3 hours. The mixture was cooled, evaporated, DCM (250 mL) was added and the mixture was washed with water (3x100 mL) and brine (5OmL), dried (MgSO4), filtered and evaporated to a sticky pale yellow solid. This was triturated with 4:1 hexane:ethyl acetate, filtered and dried to give 6-chloro-N-cyclohexyl-2- (cyclopentylthio)nicotinamide (13.8g, 55.6%) as a white solid.
IHNMR (400.13 MHz, DMSOd6) δ 1.1- 1.38 (5H, m), 1.46 - 1.78 (9H, m), 1.8-1.89 (2H, m), 2.1 - 2.21 (2H, m)5 3.62 - 3.73 (IH, m), 3.86 - 3.95 (IH, m), 7.25 (IH, d), 7.73 (IH, d), 8.29 (IH, d) m/z (ESI+) (M+H)+ = 339; HPLC tR - 3.16 min.
The following Examples were prepared in a similar manner to Example 1, using Intermediate 4 and an appropriate aminoester starting material:
Figure imgf000070_0002
Figure imgf000071_0002
Intermediate 4
6-chloro-N-cyclohexyl-2-cyclohexylsulfanyl-pyridine-3-carboxamide
Figure imgf000071_0001
This intermediate was prepared in an analogous manner to that of intermediate 3 IH NMR (400.13 MHz, DMSOd6) δ 1.08 - 1.47 (1OH, m), 1.54 - 1.63 (2H, m), 1.66 - 1.76 (4H, m), 1.78 - 1.86 (2H, m), 1.99 - 2.01 (2H, m), 3.66 - 3.75 (2H, m), 7.25 (IH, d), 7.71 (IH, d), 8.29 (IH, d) m/z (ESI+) (M+H)+ = 353; HPLC tR = 3.14 min
The following Examples were prepared in a similar manner to Example 1, using Intermediate 6 and an appropriate aminoester starting material:
Compound Ex Name 1H NMR δ MS m/e
MH+
59 2-[(3S)-l-[5-(2- 1H NMR (300. 072 MHz, CDCl3) 1 .02 472 adamantylcarba (3H, t), 1.30 - 1.39 (IH, m), 1.52 - 1.61 moyl)-6- (IH, m), 1.66 - ■ 1.81 (8H, m), 1.83 - propylsulfanyl- 2.10 (1 IH, m), 2.32 (2H, d), 2.78 - 2.89
1 pyridin-2-yl]-3- (IH, m), 2.97 ■ ■ 3.06 (IH, m), 3.09 - 3.26 piperidyl]acetic (2H5 m), 4.20 ■ ■ 4.31 (3H, m), 6.38 (IH, acid d), 7.20 (IH, d), 7.91 (IH, d)
Figure imgf000072_0001
Figure imgf000073_0002
Intermediate 5
N-(2-adamantyl)-2,6-dichloro-pyridine-3-carboxamide
Figure imgf000073_0001
Oxalyl chloride (8.72 ml, 100.00 mmol) was added dropwise to 2,6-dichloronicotinic acid (9.60 g, 50 mmol) and N,N-dimethylformamide (0.039 ml, 0.50 mmol) in DCM at 20 0C over a period of 10 minutes under nitrogen. The resulting suspension was stirred at 20 0C for 2 hours. The resulting mixture was evaporated to dryness and the residue was azeotroped with toluene to afford the crude acid chloride, which was dissolved in DCM (25mL) and added portionwise to a stirred solution of 2-adamantanamine hydrochloride (9.39 g, 50.00 mmol) and N- Ethyldiisopropylamine (26.1 ml, 150.00 mmol) in DCM cooled to O0C, over a period of 15 minutes under nitrogen. The resulting suspension was stirred at 20 0C for 2 hours. The reaction mixture was evaporated to dryness, stirred with water (5OmL) for 10 mins and the precipitate was collected by filtration, washed with water (2x25 mL) and dried under vacuum to afford N-(2-adamantyl)-2,6-dichloro-pyridine-3-carboxamide (16.01 g, 98
%) as a cream solid, which was used without further purification
IH NMR (400.132 MHz5 CDC13) δ 1.69 - 1.76 (2H, m), 1.79 (2H, s), 1.82 - 1.96 (8H, m), 2.07
(2H, s), 4.27 (IH, d), 6.92 - 7.01 (IH, m), 7.39 (IH, d), 8.19 (IH, d) m/z (ESI+) (M+H)+ = 325; HPLC tR = 2.66 min.
Intermediate 6
N-(2-adamantyl)-6-chloro-2-propylsulfanyl-pyridine-3-carboxamide
Figure imgf000074_0001
Propanethiol (1.45 mL, 16 mmol) was added to N-(2-adamantyl)-2,6-dichloro-pyridine-3- carboxamide (5.2 g, 16 mmol), and sodium carbonate (5.09 g, 48 mmol) in DMF (50 mL) at 2O0C under nitrogen. The resulting suspension was stirred at 60 0C for 3 hours. The reaction mixture was diluted with EtOAc (40OmL) and washed with water (3x50mL), and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product which was recrystallised from 15% ethyl acetate/hexane to give N-(2-adamantyl)-6- chloro-2-propylsulfanyl-pyridine-3-carboxamide (4.9 g, 84%)
1H NMR (300.072 MHz, CDC13) δ 1.06 (t, 3H), 1.63 - 1.84 (m, 6H), 1.85 - 1.99 (m, 8H), 2.02 - 2.14 (m, 2H), 3.24 (t, 2H), 4.22 - 4.31 (m, IH), 6.85 - 6.96 (m, IH), 7.06 (d, IH), 7.90 (d, IH) m/z (ESI+) (M+H)+ = 365; HPLC tR = 3.23min.
The following Examples were prepared in a similar manner to Example 1, using Intermediate 7 and an appropriate aminoester starting material:
Figure imgf000075_0002
Intermediate 7:
N-(2-adamantyl)-6-chloro-2-cyclopentylsulfanyl-pyridine-3-carboxamide
Figure imgf000075_0001
Anhydrous Sodium carbonate (2.201 niL, 52.58 mmol) was added in one portion to N-(2- adarnantyl)-2,6-dichloro-pyridine-3-carboxamide (5.7 g, 17.53 mmol) and cyclopentyl mercaptan (1.885 niL, 17.53 mmol) in DMF (50 niL) under nitrogen. The resulting suspension was stirred at 6O0C for 6 hours.
The reaction mixture was concentrated and diluted with DCM (150 mL), and washed sequentially with water (2x75 mL) and saturated brine (75 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. This was triturated with 4:1 isohexane:EtOAc to give the desired product (5.6g, 82%) as a white powder. IH NMR (400.13 MHz5 CDCl3) δ 1.60 -1.94 (18H5 m), 2.02-2.1 (2H5 m), 2.21 - 2.27 (2H5 m), 4.12 - 4.19 (IH5 m), 4.26 (IH, d), 6.90 (IH5 d), 7.05 (IH5 d), 7.89 (IH5 d) m/z (ESI+) (M+H)+ = 391; HPLC tR = 3.62 min. The following Examples were prepared in a similar manner to Example 1, using Intermediate 8 and an appropriate aminoester starting material:
Figure imgf000076_0001
Intermediate 8:
N-(2-adamantyl)-6-chloro-2-cyclohexylsulfanyl-pyridine-3-carboxamide
Figure imgf000076_0002
Anhydrous sodium carbonate (2.201 mL, 52.58 mmol) was added in one portion to N-(2- adamantyl)-2,6-dichloro-pyridine-3-carboxamide (5.7 g, 17.53 mmol) and cyclohexyl mercaptan (2.14 mL, 17.53 mmol) in DMF (50 mL) under nitrogen. The resulting suspension was stirred at 6O0C for 6 hours.
The reaction mixture was concentrated and diluted with DCM (150 mL), and washed sequentially with water (2x75 mL) and saturated brine (75 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. This was triturated with 4: 1 isohexane:EtOAc to give the desired product (6.5g, 92%) as a white powder. IH NMR (400.13 MHz, DMSOd6) δ 1.31 (IH, s), 1.36 - 1.42 (2H, m), 1.42 (2H, d), 1.45 (IH, s), 1.49 (IH, d), 1.53 (IH, s), 1.58 (IH, t), 1.70 (4H, d), 1.77 (IH, s), 1.82 (6H, d), 1.95 (2H, s), 1.97 - 2.00 (2H, m), 2.06 - 2.09 (2H, m), 3.76 (IH, t), 3.99 (IH, t), 7.25 (IH, d), 7.69 - 7.71 (IH, m), 8.28 (IH, d) m/z (ESI+) (M+H)+ = 405; HPLC tR = 3.77 min.
The following Examples were prepared in a similar manner to Example 1 , using Intermediate 9 and an appropriate aminoester starting material:
Figure imgf000077_0001
Intermediate 9
N-(2-adamantyl)-6-chloro-2-ethylsulfanyl-pyridine-3-carboxamide
Figure imgf000078_0001
Ethanethiol (0.433 niL, 5.84 mmol) was added to N-(2-adamantyl)-2,6-dichloro-pyridine-3- carboxamide (2 g, 6.15 mmol), and sodium carbonate (1.955 g, 18.45 mmol) in DMF (12 mL) at 200C under nitrogen. The resulting suspension was stirred at 60 0C for 3 hours. The reaction mixture was diluted with EtOAc (10OmL) and washed with water (3x20 mL), and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product which was recrystallised from 15% ethyl acetate/hexane to give N-(2-adamantyl)-6- chloro-2-ethylsulfanyl-ρyridine-3-carboxamide (1.489 g, 69 %)
1H NMR (300.072 MHz, CDC13) δ 1.40 (t, 3H), 1.66 - 1.81 (m, 4H), 1.85 - 1.96 (m, 8H), 2.03 - 2.12 (m, 2H), 3.26 (q, 2H), 4.22 - 4.31 (m, IH), 6.78 - 6.89 (m, IH), 7.06 (d, IH), 7.89 (d, IH) m/z (ESI+) (M+H)+ = 351; HPLC tR = 3.05 min.
The following Examples were prepared in a similar manner to Example 1, using Intermediate 10 and an appropriate aminoester starting material:
Figure imgf000078_0002
Figure imgf000079_0002
IntermediatelO
N-(2-adamantyl)-6-chloro-2-methylsulfanyl-pyridine-3-carboxamide
Figure imgf000079_0001
Sodium thiomethoxide (0.409 g, 5.84 mmol) was added to N-(2-adamantyl)-2,6-dichloro- pyridine-3-carboxamide (2 g, 6.15 mmol) in DMA (10 niL) at 2O0C under nitrogen. The resulting suspension was stirred at 60 0C for 3 hours. The reaction mixture was diluted with EtOAc (10OmL) and washed with water (3x20mL), and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product which was purified by
10 crystallisation from EtOAc/isohexane to afford N-(2-adamantyl)-6-chloro-2-methylsulfanyl- pyridine-3-carboxamide (1.150 g, 55.5 %) as a white solid
1H NMR (300.072 MHz, CDC13) δ 1.65 - 1.82 (m, 4H), 1.85 - 1.98 (m, 8H), 2.01 - 2.12 (m, 2H), 2.61 (s, 3H), 4.22 - 4.33 (m, IH), 6.73 - 6.82 (m, IH), 7.07 (d, IH), 7.87 (d, IH) m/z (ESI+) (M+H)+ = 337; HPLC tR = 2.97 min.
I5 The following Examples were prepared in a similar manner to Example 1, using Intermediate 12 and an appropriate aminoester starting material:
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Intermediate 11
2,6-dichloro-N-((2r,5s)-5-hydroxyadamantan-2-yl)nicotinamide
Figure imgf000083_0001
A solution of 2,6-dichloronicotinoyl chloride (25.2 g, 119.60 mmol) in DCM (100 niL) was added dropwise to a stirred suspension of 4-aminoadamantan-l-ol (20.00 g, 119.6 mmol) and N-Ethyldiisopropylamine (24.83 rnL, 143.52 mmol) in THF (400 mL) at 2O0C, over a period of 30 minutes under nitrogen. The resulting suspension was stirred at room temperature for 18 hours. The reaction mixture was diluted with EtOAc (500 mL), and washed sequentially with water (100 mL) and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford the crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford 2,6-dichloro-N-(5-hydroxyadamantan-2-yl)nicotinamide (20.65g, 51 %) as a white solid.
IHNMR (400.13 MHz, DMSO-d6) δ 1.31 - 1.38 (2H, m), 1.60 - 1.67 (4H, d), 1.69 - 1.76 (2H, m), 1.87 - 1.94 (2H, m), 1.99 - 2.00 (IH, m), 2.04 - 2.09 (2H, m), 3.91 - 3.96 (IH, m), 4.47 (IH, s), 7.64 (IH, d), 7.95 (IH, d), 8.49 (IH, d) m/z (ESI-) (M-H)- = 339; HPLC tR = 1.59 min.
Intermediate 12
6-chloro-N-((2r,5s)-5-hydroxy-2-adamantyl)-2-propylsulfanyl-pyridine-3-carboxamide
Figure imgf000083_0002
1-Propanethiol (1.327 mL, 14.65 mmol) was added in one portion to 2,6-dichloro-N-(5-hydroxy- 2-adamantyl)pyridine-3-carboxamide (5 g, 14.65 mmol) and sodium carbonate (4.66 g, 43.96 mmol) in DMF (50 mL). The resulting suspension was stirred at 60 0C for 3 hours. The mixture was cooled, evaporated, DCM (250 mL) was added and the mixture was washed with water (3x50 mL) and brine (5OmL), dried (MgSO4), filtered and evaporated to a sticky pale yellow solid. This was triturated with 4:1 hexane:ethyl acetate, filtered and dried to give the desired product as a white solid (5.Og, 90%).
IH NMR (400.13 MHz, DMSO-d6) δ 0.92 (3H, t), 1.22 - 1.3 (2H, m), 1.5 - 1.7 (8H, m), 1.85 -
1.96 (3H, m), 1.97-2.03 (2H5 s), 3.0 (2H, t), 3.83-3.9 (IH, m), 4.34 (IH, s), 7.2 (IH, d), 7.65 (IH, d), 8.18 (IH, d) m/z (ESI+) (M+H)+ = 381; HPLC tR = 2.34 min.
The following Examples were prepared in a similar manner to Example 1, using Intermediate 13 and an appropriate aminoester starting material:
Figure imgf000084_0001
Figure imgf000085_0002
Intermediate 13
6-chloro-2-cyclopentylsulfanyl-N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide
Figure imgf000085_0001
This intermediate was prepared in an analogous manner to that of intermediate 12 IH NMR (400.13 MHz, DMSO-d6) δ 1.31 - 1.37 (2H, m), 1.47 - 1.74 (12H, m), 1.94 - 2.00 (3H, m), 2.04 - 2.09 (2H, m), 2.12 - 2.20 (2H, m), 3.90 - 3.97 (2H, m), 4.39 (IH, s), 7.25 (IH, d), 7.71 (IH, d), 8.22 (IH, d) m/z (ESI+) (M+H)+ = 407; HPLC tR = 2.52 min.
The following Examples were prepared in a similar manner to Example 1, using Intermediate 14 and an appropriate aminoester starting material:
Figure imgf000086_0001
Intermediate 14
6-chloro-2-cyclohexylsulfanyl-N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide
Figure imgf000087_0001
This intermediate was prepared in an analogous manner to that of intermediate 12 IH NMR (400.13 MHz, DMSO-d6) δ 1.32 - 1.48 (7H, m), 1.56 - 1.74 (9H, m), 1.92 - 2.09 (7H, m), 3.74 - 3.79 (IH5 m), 3.88 - 3.93 (IH, m), 4.39 (IH, s), 7.25 (IH, d), 7.70 (IH, d), 8.23 (IH, d) m/z (ESI+) (M+H)+ = 421; HPLC tR = 2.64 min.
The following Examples were prepared in a similar manner to Example 1, using Intermediate 15 and an appropriate aminoester starting material:
Compound Ex Name 1H NMR δ MS m/e
MH+
10 2-[(3S)-l-[5- IH NMR (400.13 MHz, DMSO-d6) 516;
4 [[(2r,5s)-5- 0.89 (6H, d), 1.22 - 1.56 (6H5 ] m), 1.59 - HPLC
A r hydroxy-2- 1.74 (8H, m), 1.79 - 2.06 (7H, m), 2.12 - tR adamantyl]carba 2.26 (2H, m), 2.73 - 2.79 (IH, m), 2.92 - =2.46 moyl]-6-(3- 3.00 (2H, m), 3.03 - 3.11 (1H, m), 3.83 - min methylbutylsulfa 3.88 (IH, m), 4.21 - 4.29 (2H, m), 4.43 nyl)pyridin-2- (IH, s), 6 49 (IH, d), 7.61 (IH , d), 7.67 yl]-3- (IH, d), 12,16 (IH, s) piperidyl] acetic acid
Figure imgf000088_0002
Intermediate 15
6-chloro-N-((2r,5s)-5-hydroxy-2-adamantyl)-2-(3-methylbutylsulfanyl)pyridine-3-carboxamide
Figure imgf000088_0001
This intermediate was prepared in an analogous manner to that of intermediate 12
IH NMR (400.13 MHz, DMSO-d6) δ 0.86 - 0.98 (6H, m), 1.30 - 1.38 (2H, m), 1.48 - 1.53 (2H, m), 1.62 - 1.74 (7H3 m), 1.94 - 2.00 (3H, m), 2.07 - 2.10 (2H, m), 3.07 - 3.11 (2H, m), 3.89 - 3.94
(IH, m), 4.39 (IH, s), 7.26 (IH, d), 7.72 (IH, d), 8.23 (IH, d) m/z (ESI+) (M+H)+ = 409; HPLC tR = 2.61 min.
The following Example was prepared in a similar manner to Example 1 , using Intermediate 16 and an appropriate aminoester starting material: Compound Ex Name 1H NMR δ MS m/e
MH+
10 2-[(3S)-l-[6- IH NMR (400.13 MHz5 DMSO-d6) 536;
A 7 ben2ylsulfanyl- 1.21 - 1.46 (4H, m), 1.57 - • 1.73 (8H, m), HPLC
Λ JO 5-[[(2r,5s)-5- 1.78 - 2.05 (7H, m), 2.11 - - 2.24 (2H, m), tR hydroxy-2- 2.72 - 2.80 (IH, m), 2.92 - ■ 3.00 (IH, m), =2.30 adamantyl]carba 3.82 - 3.87 (IH, m), 4.17 ■ 4.35 (4H, m), min moyl]pyridin-2- 6.51 (IH, d), 7.19 - 7.23 (IH, m), 7.26 - yl]-3- 7.28 (2H, m), 7.35 - 7.37 ^H, m), 7. 65 - piperidyljacetic 7.70 (2H, m) acid
Intermediate 16
2-benzylsulfanyl-6-chloro-N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide
Figure imgf000089_0001
This intermediate was prepared in an analogous manner to that of intermediate 12
1H NMR (400.13 MHz, DMSOd6) δl.28 - 1.35 (2H, m), 1.58 - 1.73 (6H, m), 1.89 - 2.06 (5H, m), 3.86 - 3.90 (IH, m), 4.33 (2H, s), 4.44 (IH, s), 7.21 - 7.25 (IH, m), 7.28 - 7.32 (3H, m), 7.40
- 7.44 (2H, m), 7.78 (IH, d), 8.30 (IH, d) m/z (ESI+) (M+H)+ = 429; HPLC tR = 2.44 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 17 and an appropriate aminoester starting material:
Compound Ex Name 1H NMR δ MS m/e
MH+ oΛ O 10 2-[(3S)-l-[5- IH NMR (400.13 MHz5 : DMSO-dβ) 550;
A J 8 [[(2r,5s)-5- 1.21 - 1. 51 (4H, m), 1.59 - 1.74 (7H, m), HPLC hydroxy-2- 1.79 - 2 06 (8H, m), 2.10 - 2.22 (2H, m), tR adamantyljcarba 2.74 - 2. 80 (IH, m), 2.87 - 3.02 (3H, Hl), =2.41 moyl]-6- 3.22 - 3.40 (2H, m), 3.83 - 3.88 (IH, m), min phenethylsulfany 4.24 - 4 30 (IH, m), 4.43 (IH, s), 6.52 l-pyridin-2-yl]-3- (IH, d), 7.1 8 - 7 .31 (5H, m), 7.62 - 7 .68 piperidyl] acetic (2H, d), 12 .17 (IH, s) acid
Intermediate 17
6-chloro-N-((2r,5s)-5-hydroxy-2-adamantyl)-2-plienetliylsulfanyl-pyridine-3-carboxaniide
Figure imgf000090_0001
1H NMR (400.13 MHz, DMSO-d6) δl.29 - 1.37 (2H, m), 1.60 - 1.66 (4H, m), 1.68 - 1.75 (2H, m), 1.91 - 2.08 (5H, m), 2.89 - 2.93 (2H, m), 3.27 - 3.33 (2H, m), 3.87 - 3.92 (IH, m), 4.46 (IH, s), 7.20 - 7.26 (IH, m), 7.30 - 7.34 (5H, m), 7.77 (IH, d), 8.30 (IH, d) m/z (ESI+) (M+H)+ = 443; HPLC tR = 2.59 min
The following Examples were prepared in a similar manner to Example 1, using Intermediate 18 and an appropriate aminoester starting material:
Figure imgf000091_0002
Intermediate 18
6-chloro-N-((2r,5s)-5-hydroxy-2-adamantyl)-2-propoxy-pyridine-3-carboxamide
Figure imgf000091_0001
Bis-sodium hexamethyldisilylamide 1.0M in THF (1 ml,l mmol) was added to 2,6-dichloro-N- (5~hydroxyadamantan-2-yl)nicotinamide (341mg,lmmol) and heated at 150 0C for 2 hours. The reaction mixture was diluted with EtOAc (60 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford 6-chloro- iV-(5-hydroxyadamantan-2-yl)-2-propoxynicotinamide (341 mgs, 93 %) as a white solid. 1H NMR (400.13 MHz, DMSOd6) 50.99 (3H, t), 1.41 - 1.45 (2H, m), 1.64 - 1.67 (4H, m), 1.72 - 1.84 (5H, m), 2.01 - 2.08 (3H, m), 3.96 - 4.01 (IH, m), 4.34 (2H, t), 4.49 (IH, s), 7.22 (IH, d), 8.1O (1H, d), 8.16 (IH, d) m/z (ESI+) (M+H)+ = 365; HPLC tR = 2.39 min
Example 111
(lR,5S,6r)-3-(6-(Cvclopentylthio)-5-(3-(pyridin-3-vI)pyrrolidine-l-carbonyI)pyridin-2-yl)-3- azabicvcIo[3.1.01hexane-6-carboxyIic acid
Figure imgf000092_0001
0
Lithium hydroxide monohydrate (102 mg, 2.44 mmol) was added to a stirred solution of (lR,5S,6r)-methyl 3-(6-(cyclopentylthio)-5-(3-(pyridin-3-yl)pyrrolidine-l-carbonyl)pyridin-2- yl)-3-azabicyclo[3.1.0]hexane-6-carboxylate (400 mg, 0.81 mmol) in methanol (5 mL)/water (2 rnL). The resulting solution was stirred at ambient temperature for 24 hours. The bulk of thes organic solvent was removed in vacuo and the resulting solution was acidified with IN citric acid. The resulting suspension was extracted with EtOAc (3 x 30ml). The combined organic layers were washed with HCl solution (pH3, 3OmL), sat brine (3OmL) then dried (MgSO4), filtered and evaporated to yield (lR,5S,6r)-3-(6-(cyclopentylthio)-5-(3-(pyridin-3-yl)pyrrolidine- l-carbonyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid (195mg, 50%) 0 IH NMR (400.13 MHz, DMSO-d6) 1.25 (IH, s), 1.40 (IH, s), 1.50 - 1.72 (6H, m), 1.90 - 2.10 (IH, m), 2.10 - 2.20 (3H, m), 2.29 - 2.35 (IH, m), 3.30 - 3.55 (5H, m), 3.64 (IH, s), 3.72 - 3.95 (3H, m), 4.01 - 4.07 (IH, m), 6.16 (IH, d), 7.30 - 7.80 (2H, m), 7.71 (IH, s), 8.40 - 8.60 (2H, m), 12.18 (IH, s) m/z (ESI+) (M+H)+ = 479 5 The (lR,5S,6r)-methyl 3-(6-(cyclopentylthio)-5-(3-(pyridin-3-yl)pyrrolidine-l- carbonyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxylate used as starting material was prepared as described below
Oxalyl chloride (0.274 rnL, 3.15 mmol) was added dropwise to a stirred solution of 2- (cyclopentylthio)-6-((lR,5S,6r)-6-(methoxycarbonyl)-3-azabicyclo[3.1.0]hexan-3-yl)nicotinico acid (380 mg, 1.05 mmol) in DCM (5 mL)/DMF (1 drop) at 0 0C, under nitrogen. The resulting solution was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was evaporated to dryness and redissolved in DCM (8 mL). The solution was cooled to 0 0C then treated with a solution of 3-pyrrolidin-3-ylpyridine (171 mg, 1.15 mmol) and triethylamine (0.438 mL, 3.15 mmol) in DCM (5mL). The resulting reaction was allowed to warm to ambient temperature and stirred at this temperature for 2 hours. The reaction mixture was diluted with DCM (50 mL), and washed sequentially with IN citric acid (30 mL), water (30 mL), and saturated brine (30 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford (lR,5S,6r)-methyl 3-(6-(cyclopentylthio)-5-(3-(pyridin-3-yl)pyrrolidine-l- carbonyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxylate (400 mg, 77 %) as ayellow oil. m/z (ESI+) (M+H)+ = 493; HPLC tR= 1.84 min.
IH NMR (400.13 MHz, CDC13) δ 1.58 - 1.70 (4H, m), 1.71 - 1.80 (3H, m), 2.11 - 2.20 (3H, m), 2.25 (2H, s), 2.36 (IH, s), 3.40 - 3.60 (4H, m), 3.69 (4H, s), 3.74 - 3.87 (4H, m), 4.05 - 4.12 (2H, m), 5.99 (IH, d), 7.20 - 7.30 (2H, m), 7.57 (IH, s), 8.40 - 8.60 (IH, m)
The 2-(cyclopentylthio)-6-((lR,5S,6r)-6-(methoxycarbonyl)-3-azabicyclo[3.1.0]hexan-3- yl)nicotinic acid used as starting material was prepared as described below
A solution of (lR,5S,6r)-methyl 3-(5-(tert-butoxycarbonyl)-6-(cyclopentylthio)pyridin-2- yl)-3-azabicyclo[3.1.0]hexane-6-carboxylate (Intermediate 21, 968 mg, 2.31 mmol) in hydrogen chloride (4M in dioxane) (30 ml, 120.00 mmol) was stirred at ambient temperature for 5 hours. The solvent was removed in vacuo to yield 2-(cyclopentylthio)-6-((lR,5S,6r)-6- (methoxycarbonyl)-3-azabicyclo[3.1.0]hexan-3-yl)nicotinic acid (760 mg, 91 %) as ayellow solid, m/z (ESI+) (M+H)+ = 363; HPLC tR = 2.48 min. IH NMR (300.072 MHz, CDC13) δ 1.50 - 1.80 (7H, m), 2.10 - 2.25 (2H, m), 2.29 (2H, s), 3.61 - 3.71 (5H, m), 3.80 - 4.00 (2H, m), 4.02 - 4.11 (IH, m), 6.00 (IH, d), 8.03 (IH, d)
Intermediate 19 tert-butyl 2,6-dichloropyridine-3-carboxylate
Figure imgf000093_0001
A suspension of 2,6-dichloronicotinic acid (15 g, 78.13 mmol) in Toluene (170 mL) was warmed to 90 0C under nitrogen. To this suspension was added N,N-dimethylformamide di-tert-butyl acetal (74.9 mL, 312.50 mmol) dropwise. The resulting solution was stirred at 90 0C for 5 hours. The reaction mixture was evaporated to dryness and redissolved in EtOAc (200 mL), and washed sequentially with saturated NaHCO3 (100 mL) and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 10 to 30% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford tert-butyl 2,6-dichloronicotinate (17.13 g, 88 %) as a pale yellow oil. • IH NMR (300.073 MHz, DMSO-d6) δ 1.54 (9H, s), 7.67 (IH, d), 8.23 (IH, d)
Intermediate 20 methyl (lR,5S)-3-[6-chloro-5-[(2-methylpropan-2-yl)oxycarbonyl]pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxylate
Figure imgf000094_0001
A suspension of (lR,5S,6r)~methyl 3-azabicyclo[3.1.0]hexane-6-carboxylate (2.99 g, 21.16 mmol), tert-butyl 2,6-dichloronicotinate (5g, 20.15 mmol) and triethylamine (3.37 mL, 24.18 mmol) in DMA (50 mL) was stirred at ambient temperature overnight. The reaction mixture was evaporated to dryness and redissolved in EtOAc (150 mL), and washed sequentially with IN citric acid (50 mL), water (50 mL), and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 10 to 30% EtOAc in isohexane. Pure fractions were evaporated to afford (lR,5S,6r)-methyl 3-(5-(tert-butoxycarbonyl)-6-chloropyridin-2-yl)-3- azabicyclo[3.1.0]hexane-6-carboxylate (2.18g, 31%)
IH NMR (400.13 MHz, CDC13) δ 1.47 (IH, t), 1.50 (9H, s), 2.19 - 2.21 (2H, m), 3.50 - 3.53 (2H, m), 3.62 (3H, s), 3.77 (2H, d), 6.12 (IH, d), 7.86 (IH, d) m/z (ESI+) (M+H)+ = 353; HPLC tR = 2.75 min. Intermediate 21 methyl (lR,5S)-3- [6-cy clopentylsulfany 1-5 - [(2-methy lpropan-2-yl)oxy carbony l]pyridin-2-y 1] -3 - azabicyclo[3.1.0]hexane-6-carboxylate
Figure imgf000095_0001
Cyclopentanethiol (1.157 mL, 10.81 mmol) was added to a stirred suspension of potassium tert-butoxide (0.416 g, 3.71 mmol) in DMA (4ml). The resulting suspension was stirred at ambient temperature for 10 minutes under nitrogen then treated with a solution of (lR,5S,6r)-methyl 3-(5-(tert-butoxycarbonyl)-6-chloropyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6- carboxylate (1.09 g, 3.09 mmol) in DMA (5ml). The resulting reaction was stirred at ambeint temperature for 2 hours then treated with sat NH4C1 solution (15ml). The reaction mixture was diluted with EtOAc (75 mL), and washed sequentially with saturated NH4C1 (25 mL), water (50 mL), and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 10 to 30% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford (lR,5S,6r)-methyl 3-(5-(tert-butoxycarbonyl)-6-(cyclopentylthio)pyridin-2- yl)-3-azabicyclo[3.1.0]hexane-6-carboxylate (0.968 g, 74.9 %) as a colourless oil. IH NMR (300.072 MHz, CDC13) δ 1.55 - 1.82 (16H, m), 2.10 - 2.22 (2H, m), 2.27 (2H, t), 3.60 (2H, d), 3.70 (3H, s), 3.87 (2H, d), 4.00 - 4.08 (IH, m), 5.95 (IH, d), 7.90 (IH, d) m/z (ESI+) (M+H)+ = 419; HPLC tR = 3.43 min. The following Examples were prepared in a similar manner to Example 111, using
Intermediate 22 and an appropriate aminoester starting material:
Figure imgf000096_0002
Intermediate 22 methyl ( 1 R,5 S)-3 - [ό-cyclohexylsulfanyl-S- [(2-methylpropan-2-yl)oxycarbonyl]pyridin-2-yl]-3 - azabicyclo[3.1.0]hexane-6-carboxylate
Figure imgf000096_0001
Intermediate 22 was prepared from intermediate 20 using an analogous method to that used to prepare intermediate 21
IH NMR (400.13 MHz, CDC13) δ 1.24 - 1.46 (5H, m), 1.49 (9H, s), 1.52 (IH, t), 1.55 - 1.65
(IH, m), 1.73 - 1.76 (2H, m), 2.00 - 2.10 (2H, m), 2.20 - 2.22 (2H, m), 3.52 (2H, d), 3.63 (3H, s),
3.70 - 3.85 (3H, m), 5.87 (IH, d), 7.83 (IH, d) m/z (ESI+) (M+H)+ = 433; HPLC tR = 3.60 min.
The following Examples were prepared in a similar manner to Example 111, using Intermediate 24 and an appropriate aminoester starting material:
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0003
Intermediate 23 tert-butyl 2-chloro-6- [(3 S)-3 -(methoxy carbony lmethy I)- 1 -piperidy ljpyridine- 3 -carboxy late
Figure imgf000100_0001
Intermediate 23 was prepared from intermediate 19 using an analogous method to that used to prepare intermediate 20
1HNMR (499.8 MHz, CDCl3) δl.23 - 1.31 (IH, m), 1.48 - 1.60 (1OH, m), 1.69 - 1.74 (IH, m),
1.87 - 1.90 (IH, m), 2.01 - 2.05 (IH, m), 2.21 - 2.33 (2H, m), 2.80 - 2.85 (IH, m), 3.00 - 3.05
(IH, m), 3.68 (3H, s), 4.18 (2H, d), 6.45 - 6.47 (IH, m), 7.90 - 7.92 (IH, m) m/z (ESI+) (M+H)+ = 369; HPLC tR = 2.99 min.
Intermediate 24 tert-butyl 6- [(3 S)-3 -(methoxy carbonylmethy I)- 1 -piperidyl]-2-propylsulfanyl-pyridine-3 - carboxylate
Figure imgf000100_0002
Intermediate 24 was prepared from intermediate 23 using an analogous method to that used to prepare intermediate 21
1H NMR (400.13 MHz, CDCl3) δl.04 (3H, t), 1.30 - 1.37 (IH, m), 1.53 - 1.63 (1OH, m), 1.62 - 1.79 (3H, m), 1.89 - 1.93 (IH, m), 2.03 - 2.10 (IH, m), 2.23 - 2.34 (2H, m), 2.74 - 2.87 (IH, m), 2.99 - 3.10 (3H, m), 3.69 (3H, s), 4.28 (2H, t), 6.28 (IH, d), 7.92 (IH, d) m/z (ESI+) (M+H)+ = 409; HPLC tR = 3.49 min.
The following Examples were prepared in a similar manner to Example 111, using Intermediate 25 and an appropriate aminoester starting material:
Figure imgf000101_0002
Intermediate 25: tert-butyl 2-cyclopentylsulfanyl-6-[(3S)-3-(methoxycarbonylmethyl)-l-piperidyl]pyridine-3- carboxylate
Figure imgf000101_0001
Intermediate 25 was prepared from intermediate 23 using an analogous method to that used to prepare intermediate 21 The following Examples were prepared in a similar manner to Example 1, using Intermediate 26 and an appropriate aminoester starting material:
Figure imgf000102_0002
Intermediate 26
6-chloro-N-cyclohexyl-2-phenethylsulfanyl-pyridine-3-carboxamide
Figure imgf000102_0001
To a solution of 2-phenylethanethiol (295 μl, 2.2 mmol) in DMF (3 ml) was added NaHMDS (2.2 ml, 2.2 mmol). The reaction was stirred at ambient temperature for 2 minutes then added to a solution of 2,6-dichloro-N-cyclohexyl-pyridine-3-carboxamide (Intermediate 1, 600mg, 2.2 mmol) in DMF (2 ml). The reaction was stirred at ambient temperature for one hour. The solvent was evaporated under reduced pressure and.the resulting residue was partitioned between citric acid (20 ml) and EtOAc (40 ml). The layers were separated and the organic layer was washed with sat NaHCO3 (20 ml), water (20 ml) and brine (10 ml), then dried (MgSO4), filtered and evaporated to a solid. This solid was triturated with EtOAc/IH (1 :9) to yield the product as a white solid (700mg, 85%).
1H NMR (400.13 MHz, DMS0-d6) δl.l l - 1.35 (5H, m), 1.57 - 1.60 (IH, m), 1.70 - 1.73 (2H, m), 1.78 -1.85 (2H, m), 2.85 - 2.95 (2H, m), 3.25 - 3.29 (2H, m), 3.65 - 3.72 (IH, m), 7.20 - 7.27
(IH, m), 7.28 - 7.34 (5H, m), 7.79 (IH, d), 8.38 (IH5 d) m/z (ESI+) (M+H)+ = 375; HPLC tR = 3.04 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 27 and an appropriate aminoester starting material:
Figure imgf000103_0002
Intermediate 27
6-chloro-N-cyclohexyl-2-(2-pyridin-3-ylethylsulfanyl)pyridine-3-carboxamide
Figure imgf000103_0001
Intermediate 27 was made in an analogous method to intermediate 26
1H NMR (300.072 MHz, CDCl3) δl.16 - 1.34 (3H, m), 1.35 - 1.50 (2H, m), 1.61 - 1.78 (4H5 m), 1.95 - 2.07 (IH, m), 2.97 - 3.05 (2H, m), 3.38 - 3.45 (2H, m), 3.92 - 4.04 (IH5 m), 6.16 (IH, d), 7.06 (IH, d), 7.21 - 7.25 (IH, m), 7.62 - 7.66 (IH, m), 7.76 (IH, d), 8.45 - 8.48 (IH, m), 8.55 (IH, d) m/z (ESI+) (M+H)+ = 376; HPLC tR = 1.49 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 28 and an appropriate aminoester starting material:
Figure imgf000104_0002
Intermediate 28
6-chloro-N-cyclohexyl-2-(2-pyrazin-2-ylethylsulfanyl)pyridine-3-carboxamide
Figure imgf000104_0001
Intermediate 28 was made in an analogous method to intermediate 26
1H NMR (400.13 MHz5 DMSO-d6) δl.05 - 1.35 (5H, m), 1.53 - 1.63 (IH, m), 1.68 -1.75 (2H, m), 1.75 - 1.83 (2H, m), 3.16 (2H, t), 3.46 (2H, t), 3.63 - 3.68 (IH, m), 7.31 (IH, d), 7.79 (IH, d),
8.37 (IH, d), 8.51 (IH, d), 8.59 - 8.61 (2H, m) m/z (ESI+) (M+H)+ = 377; HPLC tR = 2.20 min.
The following Example was prepared in a similar manner to Example 1 , using Intermediate 29 and an appropriate aminoester starting material:
Figure imgf000105_0002
Intermediate 29 ό-chloro-iV-cyclohexy nicotinamide
Figure imgf000105_0001
s To a solution of 6-chloronicotinic acid (778 mg, 5 mmol) and 1-hydroxybenzotriazole
(565 mg, 5.43 mmol) stirred in dichloromethane (25 ml) was added triethylamine (1.5 ml, 10.86 mmol), followed by EDACHCl (1.04 g, 5.43 mmol). After 5 minutes cyclohexylamine (565 ul, 5 mmol) was added and stirring was continued for a further 16 hours.
The reaction was diluted with dichloromethane (50 ml) and extracted with sat. NaHCO3 solution0 (50 ml), IMHCl (50 ml), water (50 ml), brine (50 ml) and then dried over MgSO4, filtered and the solvent removed in vacuo to give 6-chloro-iV-cyclohexylnicotinamide (950 mg, 79%) as a cream solid.
1H NMR (400.13 MHz, DMSOd6) δl.12 - 1.18 (IH, m), 1.24 - 1.35 (4H, m), 1.61 (IH, d), 1.73 -
1.75 (2H, m), 1.81 - 1.82 (IH5 m), 1.84 (IH, d), 3.74 - 3.78 (IH, m), 7.63 - 7.65 (IH, m), 8.22 -s 8.25 (IH, m), 8.49 (IH, d), 8.81 - 8.82 (IH, m)
MS m/e (M-H)+ 237
The following Example was prepared in a similar manner to Example 1, using
Intermediate 30 and an appropriate aminoester starting material: 0
Figure imgf000106_0002
Intermediate 30 iV-adamantan-2-yl-6-chloronicotinamide
Figure imgf000106_0001
Intermediate 30 was prepared using an analogous method to that used to prepare intermediate 29 1H NMR (400.13 MHz, DMSOd6) δl.52 (2H, d), 1.72 (2H, s), 1.78 - 1.85 (6H, m), 1.98 (2H, s), 2.11 (2H5 d), 4.04 (IH, t), 7.61 - 7.63 (IH5 m), 8.21 - 8.29 (2H, m), 8.79 - 8.80 (IH, m) MS m/e (M+H)+ 291
The following Example was prepared in a similar manner to Example 1, using Intermediate 31 and an appropriate aminoester starting material:
Figure imgf000106_0003
Intermediate 31
6-chloro-N-cyclohexyl-2-[2-(4-fluorophenyl)ethoxy]nicotinamide
Figure imgf000107_0001
2,6-dichloro-N-cyclohexylnicotinamide (Intermediate 1, 273 mg, 1 mmol) was stirred in 1,4- dioxane (4 ml). To this solution was added 4-fluorophenethyl alcohol (154 mg, 1.1 mmol) followed by bis-sodium hexamethyldisilylamide 1.0M in THF (1.1 ml, 1.1 mmol). The tube was sealed and subjected to microwave heating 150 °C (Biotage Initiator 300W) for 2 hours. The solvent was evaporated and the residue was diluted with water (15 ml) and extracted with dichloromethane (2x20 ml). The combined extract was washed with brine (20 ml) dried over MgSO4, filtered and evaporated. The crude product was purified on SiO2 (40 g) eluting with ethyl acetate/isohexane 0-40% and gave 6-chloro-iV-cyclohexyl-2-[2-(4- fluorophenyl)ethoxy]nicotinamide (153 mg, 40%) as a white solid
1HNMR (400.13 MHz, DMSO-d6) δθ.99 - 1.33 (5H, m), 1.54 - 1.74 (5H3 m), 3.10 (2H, t), 3.65 - 3.72 (IH, m), 4.63 (2H, t), 7.12 - 7.18 (2H, m), 7.21 (IH, d), 7.35 - 7.39 (2H, m), 7.70 (IH, d), 8.11 (IH, d)
MS m/e (M+H)+ 377.
The following Example was prepared in a similar manner to Example 1, using Intermediate 32 and an appropriate aminoester starting material:
Figure imgf000107_0002
Intermediate 32
6-chloro-N-cyclohexyl-2-isoamylnicotinamide
Figure imgf000108_0001
Intermediate 32 was prepared using an analogous method to that used to prepare intermediate 31
1HNMR (400.13 MHz, DMSOd6) δθ.94 (6H, d), 1.17 - 1.24 (IH, m), 1.28 (2H, d), 1.36 (2H5 1), 1.55 - 1.59 (IH, m), 1.63 - 1.71 (2H, m), 1.66 - 1.71 (2H, m), 1.75 - 1.83 (2H, m), 1.85 (IH, s), 3.77 (IH, t), 4.38 (2H, t), 7.20 (IH, d), 7.94 (IH, d), 8.09 (IH, d) MS m/e (M+H)+325
The following Example was prepared in a similar manner to Example 1, using Intermediate 33 and an appropriate aminoester starting material:
Figure imgf000108_0003
Intermediate 33
6-chloro-iV-cyclohexyl-2-(3-phenylpropoxy)nicotinamide
Figure imgf000108_0002
Intermediate 33 was prepared using an analogous method to that used to prepare intermediate 31 1H NMR (400.13 MHz, DMSOd6) δl.23 (5H, d), 1.56 (IH, d), 1.69 (2H, d), 1.86 (2H, d), 2.04 - 2.11 (2H, m), 2.77 (2H, t), 3.77 - 3.80 (IH, m), 4.33 (2H, t), 7.18 - 7.21 (2H, m), 7.22 - 7.24 (2H, m), 7.28 - 7.32 (2H, m), 8.02 (IH, d), 8.07 (IH, d) MS m/e (M+H)+373.
The following Example was prepared in a similar manner to Example 1, using Intermediate 34 and an appropriate aminoester starting material:
Figure imgf000109_0002
IQ Intermediate 34
6-chloro-iV-cyclohexyl-2-(2-pyridin-3-ylethoxy)nicotinamide
Figure imgf000109_0001
Intermediate 34 was prepared using an analogous method to that used to prepare intermediate 31 1H NMR (400.13 MHz, DMSOd6) δl.01 - 1.05 (IH, m), 1.08 (IH, s), 1.10 - 1.11 (IH, m), 1.14 -
I5 1.18 (IH, m), 1.25 (IH, d), 1.53 - 1.57 (IH, m), 1.62 - 1.66 (2H, m), 1.69 - 1.74 (2H, m), 3.13 (2H, t), 3.66 - 3.70 (IH, m), 4.65 (2H, t), 7.21 (IH, d), 7.33 - 7.36 (IH, m), 7.73 - 7.78 (2H, m), 8.08 (IH, d), 8.45 - 8.46 (IH, m), 8.54 (IH, d) MS m/e (M+H)+ 360
The following Examples were prepared in a similar manner to Example 1, using Intermediate 35 and an appropriate aminoester starting material:
Figure imgf000110_0002
Intermediate 35
6-chloro-N-cyclohexyl-2-methoxynicotinamide
Figure imgf000110_0001
Intermediate 35 was prepared using an analogous method to that used to prepare intermediate 31 1H NMR (499.8 MHz, DMSOd6) δl.19 (IH, d), 1.27 - 1.37 (4H, m), 1.57 - 1.59 (IH, m), 1.71 (2H, t), 1.83 (2H, d), 3.77 (IH, d), 3.97 (3H, d), 7.19 - 7.21 (IH, m), 7.97 (IH, d), 8.05 - 8.07 (IH, m) MS m/e (M+H)+ 269
The following Examples were prepared in a similar manner to Example 1, using Intermediate 36 and an appropriate aminoester starting material:
Figure imgf000111_0002
Intermediate 36
6-chloro-N-cyclohexyl-2-propoxynicotinamide
Figure imgf000111_0001
Intermediate 36 was prepared using an analogous method to that used to prepare intermediate 31 IH NMR (400.13 MHz, DMSO-d6) δl.00 (3H, t), 1.17 - 1.39 (5H, m), 1.54 - 1.57 (IH, m), 1.67 1.70 (2H, m), 1.75 - 1.81 (2H, m), 1.84 (2H, s), 3.76 - 3.79 (IH, m), 4.30 (2H, t), 7.20 (IH, d), 7.97 (IH, d), 8.09 (IH, d) MS m/e (M+H)+ 297
The following Example was prepared in a similar manner to Example 1, using Intermediate 37 and an appropriate aminoester starting material:
Figure imgf000111_0003
Intermediate 37
6-chloro-iV-cyclohexyl-2-piperidin- 1 -ylnicotinamide
Figure imgf000112_0001
2,6-dichloro-N-cyclohexylnicotinamide (273 mg, 1 mmol), piperidine (109 ul, 1.1 mmol) and potassium carbonate (345 mg, 2.5 mmol) in butyronitrile (4 ml) were sealed in a microwave tube and heated (Biotage initiator) at 150 °C for 1 hour. The reaction was diluted with water (25 ml) and extracted with dichloromethane (2x25 ml). The combined extracts were dried over MgSO4, filtered and evaporated. The crude product was purified on SiO2 (12 g) eluting with ethyl
10 acetate/isohexane 0-30% and gave 6-chloro-2 (piperidine)-N-cyclohexy nicotinamide (lOOmg, 33%) as a white powder.
1H NMR (400.13 MHz, DMSO-d6) δl.21 (5H, d), 1.56 - 1.60 (7H, m), 1.69 - 1.73 (2H, m), 1.83 (2H, d), 3.29 - 3.30 (4H, m), 3.65 - 3.68 (IH, m), 6.80 (IH, d), 7.55 (IH, d), 8.31 (IH, d) MS m/e (M+H)+ 322
I5 The following Example was prepared in a similar manner to Example 1, using Intermediate 38 and an appropriate aminoester starting material:
Figure imgf000112_0002
Intermediate 38
2o 6-chloro-2-{[2-(4-chloroρhenyl)ethyl]amino}-JV-cyclohexylnicotinamide
Figure imgf000113_0001
Intermediate 38 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSOd6) δl.09 - 1.29 (5H, m), 1.58 - 1.78 (5H, m), 2.85 (2H, t), 3.57 (2H, q), 3.68 (IH, d), 6.62 (IH, d), 7.28 (2H, d), 7.35 (2H, d), 7.94 (IH, d), 8.25 (IH, d), 8.62 (IH, t) MS m/e(M+H)+393.
The following Example was prepared in a similar manner to Example 1, using Intermediate 39 and an appropriate aminoester starting material:
Figure imgf000113_0003
Intermediate 39
6-chloro-N-cyclohexyl-2-[3-(4-fluorophenyl)pyrrolidin-l-yl]nicotinamide
Figure imgf000113_0002
Intermediate 39 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSOd6) δl.19 (5H, d), 1.66 (5H, d), 1.96 - 2.02 (IH, m), 2.26 - 2.28 (IH, m), 3.39 (IH, d), 3.44 (IH, d), 3.51 - 3.55 (2H, m), 3.63 - 3.66 (IH, m), 3.71 - 3.75 (IH, m), 6.65 (IH, d), 7.14 - 7.19 (2H5 m), 7.32 - 7.36 (2H, m), 7.46 (IH, d), 8.31 (IH, d) MS m/e (M+H)+402.
The following Example was prepared in a similar manner to Example 1, using Intermediate 40 and an appropriate aminoester starting material:
Figure imgf000114_0002
Intermediate 40
6-chloro-N-cyclohexyl-2-(354-dihydroisoquinolin-2(lH)-yl)nicotinamide
Figure imgf000114_0001
Intermediate 40 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz5 DMSO-d6) δl.05 - 1.40 (5H5 m), 1.53 - 1.61 (IH5 m), 1.71 (IH, d), 1.68 - 1.73 (IH, m), 1.85 (2H, d),2.90 (2H5 m) 3.63 (2H5 1), 3.68 - 3.76 (IH5 m), 4.47 - 4.57 (2H5 m), 6.82 (IH, t), 7.15 - 7.19 (4H5 m), 7.56 (IH, d), 8.35 (IH5 d) MS m/e (M+H)+ 370
The following Example was prepared in a similar manner to Example 1 , using Intermediate 41 and an appropriate aminoester starting material:
Figure imgf000115_0002
Intermediate 41
6-chloro-iV-cyclohexyl-2-(4-phenylpiperazin- 1 -yl)nicotinamide
Figure imgf000115_0001
Intermediate 41 was prepared using an analogous method to that used to prepare intermediate 37
1H NMR (400.13 MHz, DMSOd6) δl.15 - 1.33 (5H, m), 1.51-1.61 (IH, m), 1.68-1.77 (2H, m), 1.80-1.91 (2H, m), 3.22 (IH, s), 3.24 (3H, t), 3.49 (4H, t), 3.71 (IH, t), 6.80 (IH, t), 6.88 (IH, d), 6.96 - 6.99 (2H, m), 7.22 - 7.26 (2H, m), 7.61 (IH, d), 8.32 (IH, d) MS m/e (MH-H)+ 399.
The following Example was prepared in a similar manner to Example 1, using Intermediate 42 and an appropriate aminoester starting material:
Figure imgf000116_0002
Intermediate 42
6-chloro-iV-cycloliexyl-2-[4-(4-fluorobenzoyl)piperazin-l-yl]nicotinamide
Figure imgf000116_0001
Intermediate 42 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSOd6) δl.02-1.35 (6H, m), 1.58 (IH, d), 1.71 (2H, d), 1.83 (2H, d), 3.39 (5H, s), 3.64 - 3.69 (3H5 m), 6.90 (IH, d), 7.27 - 7.32 (2H, m), 7.51 - 7.54 (2H, m), 7.61 (IH, d), 8.36 (IH, d) MS m/e (M+H)+445.
The following Example was prepared in a similar manner to Example 1, using Intermediate 43 and an appropriate aminoester starting material:
Figure imgf000117_0002
Intermediate 43
2-(4-acetylpiperazin- 1 -yl)-6-chloro-iV-cyclohexylnicotinamide
Figure imgf000117_0001
Intermediate 43 was prepared using an analogous method to that used to prepare intermediate 37
1HNMR (400.13 MHz, DMSO-d6) 51.21 (5H, d), 1.59 (IH, d), 1.72 (2H, d), 1.84 (2H, d), 2.01
(3H, s), 3.36 - 3.39 (4H, m), 3.52 (4H, q), 3.66 - 3.70 (IH, m), 6.88 (IH, d), 7.60 (IH, d), 8.36
(IH, d)
MS m/e (M+H)+365.
The following Example was prepared in a similar manner to Example 1, using Intermediate 44 and an appropriate aminoester starting material:
Figure imgf000117_0003
Intermediate 44
6-chloro-iV-cyclohexyl-2-[4-(ethylsulfonyl)piperazin-l-yl]nicotinamide
Figure imgf000118_0001
Intermediate 44 was prepared using an analogous method to that used to prepare intermediate 37 IH NMR (400.13 MHz, DMSO-d6) δ 1.11 - 1.35 (8H, m), 1.54 - 1.62 (IH, m), 1.71 (2H, d), 1.83 (2H, s), 3.11 (2H, q), 3.25 (4H, t), 3.39 - 3.42 (4H, m), 3.63 - 3.70 (IH, m), 6.90 (IH, d), 7.60 (IH, d), 8.36 (IH, d) MS m/e (M+H)+415
The following Example was prepared in a similar manner to Example 1, using Intermediate 45 and an appropriate aminoester starting material:
Figure imgf000118_0003
Intermediate 45
6-chloro-iV-cyclohexyl-2- [4-(phenylsulfonyl)piperazin- 1 -yl]nicotinamide
Figure imgf000118_0002
Intermediate 45 was prepared using an analogous method to that used to prepare intermediate 37 MS m/e (M+H)+464.
The following Example was prepared in a similar manner to Example 1, using Intermediate 46 and an appropriate aminoester starting material:
Figure imgf000119_0002
Intermediate 46 benzyl 4-[6-chloro-3-(cyclohexylcarbamoyl)pyridin-2-yl]piperazine-l-carboxylate
Figure imgf000119_0001
Intermediate 46 was prepared using an analogous method to that used to prepare intermediate 37
IH NMR (400.13 MHz, DMSOd6) δ 1.05-1.35 (5H, m), 1.58 (IH, d), 1.71 (2H, d), 1.83 (2H, d), 3.4-3.48(4H, m), 3.50 (4H, s), 3.69 (IH, d), 5.11 (2H, s), 6.88 (IH, d), 7.32 - 7.39 (5H, m), 7.60 (IH, d), 8.35 (IH, d) MS m/e (M+H)+ 457
The following Example was prepared in a similar manner to Example 1 , using Intermediate 47 and an appropriate aminoester starting material:
Figure imgf000120_0002
Intermediate 47
6-chloro-N-cyclohexyl-2-(propylamino)nicotinamide.
Figure imgf000120_0001
Intermediate 47 was prepared using an analogous method to that used to prepare intermediate 37
1H NMR (400.13 MHz5 DMSO-d6) 50.91 (3H, t), 1.21-35 (5H, m), 1.57 (3H, d), 1.75 (4H, d),
3.27 - 3.31 (2H, m), 3.70 (lH,m), 6.59 (IH, d), 7.95 (IH, d), 8.26 (IH, d), 8.68 (IH, t)
MS (M+H)= 296
The following Example was prepared in a similar manner to Example 1, using Intermediate 48 and an appropriate aminoester starting material:
Figure imgf000120_0003
Intermediate 48
6-chloro-iV-cy clohexyl-2- [(2-phenylethyl)amino] nicotinamide
Figure imgf000121_0001
Intermediate 48 was prepared using an analogous method to that used to prepare intermediate 37 1HNMR (400.13 MHz, DMSO-d6) δl.24 - 1.30 (5H, m), 1.75 (5H, d), 2.85 (2H, t), 3.55 - 3.60 (2H, m), 3.60-3.71 (lH,m), 6.62 (IH, d), 7.21 - 7.32 (5H, m), 7.94 (IH, d), 8.25 (IH, d), 8.65 (IH, s) MS (M+H)= 358
The following Example was prepared in a similar manner to Example 1, using Intermediate 49 and an appropriate aminoester starting material:
Figure imgf000121_0003
Intermediate 49
6-chloro-N-cyclohexyl-2-[methyl(2-phenylethyl)amino]nicotinamide
Figure imgf000121_0002
Intermediate 49 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSO-d6) δl.10-1.33 (5H, m), 1.50-1.80 (5H, m), 2.83 (2H, t), 2.94 (3H, s), 3.57 (IH, d), 3.59 (IH, d), 3.64 - 3.67 (IH, m), 6.69 (IH, d), 7.19 - 7.22 (IH, m), 7.25 7.32 (4H, m), 7.46 (IH, d), 8.32 (IH, d) MS (M+H)= 372
The following Example was prepared in a similar manner to Example 1, using Intermediate 50 and an appropriate aminoester starting material:
Figure imgf000122_0002
Intermediate 50
6-chloro-iV-cyclohexyl-2-[methyl(propyl)amino]mcotinamide
Figure imgf000122_0001
Intermediate 50 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSOd6) δθ.81 (3H5 1), 1.10 - 1.34 (5H, m), 1.48-1.60 (3H, m), 1.69 - 1.73 (2H, m), 1.81 (2H, d), 2.89 (3H, s), 3.30-3.40 (2H, m), 3.63 - 3.67 (IH, m), 6.64 (IH, d), 7.42 (IH, d), 8.32 (IH, d) MS (M+H)= 310
The following Example was prepared in a similar manner to Example 1, using Intermediate 51 and an appropriate aminoester starting material:
Figure imgf000123_0002
Intermediate 51 ό-chloro-JV-cyclohexyl^-pyrrolidin- 1 -y nicotinamide
Figure imgf000123_0001
Intermediate 51 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSOd6) δl.00-1.35 (6H, m) 1.50- 1.71 (4H, m), 1.80 - 1.87 (6H, m), 3.33-3.37 (2H,m), 3.64 - 3.67 (IH, m), 6.60 (IH, d), 7.41 (IH, d), 8.28 (IH, d) MS (M+H)= 308.
The following Example was prepared in a similar manner to Example 1, using Intermediate 52 and an appropriate aminoester starting material:
Figure imgf000123_0003
Intermediate 52
6-chloro-iV-cyclohexyl-2-morpholin-4-ylnicotinamide
Figure imgf000124_0001
Intermediate 52 was prepared using an analogous method to that used to prepare intermediate 37 1H NMR (400.13 MHz, DMSOd6) δl.02-1.33 (5H, m), 1.52-1.65 (IH, d), 1.70-1.80 (2H, m), 1.81-1.90 (2H, m), 3.30-3.40 (4H, m), 3.68-3.72 (5H, m), 6.88 (IH, d), 7.59 (IH, d), 8.30 (IH, d) MS (MH-H)= 324.
The following Example was prepared in a similar manner to Example 1, using Intermediate 53 and an appropriate aminoester starting material:
Figure imgf000124_0003
Intermediate 53
6-chloro-iV-cyclohexyl-N-methyl-2-(propylamino)nicotinamide
Figure imgf000124_0002
Intermediate 53 was prepared using an analogous method to that used to prepare intermediate 37 m/z (EI+) (M+H)+ = 310; HPLC tR = 2.93 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 54 and an appropriate aminoester starting material:
Figure imgf000125_0002
Intermediate 54
6-chloro-N-cyclohexyl-iV-metliyl-2-[methyl(piOpyl)amino]nicotinamide
Figure imgf000125_0001
Intermediate 54 was prepared using an analogous method to that used to prepare intermediate 37 m/z (EI+) (M+H)+ = 324; HPLC tR = 2.90 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 55 and an appropriate aminoester starting material:
Figure imgf000125_0003
Intermediate 55
6-chloro-N-cyclohexyl-2-methylnicotinamide
Figure imgf000126_0001
A solution of 2-methyl-6-chloronicotinic acid (300 mg, 1.75 mmol) and 1-hydroxybenzotriazole (260 mg,1.92 mmol) was stirred in dichloromethane (25 ml) then triethylamine (561 ul,4.02 mmol) and EDAC (401 mg,2.1 mmol) were added and stirred for 5 minutes then cyclohexylamine (201 ul,1.75mmoi) was added and the reaction was stirred for a further 16 hours at room temperature. The reaction was diluted with dichloromethane (25 ml), washed with sat. NaHCO3, IM HCl, water, brine and dried over MgSO4, filtered and the solvent evaporated to give 6-chloro-2-methyl-N-cyclohexylnicotinamide (340 mg, 77%) as a fawn coloured powder 1H NMR (400.13 MHz, DMSO-d6) δl.23 (5H, d), 1.58 (IH, s), 1.70 - 1.74 (2H, m), 1.82 - 1.85 (2H, m), 2.47 (3H, s), 3.72 (IH, t), 7.39 (IH, d), 7.73 (IH, d), 8.37 (IH, d) MS m/e (M+H)+253
The following Example was prepared in a similar manner to Example 1, using Intermediate 56 and an appropriate aminoester starting material:
Figure imgf000126_0003
Intermediate 56 iV-adamantan- 1 -yl-6-chloro-2-methylnicotinamide
Figure imgf000126_0002
Intermediate 56 was prepared using an analogous method to that used to prepare intermediate 55 1H NMR (400.13 MHz, DMSO-d6) δl.65 (6H, s), 2.04 (9H, s), 2.47 (3H, d), 7.36 (IH, d), 7.37 7.40 (IH, m), 7.68 (IH, d), 7.96 (IH, s) MS m/e (M+H)+ 305
The following Example was prepared in a similar manner to Example 1, using Intermediate 57 and an appropriate aminoester starting material:
Figure imgf000127_0002
Intermediate 57 iV-adamantan-2-yl-6-chloro-2-methylnicotinamide
Figure imgf000127_0001
Intermediate 57 was prepared using an analogous method to that used to prepare intermediate 55 1H NMR (400.13 MHz, DMSOd6) δl.52 (2H, d), 1.71 (2H, s), 1.78 - 1.82 (5H, m), 1.85 (IH, s), 1.94 (2H, s), 2.03 (2H, d), 2.47 (3H, s), 4.04 (IH, d), 7.38 - 7.40 (IH, m), 7.73 (IH, d), 8.39 (IH, d)
MS m/e (M+H)+305
The following Examples were prepared in a similar manner to Example 1, using Intermediate 63 and an appropriate aminoester starting material:
Figure imgf000128_0002
Intermediate 58
Ethyl)-3 -aminohept-2-enoate
Figure imgf000128_0001
Ethyl 3-oxoheptanoate (8.28 g, 48.13 mmol) and ammonium acetate (18.55 g, 240mmol) were stirred in ethanol (80 ml) at room temperature for 96 hours. The solvent was evaporated and the residue stirred in dichloromethane (100 ml) for 30 minutes. The solid formed was filtered and the filtrate was washed with water (50 ml), saturated brine (50 ml) and dried over MgSO4 filtered and evaporated to give ethyl 3 -aminohept-2-enoate (7.8 g, 94%) as a pale yellow oil. IH NMR (300.072 MHz, CDCl3) δ 0.90 (3H, t), 1.19 - 1.29 (3H, m), 1.31 - 1.38 (2H, m), 1.47 - 1.57 (2H, m), 2.06 - 2.13 (2H, m), 4.09 (2H, q), 4.52 (IH, s) MS m/e (M+H) +172.
Intermediate 59
5-ethyl 1 -methyl-4-( 1 -aminopentylidene)pent-2-enedioate
Figure imgf000129_0001
Ethyl -3-aminohept-2-enoate (7.8 g, 45.16 minol) was stirred in toluene (80 ml), methyl propiolate (4.865 ml, 54.73 mmol) was added and the reaction was stirred under N2 at 100 0C for 96 hours. The solvent was evaporated to give a orange oil. Chromatography (SiO2) eluting with ethyl acetate/isohexane 20-40% gave 5-ethyl 1 -methyl -4-(l-aminopentylidene) pent-2-enedioate (9.5 g, 81%) as a yellow oil.
IH NMR (300.072 MHz, CDCl3) δ 0.96 (3H, q), 1.35 - 1.50 (5H, m), 1.60 - 1.68 (2H, m), 2.05 (IH, s), 2.54 (2H, t), 3.74 (3H, s), 4.13 (IH, q), 4.26 (2H, q), 6.21 (IH, d), 7.64 - 7.70 (IH, m) MS m/e (M+H)+256.
Intermediate 60 ethyl 2-butyl-6-oxo- 1 ,6-dihydropyridine-3 -carboxylate
Figure imgf000129_0002
5-ethyl l-methyl-4-(l-aminopentylidene) pent-2-enedioate (2 g, 7.8 mmol) and sodium tertButoxide (100 mg,l mmol) were stirred in NMP (20 ml). The solution was heated at 180 0C for 4 hours giving a very dark solution. On cooling the reaction was diluted with ice/water (50 ml) and the resulting precipitate was filtered and washed with water (10 ml) and dried to give ethyl 2-butyl-6-oxo-l,6-dihydropyridine-3 -carboxylate (1.35 g, 78%) as a grey powder. 1H NMR (400.13 MHz, DMSO-d6) δθ.90 (3H, t), 1.28 (3H, t), 1.31 - 1.38 (2H, m), 1.50 - 1.58 (2H, m), 2.90 (2H, m), 4.22 (2H, q), 6.21 (IH, d), 7.82 (IH, d), 11.97 (IH, s) MS m/e (M+H)+224.
Intermediate 61 ethyl 2-butyl-6-chloronicotinate
Figure imgf000130_0001
Ethyl 2-butyl-6-oxo-l,6-dihydropyridine-3-carboxylate (450 mg,2.02 mmol) was stirred in phosphorous oxychloride (10 ml, 30.5 mmol) and heated to 120 0C for 2 hours giving a clear brown solution. The reaction was evaporated and the residue was taken up in EtOAc (25 ml), washed with water (25 ml), saturated brine (25 ml) then dried over MgSO4 filtered and evaporated. Chromatography of the residue (SiO2) eluting with ethyl acetate/isohexane 10-30% gave ethyl 2-butyl-6-chloronicotinate (395 mg, 81%) as a clear oil.
1H NMR (400.13 MHz, DMSO-d6) δθ.91 (3H, t), 1.30 - 1.39 (5H, m), 1.58 - 1.65 (2H, m), 3.02
(2H, t), 4.34 (2H, q), 7.48 (IH, d), 8.16 - 8.19 (IH, m) MS m/e (M+H)+ 242
Intermediate 62
2-butyl-6-chloronicotinic acid
Figure imgf000130_0002
Ethyl 2-butyl-6-chloronicotinate (395 mg, 1.63 mmol) was stirred in methanol (10 ml) and 2M sodium hydroxide (2 ml, 4 mmol) was added. The solution was stirred at room temperature for 16 hours. The solvent was evaporated and the residue taken up in ice/water (10 ml) and acidified with 2M HCl. The milky solution was extracted with dichloromethane (2x15 ml) and the combined extracts were dried over MgSO4, filtered and evaporated, trituration with isohexane gave 2-butyl-6-chloronicotinic acid (300 mg, 86%) as a white solid.
1H NMR (400.13 MHz, DMSO-d6) δθ.90 (3H, t), 1.29 - 1.38 (2H, m), 1.58 - 1.66 (2H, m), 3.06 (2H, t), 7.45 (IH, d), 8.17 (IH, d), 13.41 (IH, s) MS m/e (M+H)+ 214. Intermediate 63
N-adamantan-2-yl-2-butyl-6-chloiOnicotinamide
Figure imgf000131_0001
A solution of oxalyl chloride (0.105 niL, 1.20 mmol) in dichloromethane (2 mL) was added dropwise to a stirred suspension of 2-butyl-6-chloronicotinic acid (214 mg, 1.00 mmol), in dichloromethane (25 mL) over a period of 2 minutes under nitrogen. The resulting solution was stirred at room temperature for 4 hours. The reaction mixture was evaporated to dryness and dissolved in DCM (5 mL). This solution was added dropwise to a stirred solution of 2- adamantanamine hydrochloride (188 mg, 1.00 mmol) and N-ethyldiisopropylamine (0.693 mL, 4.01 mmol) in dichloromethane (2OmL) over a period of 2 minutes under nitrogen. The resulting solution was stirred at room temperature for 16 hours. The reaction mixture was diluted with DCM (20 mL), and washed sequentially with 0.1M HCl (20 mL), saturated NaHCO3 (20 mL), and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford N-adamantan-2-yl-2-butyl-6-chloronicotinamide (290 mg, 83%)
IHNMR (400.13 MHz, DMSO-d6) δ 0.87 (3H, t), 1.24 - 1.34 (2H, m), 1.50 (2H, d), 1.57 - 1.64 (2H, m), 1.71 (2H, s), 1.82 (6H, d), 1.92 (2H5 s), 2.03 (2H5 d), 2.77 (2H, t), 4.05 (IH51), 7.38 (IH5 d), 7.70 (IH, d), 8.43 (IH5 d) MS m/e (M+H)+ = 347
The following Example was prepared in a similar manner to Example I5 using Intermediate 64 and an appropriate aminoester starting material:
Figure imgf000131_0002
Intermediate 64
2-butyl-6-chloro-iV-cyclohexylnicotinamide
Figure imgf000132_0001
Intermediate 64 was prepared using an analogous method to that used to prepare intermediate 63 IH NMR (400.13 MHz, DMSO-d6) δ 0.87 (3H, t), 1.09 - 1.36 (7H, m), 1.56 - 1.63 (3H, m), 1.70 - 1.74 (2H, m), 1.83 (2H, s), 2.78 (2H, t), 3.69 - 3.76 (IH, m), 7.38 (IH, d), 7.70 (IH, d), 8.39 (IH, d) MS m/e (M+H)+ 295
The following Example was prepared in a similar manner to Example 1, using Intermediate 65 and an appropriate aminoester starting material:
Figure imgf000132_0003
Intermediate 65
6-chloro-N-cyclohexylnicotinamide
Figure imgf000132_0002
A solution of 6-chloro-2-cycloproρymicotinoyl chloride (PATENT WO2005/080342) (0.216 g, 1 mmol) in DCM (2.5 mL) was added drop wise to a stirred solution of cyclohexylamine (0.171 mL, 1.50 mmol) and N-ethyldiisopropylamine (0.606 mL, 3.50 mmol) in THF (5 mL) at 20 0C, over a period of 2 minutes under nitrogen. The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (10 mL) and washed sequentially with 2M HCl (10 mL), saturated NaHCCβ (10 mL), and saturated brine (10 mL). The organic layer was collected from a phase separation cartridge (15 ml) and evaporated to afford crude product. This was triturated with Et2O to give a solid that was collected by filtration and dried under vacuum to give 6-chloro-N-cyclohexyl-2-cyclopropylnicotinamide (79 %) as a white solid, m/z (EI+) (M+H)+ = 279; HPLC tR = 2.43 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 66 and an appropriate aminoester starting material: 0
Figure imgf000133_0002
Intermediate 66
N-adamantan-2-yl-6-chloro-2-cyclopropylnicotinamide
Figure imgf000133_0001
5 Intermediate 66 was prepared using an analogous method to that used to prepare intermediate 65 m/z (EI+) (M+H)+ = 331; HPLC tR = 2.92 min.
The following Example was prepared in a similar manner to Example 1, using Intermediate 67 and an appropriate aminoester starting material: Q
Figure imgf000134_0003
Intermediate 67
Trans-4-chloro-2-cyclopropyl-N-((2r,5s)-5-hydroxyadamantan-2-yl)nicotinainide
Figure imgf000134_0001
Intermediate 67 was prepared using an analogous method to that used to prepare intermediate 65 m/z (EI+) (M+H)+ = 347; HPLC tR = 1.86 min.
Example 168 2-[(3RVM5-(Cyclohexyl-methyl-carbamoylV6-propylsulfanyl-pyridin-2-yl1-3- piperidyll acetic acid
Figure imgf000134_0002
6-Chloro-N-cyclohexyl-2-proρylsulfanyl-pyridine-3-carboxamide (Intermediate 2, 1.46 g, 4.66 mmol ), methyl-(R)-3-piperidine acetate hydrochloride (0.90 g, 4.66 mmol), K2CO3 (1.93 g, 13.98 mmol) and butyronitrile were mixed in a microwave tube and stirred at 170 °C for 2 hours. The mixture changed from a poorly soluble white mixture to an orange solution. Most of the butyronitrile was evaporated under reduced pressure. Water (20 mL) was added and the product was extracted in EtOAc (2 x 40 mL), washed with brine (10 mL), dried over MgSO4, filtered and evaporated under reduced pressure to give an orange oil. It was preloaded on Celite and purified by flash column chromatography (SiO2, eluent gradient: 0% to 50%, hexane:EtOAc) to afford methyl 2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetate as a slightly yellow oil which crystallised to give a white solid (1.15 g, 57%).
The crude mixture was then dissolved in THF (25 mL), under N2, in dry glassware and a IN solution of LiHMDS (2.92 mL, 2.92 mmol) was added at room temperature. After stirring for 2 hours at room temperature MeI (199 μl, 3.12 mmol) was added and the resulting clear yellow solution was stirred at room temperature overnight. The reaction was stopped and partitioned between EtOAc (50 mL) and saturated NH4C1 aq. (20 mL). The aqueous layer was extracted with EtOAc (2x20 mL) and the combined organics were dried over Na2SO4, filtered and evaporated to give a clear yellow gum. Purification by flash column chromatography (SiO2, eluent gradient: hexane:EtOAc , 30% to 80% EtOAc) afforded methyl 2-[(3R)-l-[5-(cyclohexyl-methyl- carbamoyl)-6-propylsulfanyl-pyridm-2-yl] -3 -piperidyl] acetate as a colourless gum (400 mg, 34%).
The gum was dissolved in methanol and a 2N aqueous solution of NaOH (2.6 mL, 5.22 mmol) was added. The reaction was stirred at room temperature for 4 hours. TLC showed no more starting material. The MeOH was evaporated under reduced pressure and the remaining solution was acidified to pH 4.6. The product was extracted in DCM (2x25 mL), washed with brine (10 mL), dried over MgSO4 and the solvent evaporated under reduced pressure to give 2- [(3R)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-ρropylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid as a colourless gum. It was triturated in ether and to give a white solid (352 mg, 93%). 1H NMR (400.13 MHz, DMSO-d6) δθ.94 (3H, t), 1.00 - 1.09 (2H, m), 1.25 - 1.40 (2H, m), 1.47 - 1.55 (4H, m), 1.56 - 1.81 (8H, m), 1.84 - 1.91 (2H, m), 2.20 - 2.26 (2H, m), 2.70 - 2.90 (4H, m), 2.95 (IH, m), 2.97 - 3.11 (2H, m), 4.15 (IH, d), 4.27 (IH, d), 6.50 (IH, d), 7.23 (IH, d), 12.22 (IH, br s) MS m/e MH+434 The following Example was prepared in a similar manner to Example 168, using
Intermediate 2 and an appropriate aminoester starting material:
Figure imgf000136_0002
Example 170 f(3S)-l-{5-f((2r,5s)-5-Methoxyadamantan-2-yI)(methvI)carbamoyll-6-(propylthio)pyridin-2- yl)piperidin-3-yll acetic acid
Figure imgf000136_0001
A solution of sodium hydroxide (0.036g, 0.9 mmol) in water (0.45 niL) was added dropwise to a stirred solution of methyl [(3S)-l~{5-[((2r,5s)-5-methoxyadamantan-2- yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3-yl]acetate (Intermediate 69, 96 mg, 0.18 mmol) in MeOH (5 mL) at 18 0C, over a period of 1 minute. The resulting solution was stirred at 18 °C for 45 hours. The reaction mixture was adjusted to pH 4.5 with 2M HCl and the reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by preparative HPLC (Phenomenex Gemini Cl 8 HOA (axia) column, 5μ silica, 21 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 0.5% NH3) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to remove the bulk of the CH3CN. The colourless solution was adjusted to pH 4.5 with 2M HCl and the white solid filtered off and washed with water (2 x 5 ml), dried under vacuum to afford [(3*S)-l-{5-[((2r,5s)-5- methoxyadamantan-2-yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3-yl]acetic acid (54 mg, 58%) as a white solid. IH NMR (400.13 MHz, DMSOd6) δ 0.95 (3H, t), 1.21 - 1.33 (IH, m), 1.40 - 1.53 (3H, m), 1.58 - 1.77 (9H, m), 1.80 - 2.00 (4H, m), 2.14 - 2.26 (3H, m), 2.39 - 2.45 (2H, m), 2.70 - 2.75 (IH, m), 2.91 - 3.13 (9H, m), 4.01 - 4.04 (IH, m), 4.11 - 4.19 (IH, m), 4.25 - 4.28 (IH, m), 6.51 (IH, d), s 7.27 (IH, d), 12.09 (IH, s) m/z (ESI+) (M+H)+ = 516; HPLC tR = 2.67 min
Intermediate 68
6-cUoro-N-((2r,5s)-5-methoxyadamantan-2-yl)-N-methyl-2-(propylthio)nicotinamide and 6-o chloro-iV-((2r,5s)-5-hydiOxyadamantan-2-yl)-iV-methyl-2-(propylthio)nicotinamide
Figure imgf000137_0001
6-chloro-N-((2r,5s)-5-hydroxyadamantaii-2-yl)-2-(propylthio)nicotinamide (Intermediate 12, 0.38 g, 1 mmol) was added portionwise to sodium hydride (60% dispersion in oil) (0.043 g, 1.07 mmol) in DMF (5 mL) cooled to O0C over a period of 2 minutes under nitrogen. The resultings suspension was warmed and stirred at 20 °C for 1 hour. The temperature was decreased to O0C and methyl iodide (0.069 ml, 1.1 mmol) was added in one portion and the suspension was warmed and stirred at 20 °C for a further 18 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride (5 mL) then diluted with EtOAc (50 mL), and washed sequentially with water (10 mL) and saturated brine (10 mL). The organic layer was dried over0 MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford 6-chloro-N-((2r,5s)-5-methoxyadamantan-2-yl)-N-methyl-2- (propylthio)nicotinamide (0.077g, 19%) as a clear glass and 6-chloro-JV-((2r,5s)-5- hydroxyadamantan-2-yl)-iV-methyl-2-(propylthio)nicotinamide (0.303g, 77%) as a white solid.5
6-chloro-N-((2r,5s)-5-methoxyadamantan-2-yl)-iV-methyl-2-(propylthio)nicotinamide IH NMR (400.13 MHz, DMSOd6) δ 0.97 (IH, t), 1.49 - 1.55 (2H, m), 1.61 - 1.77 (8H, m), 1.92 - 1.99 (2H, m), 2.15 - 2.20 (IH, m), 2.39 - 2.46 (2H, m), 2.99 (3H, s), 3.11 - 3.16 (5H, m), 3.95 - 4.15 (IH, m), 7.29 (IH, d), 7.64 (IH, d) m/z (ESI+) (M+H)+ = 409; HPLC tR = 2.88 min 5 6-chloro-iV-((2r,5s)-5-hydroxyadamantan-2-yl)-N-methyl-2-(propylthio)nicotinamide
IH NMR (400.13 MHz, DMSO-d6) δ 0.97 (IH, t), 1.46 - 1.52 (2H, m), 1.59 - 1.77 (8H, m), 1.90 - 1.98 (2H, m), 2.10 - 2.14 (IH, m), 2.29 - 2.37 (2H, m), 3.00 (3H, s), 3.14 (2H, t), 3.95 - 4.12 (IH, m), 4.41 (IH, s), 7.29 (IH, d), 7.64 (IH, d) io m/z (ESI+) (M+H)+ = 395; HPLC tR = 2.42 min
Intermediate 69
Methyl [(3iS)-l-{5-[((2r,5s)-5-methoxyadamantan-2-yl)(methyl)carbamoyl]-6- (pr opy lthio)pyridin-2 -y 1 } piper idin- 3 -y 1] acetate
Figure imgf000138_0001
6-chloro-N-((2r,5s)-5-methoxyadamantan-2-yl)-N-methyl-2-(propylthio)nicotinamide (0.074 g, 0.18 mmol) was added to (S)-methyl 2-(piperidin-3-yl)acetate. HCl (0.053 g, 0.27 mmol) and Potassium carbonate (0.088 g, 0.63 mmol) in Butyronitrile (3 mL) warmed to 130 0C over a period of 1 hour under nitrogen. The resulting suspension was stirred at 130 °C for 168 hours. 20 The reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product, methyl [(35)-l-{5-[((2r,5s)-5-methoxyadamantan~2-yl)(methyl)carbamoyl]- 6-(propylthio)pyridin-2-yl}piperidin-3-yl]acetate (97 mg, 100%) as a yellow gum.
2s m/z (ESI+) (M+H)+ = 530; HPLC tR = 3.13 min Example 171 f(35)-l-{5-f((2r,5s)-5-Hvdroxyadamantan-2-yl)(methvI)carbamovπ-6-(propylthio)pyridin-2- γUpiperidin-3-yliacetic acid
Figure imgf000139_0001
A solution of sodium hydroxide (0.066 g, 1.65 mmol) in water (0.83 niL) was added dropwise to a stirred solution of methyl [(3S)-l-{5-[(5-hydroxyadamantan-2-yl)(methyl)carbamoyl]-6- (propylthio)pyridin-2-yl}piperidin-3-yl]acetate (171 mg, 0.33 mmol) in MeOH (5 mL) at 18 0C, over a period of 1 minute. The resulting solution was stirred at 18 0C for 20 hours. The reaction mixture was adjusted to pH 4.5 with 2M HCl and the reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The residue was dissolved in DCM (10 ml) and the slight suspension filtered through a nylon millipore filter to remove the solid. Evaporation gave the product, [(3<S)-l-{5-[((2r,5s)-5-hydroxyadamantan-2- yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3-yl]acetic acid (162 mg, 98%), as a white solid
IHNMR (400.13 MHz, DMSO-d6) δ 0.95 (3H, t), 1.24 - 1.29 (2H, m), 1.41 - 1.52 (3H, m), 1.57 - 1.72 (8H, m), 1.82 - 2.00 (4H, m), 2.10 - 2.26 (3H, m), 2.30 - 2.35 (2H, m), 2.69 - 2.75 (IH, m), 2.90 - 3.11 (6H, m), 3.99 - 4.03 (IH, m), 4.11 - 4.88 (IH, m), 4.24 - 4.30 (IH, m), 4.38 (IH, s), 6.51 (IH, d), 7.26 (IH, d), 12.09 (IH, s) m/z (ESI+) (M+H)+ = 502; HPLC tR = 2.29 min
Intermediate 70
Methyl [(35)- 1 - { 5- [((2r,5 s)-5-hydroxyadamantan-2-yl)(methyl)carbamoyl]-6- (propy lthio)pyridin-2-yl } piperidin-3 -y 1] acetate
Figure imgf000140_0001
6-chloro-iV-((2r,5s)-5-hydiOxyadamantan-2-yl)-iV-methyl-2-(propylthio)nicotinaniide (0.289 g, 0.73 mmol) was added to (S)-methyl 2-(piperidin-3-yl)acetate.HCl (0.213 g, 1.1 mmol) and potassium carbonate (0.354 g, 2.56 mmol) in butyronitrile (5 mL) warmed to 130 0C over a period of 1 hour under nitrogen. The resulting suspension was stirred at 130 °C for 168 hours. The reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford methyl [(35)-l-{5-[((2r,5s)-5-hydroxyadamantan-2-yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2- yl}ρiperidin-3-yl]acetate(0.282g, 75%) as a white solid.
IH NMR (400.13 MHz, DMSO-d6) δ 0.95 (3H, t), 1.27 - 1.32 (IH, m), 1.41 - 1.52 (3H, m), 1.58 - 1.70 (9H, m), 1.79 - 2.00 (4H, m), 2.11 (IH, s), 2.25 - 2.36 (4H, m), 2.71 - 2.77 (IH, m), 2.90 - 3.10 (6H, m), 3.62 (3H, s), 3.99 - 4.03 (IH, m), 4.11 - 4.17 (IH, m), 4.22 - 4.28 (IH, m), 4.38 (IH, s), 6.52 (IH, d), 7.27 (IH, d)
m/z (ESI+) (M+H)+ = 516; HPLC tR = 2.68 min
Example 172 fOt-D-l-fS-rAdamantan-l-vIcarbamovD-ό-fpropylthio^pyridin-l-vIlpiperidin-S-yllacetic acid
Figure imgf000140_0002
A solution of lithium hydroxide (0.053 g, 1.26 mmol) in water (1 mL) was added dropwise to a stirred solution of methyl {(3<S)-l-[5-(adamantan-l-ylcarbamoyl)-6-(propylthio)pyridin-2- yl]piperidin-3-yl}acetate (Intermediate 73, 204 mg, 0.42 mmol) in MeOH (3 mL) and THF (2 mL) at 18 0C, over a period of 1 minute. The resulting solution was stirred at 18 °C for 20 hours. The reaction mixture was adjusted to pH 4.5 with 2M HCl and the reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford {(3S)-l-[5-
(adamantan-l-ylcarbamoyl)-6-(propylthio)pyridin-2-yl]piperidin-3-yl} acetic acid (180 mg, 91%), as a white solid.
1H NMR (400.13 MHz, DMSO-d6) δθ.95 (3H, t), 1.21 - 1.49 (2H, m), 1.55 - 1.70 (9H, m), 1.78 - 1.89 (2H, m), 1.99 - 2.06 (9H, m), 2.11 - 2.25 (2H, m), 2.70 - 2.76 (IH, m), 2.87 - 3.03 (3H, m), 4.19 (IH, d), 4.27 (IH, d), 6.45 (IH, d), 7.31 (IH, s), 7.53 (IH, d) m/z (ESI+) (M+H)+ = 472; HPLC tR = 3.12 min
Intermediate 71 N-adamantan- 1 -yl-2,6-dichloronicotinamide
Figure imgf000141_0001
cr >rxcι
A solution of 2,6-dichloronicotinoyl chloride (4.21 g, 20 mmol) in DCM (20 mL) was added dropwise to a stirred suspension of 1-aminoadamantane (3.03 g, 20 mmol) and N- ethyldiisopropylamine (4.19 mL, 24 mmol) in DCM (20 mL) at 0 0C, over a period of 30 minutes under nitrogen. The resulting suspension was stirred at room temperature for 18 hours. The reaction mixture was diluted with EtOAc (500 mL), and washed sequentially with water (100 mL) and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 5% Et20 in DCM. Pure fractions were evaporated to dryness to afford N-adamantan-l-yl-2,6-dichloronicotinamide (5.57g, 76 %) as a white solid.
1H NMR (400.13 MHz, DMSO-d6) δl.63 - 1.67 (6H, m), 2.01 - 2.08 (9H, m), 7.61 (IH, d), 7.90
(IH, d), 8.12 (IH, s) m/z (ESI+) (M+H)+ = 366; HPLC tR = 2.66 min Intermediate 72
JV-adamantan- 1 -yl-6-chloro-2-(propylthio)nicotinamide
Figure imgf000142_0001
1-Proρanethiol (0.499 mL, 5.50 mmol) was added dropwise to iV-adamantan-l-yl-2,6- dichloronicotinamide ( 1.63g, 5 mmol) and potassium carbonate (2.07 g, 15.00 mmol) in butyronitrile (15 mL) at 20 0C over a period of 2 minutes under nitrogen. The resulting suspension was heated at 150 0C for 2 hours. The reaction mixture was diluted with EtOAc (60 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford iV-adamantan-l-yl-6-chloro-2- (propylthio)nicotinamide (2.21 g, 100 %) as a white solid.
1H NMR (400.13 MHz, DMSO-d6) δθ.97 (3H, t), 1.61 - 1.66 (8H, m), 2.01 - 2.07 (9H, m), 3.04 (2H5 1), 7.24 (IH, d), 7.67 (IH, d), 7.94 (IH, s) m/z (ESI+) (M+H)+ = 365; HPLC tR = 3.30 min
Intermediate 73
Methyl {(35)-l-[5-(adamantan-l-ylcarbamoyl)-6-(propylthio)pyridin-2-yl]piperidin-3-yl}acetate
Figure imgf000142_0002
N-adamantan-l-yl-6-chloro-2-(propylthio)nicotinamide (0.365 g, 1 mmol) was added to (S)- methyl 2-(piperidin-3-yl)acetate.HCl (0.194 g, 1 mmol) and potassium carbonate (0.415 g, 3 mmol) in butyronitrile (4 mL) was heated at 150 °C for 2 hours. The reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in hexane. Pure fractions were evaporated to dryness to afford methyl {(3S)-l-[5-(adamantan-l- ylcarbamoyl)-6-(propylthio)pyridin-2-yl]piperidin-3-yl}acetate (0.215g, 44%) as a white solid. 1H NMR (400.13 MHz, DMSOd6) δθ.96 (3H, t), 1.22 - 1.33 (IH, m), 1.37 - 1.48 (IH, m), 1.55 - 1.69 (9H, m), 1.76 - 1.91 (2H3 m), 1.99 - 2.06 (9H, m), 2.23 - 2.35 (2H, m), 2.72 - 2.78 (IH, m), 2.87 - 3.02 (3H, m), 3.61 (3H, s), 4.18 (IH, d), 4.26 (IH, d), 6.46 (IH, d), 7.31 (IH, s), 7.54 (IH, d) m/z (ESI+) (M+H)+ = 486; HPLC tR = 3.54 min
Example 173
3S)-l-r6-(Propylthio)-5-(tetrahvdro-2H-pyran-4-vIcarbamoyl)pyridin-2-yl1piperidin-3-o y I) acetic acid
Figure imgf000143_0001
A solution of lithium hydroxide (0.055 g, 1.29 mniol) in water (1 mL) was added dropwise to a stirred solution of methyl {(3S)-l-[6-(propylthio)-5-(tetrahydro-2H-pyran-4-ylcarbamoyl)pyridin- 2-yl]piperidin-3-yl} acetate (188 mg, 0.43 mmol) in MeOH (3 mL) and THF (2 mL) at 18 0C,s over a period of 1 minute. The resulting solution was stirred at 18 0C for 20 hours. The reaction mixture was adjusted to pH 4.5 with 2M HCl and the reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford {(35)-l-[6-(propylthio)-5- (tetrahydro-2H-pyran-4-ylcarbamoyl)pyridin-2-yl]piperidin-3-yl}acetic acid (191 mg, 100%), as0 a white solid.
1H NMR (400.13 MHz, DMSO-d6) δθ.95 (3H, t), 1.25 - 1.88 (1 IH, m), 2.13 - 2.25 (2H, m), 2.72 - 2.77 (IH, m), 2.85 - 3.02 (3H, m), 3.33 - 3.40 (2H, m), 3.84 - 3.90 (3H, m), 4.21 (IH, d), 4.30 (IH, d), 6.49 (IH, d), 7.64 (IH, d), 7.91 (IH, d), 12.18 (IH, s) s m/z (ESI+) (M+H)+ = 422; HPLC tR = 2.05 min
Intermediate 74
2,6-dichloro-N-(tetrahydro-2//-pyran-4-yl)nicotinamide
Figure imgf000144_0001
A solution of 2,6-dichloronicotinoyl chloride (4.21 g, 20 mmol) in DCM (20 mL) was added dropwise to a stirred suspension of 4-aminotetrahydropyran (2.03 g, 20 mmol) and N- ethyldiisopropylamine (4.19 mL, 24 mmol) in DCM (20 mL) at 0 0C, over a period of 30 minutes under nitrogen. The resulting suspension was stirred at room temperature for 18 hours. The reaction mixture was diluted with DCM (200 mL), and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford 2,6- dichloro-iV-(tetrahydro-2H-pyran-4-yl)nicotinamide (5.03g, 92%) as a white solid.
1H NMR (400.13 MHz, DMSOd6) δl.43 - 1.53 (2H, m), 1.78 - 1.83 (2H, m), 3.37 - 3.43 (2H, m), 3.83 - 3.88 (2H, m), 3.91 - 4.00 (IH, m), 7.66 (IH, d), 7.98 (IH, d), 8.65 (IH, d) m/z (ESI+) (M+H)+ = 273; HPLC tR = 1.28 min
Intermediate 75
6-chloro-2-(propylthio)-N-(tetrahydro-2H-pyran-4-yl)nicotinamide
Figure imgf000144_0002
Sodium hexamethyldisilazide (IM in THF)(9 mL, 9 mmol) was added to a solution of 1- propanethiol (0.684g, 9 mmol) in DMF (14 mL) under N2. This solution was added to a solution of 2,6-dichloro-iV-(tetrahydro-2/f-pyran-4-yl)nicotinamide (2.93 g, 9 mmol) in DMF (14 mL) under N2 and stirred for 18 hours. The reaction mixture was diluted with EtOAc (200 mL), and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in DCM. Pure fractions were evaporated to dryness to afford 2,6-dichloro-iV-(tetrahydro-2/i-pyran-4-yl)nicotinamide (2.6Og, 92 %) as a white solid. 1H NMR (400.13 MHz3 DMSOd6) δθ.97 (3H, t), 1.45 - 1.55 (2H3 m), 1.59 - 1.68 (2H, m), 1.75 ■ 1.79 (2H, m), 3.04 (2H5 1), 3.34 - 3.43 (2H, m), 3.84 - 3.96 (3H, m), 7.29 (IH, d), 7.78 (IH, d), 8.49 (IH, d) m/z (ESI+) (M+H)+ - 315; HPLC tR = 2.17 min
Intermediate 76
Methyl {(35)-l-[6-(propylthio)-5-(tetraliydro-2//-pyran-4-ylcarbamoyl)pyridin-2-yl]piperidin-3- yl} acetate
Figure imgf000145_0001
6-chloro-2-(propylthio)-iV-(tetrahydro-2H"-pyran-4-yl)nicotinamide (0.205 g, 0.65 mmol) was added to (S)-methyl 2-(piperidin-3-yl)acetate. HCl (0.189 g, 0.98 mmol) and potassium carbonate (0.607 g, 2.93 mmol) in butyronitrile (3 niL) was heated at 150 0C for 4 hours. The reaction mixture was diluted with DCM (50 mL), and washed sequentially with water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc:MeOH (19:1) in hexane. Pure fractions were evaporated to dryness to afford Methyl { (3S)- 1 - [6-(propylthio)-5-(tetrahydro-2H-pyran-4-ylcarbamoyl)pyridin-2-yl]piperidin-3 - yl} acetate (0.214g, 76%) as a white solid.
1HNMR (400.13 MHz, DMSO-d6) δθ.95 (3H, t), 1.23 - 1.34 (IH, m), 1.37 - 1.93 (10H3 m), 2.24 - 2.35 (2H, m), 2.73 - 2.79 (IH, m), 2.86 - 3.00 (3H, m), 3.33 - 3.41 (2H3 m), 3.61 (3H, s), 3.83 - 3.93 (3H, m), 4.19 (IH, d), 4.29 (IH3 d), 6.50 (IH, d), 7.64 (IH, m), 7.92 (IH, m) m/z (ESI+) (M+H)+ = 436; HPLC tR = 2.46 min
Example 174 f(3SVl-(5-fMethyl(tetrahvdro-2H-pyran-4-yl)carbamoyll-6-(propylthio)pyridin-2- yl)piperidin-3-yIl acetic acid
Figure imgf000146_0001
A solution of sodium hydroxide (0.130 g, 3.25 mmol) in water (1.63 mL) was added dropwise to a stirred solution of methyl [(3S)-l-{5-[methyl(tetrahydro-2H-pyran-4-yl)carbamoyl]-6- (ρropylthio)pyridin-2-yl}ρiperidin-3-yl]acetate (293 mg, 0.65 mmol) in MeOH (5 mL) at 18 0C, over a period of 1 minute. The resulting solution was stirred at 18 °C for 20 hours. The reaction mixture was adjusted to pH 4.5 with 2M HCl and the reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (20 mL) and saturated brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The residue was dissolved in DCM (10 ml) and the slight suspension filtered through a nylon millipore filter to remove the solid. Evaporation gave the product, [(3<S)-l-{5-[methyl(tetrahydro-2H-pyran-4- yl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3-yl]acetic acid (281 mg, 100%), as a white solid
1H NMR (400.13 MHz, DMSO-d6) δθ.93 (3H, t), 1.23 - 1.29 (IH, m), 1.40 - 1.92 (1OH, m), 2.14 - 2.26 (2H, m), 2.67 - 3.55 (9H, m), 3.89 (2H, d), 4.15 (IH, d), 4.28 (IH, d), 4.36 - 4.66 (IH, m), 6.51 (IH, d), 7.26 (IH, d), 12.16 (IH, s) m/z (ESI+) (M+H)+ = 434; HPLC tR = 2.13 min
Intermediate 77 6-chloro-N-methyl-2-(propylthio)-N-(tetrahydro-2H-pyran-4-yl)nicotinamide
Figure imgf000146_0002
6-chloro-2-(propylthio)-iV-(tetraliydro-2/f-pyran-4-yl)mcotinamide (0.410 g, 1.3 mmol) in DMF (4 mL) was added portionwise to sodium hydride (60% dispersion in oil) (0.063 g, 1.56 mmol) in DMF (2 mL) cooled to 0 0C over a period of 2 minutes under nitrogen and stirred for 25 minutes. Methyl iodide (0.069 ml, 1.1 mmol) was added in one portion and the suspension was warmed and stirred at 20 0C for 72 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride (5 mL) then diluted with EtOAc (50 mL), and washed sequentially with water (10 mL) and saturated brine (10 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford 6-chloro-N-methyl-2-(propylthio)-iV-(tetrahydro-2iϊ-pyran-4-yl)nicotmamide (0.422g, 99%) as a colourless clear gum.
1H NMR (400.13 MHz, DMSO-d6) (Rotamers) δθ.95 (3H + 3H, q), 1.18 (IH, t), 1.50 - 1.68 (4H + 4H, m), 1.75 - 1.85 (2H + 2H, m), 2.67 (3H, s), 2.89 (3H, s), 3.07 - 3.18 (3H + 3H, m), 3.27 - 3.37 (IH, m), 3.42 (IH + IH, d), 3.81 (IH + IH, d), 3.93 - 3.97 (IH + IH, m), 4.53 - 4.63 (IH, m), 7.28 - 7.31 (IH + IH, m), 7.64 - 7.68 (IH + IH, m) m/z (ESI+) (M+H)+ = 329; HPLC tR = 2.28 min
Intermediate 78 Methyl [(35)-l-{5-[methyl(tetrahydro-2H-pyran-4-yl)carbamoyl]-6-(propylthio)pyridin-2- yl}piperidin-3-yl]acetate
Figure imgf000147_0001
6-chloro-iV-methyl-2-(propylthio)-iV-(tetrahydro-2H-pyran-4-yl)nicotinamide (0.398 g, 1.21 mmol) was added to (S)-methyl 2-(piperidin-3-yl)acetate.HCl (0.353 g, 1.82 mmol) and potassium carbonate (0.753 g, 5.45 mmol) in butyronitrile (3 mL) was heated at 150°C for 4 hours. The reaction mixture was diluted with DCM (60 mL), and washed sequentially with water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in DCM. Pure fractions were evaporated to dryness to afford methyl [(35)-l-{5-[methyl(tetrahydro-2//-pyran-4-yl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3- yl]acetate (0.31Og, 57%) as a white solid. 1H NMR (400.13 MHz, DMSOd6) δθ.94 (2H, t), 1.25 - 1.31 (IH3 m), 1.44 - 1.93 (10H5 m), 2.25 - 2.36 (2H, m), 2.68 - 2.84 (4H, m), 2.88 - 3.11 (3H, m), 3.13 - 3.49 (2H, m), 3.83 - 3.94 (2H, M), 4.14 (IH, d), 4.24 - 4.27 (IH, m), 6.52 (IH, d), 7.26 (IH, d)
m/z (ESI+) (M+H)+ = 450; HPLC tR = 2.52 min
Example 175 l-rfSSVl-rό-CvcIohexylsulfanvI-S-rrαnSsVS-rdifluoromethoxy)-!- adamantyll carbarn oyll pyridin-2-yIl pyrroIidin-3-vπ acetic acid
Figure imgf000148_0001
To a solution of methyl 2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetate (600 mg, 1.04 mmol) in methanol (30 niL) was added 2M sodium hydroxide (5.19 niL, 10.39 mmol) and the mixture was stirred at ambient temperature for 20 hours. The reaction was acidified with IM citric acid (30 mL), evaporated to approximately half volume then ethyl acetate (50 mL) was added and the mixture was washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford the desired product (430 mg, 73%) as a white powder.
IH NMR (400.13 MHz, DMSOd6) δ 1.22-1.47 (7H, m), 1.55-1.64 (IH, m), 1.66-1.79 (3H, m), 1.81 - 2.25 (14H, m), 2.36 - 2.46 (2H, m), 2.55 - 2.64 (IH, m), 3.08 (IH, dd), 3.36 - 3.40 (IH, m), 3.5-3.6 (IH, m), 3.7 - 3.85 (2H, m), 3.9-3.96 (IH, m), 6.12 (IH, d), 6.86 (IH, t), 7.6 (IH, d), 7.62 (IH, d), 12.15 (IH, s) m/z (ESI+) (M+H)+ = 564; HPLC tR = 3.12 min.
Intermediate 79
6-chloro-2-cyclohexylsulfanyl-N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide
Figure imgf000149_0001
Anhydrous sodium carbonate (1.104 niL, 26.37 mmol) was added in one portion to 2,6-dichloro- N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide (3 g, 8.79 mmol) and cyclohexyl mercaptan (1.022 g, 8.79 mmol) in DMF (50 mL) under nitrogen. The resulting suspension was stirred at 600C for 6 hours.
The reaction mixture was concentrated and diluted with DCM (150 mL), and washed sequentially with water (2x75 mL) and saturated brine (75 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product that was triturated with 4:1 isohexane:EtOAc to give the desired product (3.5g, 95%) as a white powder.
IH NMR (400.13 MHz, DMSOd6) δ 1.32 - 1.5 (7H, m), 1.59 - 1.8 (1OH, m), 1.94-2.05 (5H, m), 2.06-2.15 (2H, m), 3.7-3.85 (IH, m), 3.91-3.97 (IH, m), 4.39 (IH, s), 7.25 (IH, d), 7.69 (IH, d), 8.23 (IH, d) m/z (ESI+) (M+H)+ = 421; HPLC tR = 2.7min.
Intermediate 80 methyl 2- [(3 S)- 1 - [6-cy clohexy lsulfanyl-5 - [((2r,5 s)- 5 -hy droxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3 -y 1] acetate
Figure imgf000149_0002
Anhydrous potassium carbonate (0.985 g, 7.13 mmol) was added in one portion to (S)-methyl 2- (pyrrolidin-3-yl)acetate hydrochloride (0.427 g, 2.38 mmol) and 6-chloro-2-cyclohexylsulfanyl- N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide (1.0 g, 2.38 mmol) in butyronitrile (15 mL). The resulting suspension was stirred at 115 0C for 3 days.
The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (2x30 mL) and brine (30 mL), the organic phase dried (MgSOφ), filtered and evaporated to an orange oil. The crude product was purified by flash silica chromatography with EtOAc. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)-l-[6-cyclohexylsulfanyl-5- [((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]ρyrrolidin-3-yl]acetate (740mg, 59%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 1.22 - 1.45 (7H, m), 1.57-1.8 (1OH, m), 1.92-2.09 (7H, m), 2.14-2.23 (IH, m), 2.53-2.65 (IH, m), 3.1 (IH, dd), 3.36-3.44 (IH, m), 3.5-3.6 (IH, m), 3.63 (3H, s), 3.66-3.84 (2H, m), 3.84 - 3.9 (IH, m), 4.37 (IH, s), 6.12 (IH, d), 7.54 (IH, d), 7.63 (IH, d) m/z (ESI+) (M+H)+ = 528; HPLC tR = 2.84 min.
Intermediate 81 methyl 2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difiuoromethoxy)-2- adamantyl] carbamoyl]pyridin-2-yl]pyrrolidin-3 -yl] acetate
Figure imgf000150_0001
A solution of 2-(fluorosulphonyl)difluoroacetic acid (0.286 mL, 2.77 mmol) in anhydrous acetonitrile (3 mL) was added dropwise to a solution of methyl 2-[(3 S)-I- [6-cyclohexylsulfanyl- 5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetate (730 mg, 1.38 mmol) and copper (I) iodide (52.7 mg, 0.28 mmol) in anhydrous acetonitrile (27 mL) and warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 °C for 30 minutes.
The reaction mixture was concentrated and diluted with EtOAc (50 mL), and washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product as an orange oil. The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (640 mg, 80%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 1.1 - 1.34 (8H, m), 1.43-1.52 (IH, m), 1.53-1.67 (3H, m), 1.72 - 1.83 (4H, m), 1.84 - 2.1 (HH, m), 2.4 - 2.58 (IH, m), 2.99 (IH, dd), 3.23 - 3.33 (IH, m), 3.39 - 3.47 (IH, m), 3.5 (3H, s), 3.54 - 3.7 (2H, m), 3.79 - 3.85 (IH, m), 6.12 (IH, d), 6.75 (IH, t), 7.48 (IH, d), 7.51 (IH, d). m/z (ESI+) (M+H)+ = 578; HPLC tR - 3.6 min. 0
Example 176
2-r(3SVl-r6-CvclohexylsulfanvI-5-rrf2r,5s)-5-(difluoromethoxyV2- adamantyll carbamoyl] py ridin-2-vII -3-piperidyIl acetic acid
Figure imgf000151_0001
s To a solution of methyl 2-[(3 S)- 1 -[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl] -3 -piperidyl] acetate (600 mg, 1.01 mmol) in methanol (30 mL) was added 2M sodium hydroxide (5.07 mL, 10.14 mmol) and the mixture was stirred at ambient temperature for 20 hours.
The mixture was acidified with IM citric acid (30 mL), evaporated to approximately half0 volume then ethyl acetate(50 mL) added, and the mixture was washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford desired product (500 mg, 85%) as a white foam.
IH NMR (400.13 MHz, DMSOd6) δ 1.26-1.5 (1OH, m), 1.55-1.78 (4H, m), 1.8-2.08 (12H, m),s 2.10-2.3 (4H, m), 2.75 (IH, dd), 2.97 (IH, dd), 3.68-3.78 (IH, m), 3.92 - 3.97 (IH, m), 4.18-4.3 (2H, m), 6.49 (IH, d), 6.87 (IH, t), 7.60 (IH, d), 7.68 (IH, d), 12.07 (IH, s) m/z (ESI+) (M+H)+ = 578; HPLC tR = 3.28 min. Intermediate 82 methyl 2-[(3S)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- y 1] -3 -piperidy 1] acetate
Figure imgf000152_0001
Anhydrous potassium carbonate (0.985 g, 7.13 mmol) was added in one portion to (S)-methyl 2- (piperidin-3-yl)acetate hydrochloride (0.460 g, 2.38 mmol) and 6-chloro-2-cyclohexylsulfanyl-N- ((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide (1 g, 2.38 mmol) in butyronitrile (15 mL). The resulting suspension was stirred at 115 °C for 3 days.
The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (2x30 mL) and brine (30 mL) and the organic phase was dried (MgSO^.), filtered and evaporated to an orange oil.
The crude product was purified by flash silica chromatography with ethyl acetate. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)-l-[6-cyclohexylsulfanyl-5- [((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]-3-piperidyl]acetate (960 mg, 74%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSOd6) δ 1.15-1.43 (9H, m), 1.48-1.69 (1OH, m), 1.70 - 2.0 (9H, m), 2.14-2.31 (2H, m), 2.71 (IH, dd), 2.85 - 2.95 (IH, m), 3.54 (3H, s), 3.6-3.7 (IH, m), 3.77-3.83 (IH, m), 4.07-4.21 (2H, m), 4.3 (IH, s), 6.43 (IH, d), 7.53 (2H, d), 7.55 (IH, d) m/z (ESI+) (M+H)+ = 542; HPLC tR = 3.00 min.
Intermediate 83 methyl 2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl] carbamoy l]pyridin-2-yl] -3 -piperidy 1] acetate
Figure imgf000153_0001
A solution of 2-(fluoiOsulphonyl)difluoroacetic acid (0.362 mL, 3.51 mmol) in anhydrous acetonitrile (3 mL) was added dropwise to a solution of methyl 2-[(3S)-l-[6-cyclohexylsulfanyl- 5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]-3-piperidyl]acetate (950 mg, 1.75 mmol) and copper (I) iodide (66.8 mg, 0.35 mmol) in anhydrous acetonitrile (27 mL) warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 0C for 30 minutes.
The reaction mixture was concentrated and diluted with EtOAc (50 mL), and washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product as an orange oil. The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (650 mg, 62%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 1.26 - 1.52 (1OH, m), 1.58 - 2.08 (15H, m), 2.09-2.12 (3H, m), 2.24 - 2.39 (2H, m), 2.78 (IH, dd), 2.94 - 3.01 (IH, m), 3.62 (3H, s), 3.68-3.77 (IH, m), 3.92 - 3.97 (IH3 m), 4.15-4.3 (2H, m), 6.49 (IH, d), 6.87 (IH, t), 7.61 (IH, d), 7.69 (IH, d) m/z (ESI+) (M+H)+ = 592; HPLC tR = 3.72 min.
Example 177
2-r(3S)-l-r6-CvclopentylsuIfanyl-5-fr(2r,5s)-5-(difluoromethoxy)-2- adamantyli carbamoyll pyridin-2-vII pyrrolidin-3-yll acetic acid
Figure imgf000153_0002
To a solution of methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetate (700 mg, 1.24 mmol) in methanol (30 mL) was added 2M sodium hydroxide (6.21 mL, 12.42 mmol) and the mixture was stirred at ambient temperature for 20 hours. The mixture was acidified with IM citric acid (30 mL), evaporated to approximately half volume then ethyl acetate(50 mL) was added and the mixture was washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford desired product (560 mg, 82%) as a white powder.
IH NMR (400.13 MHz, DMSOd6) δ 1.42 (2H, d), 1.49 - 1.75 (7H, m), 1.84 -2.25 (14H5 m), 2.42 (2H, d), 2.55 - 2.62 (IH, m), 3.08 (IH, dd), 3.37 - 3.41 (IH, m), 3.5-3.6 (IH, m), 3.69 - 3.74 (IH, m), 3.92 - 4.05 (2H, m), 6.12 (IH, d), 6.86 (IH, t), 7.58 (IH, d), 7.64 (IH, d), 12.15 (IH, s) m/z (ESI+) (M+H)+ = 550; HPLC tR = 3.01 min.
Intermediate 84
6-chloro-2-cyclopentylsulfanyl-N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide
Figure imgf000154_0001
Anhydrous sodium carbonate (1.104 mL, 26.37 mmol) was added in one portion to 2,6-dichloro- N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide (3 g, 8.79 mmol) and cyclopentyl mercaptan (0.946 mL, 8.79 mmol) in DMF (50 mL) under nitrogen. The resulting suspension was stirred at 6O0C for 6 hours.
The reaction mixture was concentrated and diluted with DCM (150 mL), and washed sequentially with water (2x75 mL) and saturated brine (75 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product that was triturated with 4: 1 isohexane:EtOAc to give the desired product (3.2g, 89%) as a white powder. IH NMR (400.13 MHz, DMSO-d6) δ 1.38 (2H, d), 1.47 - 1.6 (2H, m), 1.64-1.85 (1OH, m), 1.94- 2.08 (3H, m), 2.1-2.15 (2H, m), 2.16 - 2.28 (2H, m), 3.90 - 3.97 (2H, m), 4.45 (IH, s), 7.3 (IH, d), 7.70 - 7.75 (IH, m), 8.28 (IH, d) m/z (ESI+) (M+H)+ = 407; HPLC tR = 2.55 min.
Intermediate 85 methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin- 2-y l]pyrrolidin-3 -yl] acetate
Figure imgf000155_0001
Anhydrous potassium carbonate (1.019 g, 7.37 mmol) was added in one portion to (S)-methyl 2- (pyrrolidin-3-yl)acetate hydrochloride (0.441 g, 2.46 mmol) and 6-chloro-2-cyclopentylsulfanyl- N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide (1.0 g, 2.46 mmol) in butyronitrile (15 mL). The resulting suspension was stirred at 115 °C for 3 days. The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (2x30 mL) and brine (30 mL) and the organic phase dried (MgSC^), filtered and evaporated to an orange oil.
The crude product was purified by flash silica chromatography with EtOAc. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5- [((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetate (l.Og, 79%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 1.3-1.4 (2H, m), 1.48-1.78 (13H, m), 1.9-2.22 (8H, m), 2.55-2.7 (IH, m), 3.1 (IH, dd), 3.35-3.45 (IH, m), 3.52-3.6 (IH, m), 3.63 (3H, s), 3.68 - 3.73 (IH, m), 3.85-3.92 (IH, m), 3.98 - 4.05 (IH, m), 4.37 (IH, s), 6.12 (IH, d), 7.52 (IH, d), 7.64 (IH, d) m/z (ESI+) (M+H)+ = 514; HPLC tR = 2.68 min. Intermediate 86 methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl] carbamoyl]pyridin-2-yl]pyrrolidin-3 -yl] acetate
Figure imgf000156_0001
A solution of 2-(fluorosulphonyl)difluoroacetic acid (0.382 mL, 3.70 mmol) in anhydrous acetonitrile (3 mL) was added dropwise to a solution of methyl 2-[(3S)-l-[6-cyclopentylsulfanyl- 5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetate (950 mg, 1.85 io mmol) and copper (I) iodide (70.4 mg, 0.37 mmol) in anhydrous acetonitrile (27 mL) warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 °C for 30 minutes.
The reaction mixture was concentrated and diluted with EtOAc (50 mL), and washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over
I5 MgSO4, Filtered and evaporated to afford crude product as an orange oil.
The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (740 mg, 71%) as a pale yellow foam.
20 IH NMR (400.13 MHz, DMSO-d6) δ 1.27-1.36 (2H, m), 1.37-1.65 (7H, m), 1.73 - 1.82 (5H, m), 1.83-1.92 (5H, m), 1.96-2.1 (6H, m), 2.4-2.57 (IH, m), 3.0 (IH, dd), 3.25 - 3.35 (IH, m), 3.4-3.5 (IH, m), 3.51 (3H, s), 3.55-3.65 (IH, m), 3.8-3.93 (2H, m), 6.12 (IH, d), 6.57 (IH, t), 7.49 (IH, d), 7.54 (IH, d) m/z (ESI+) (M+H)+ - 564; HPLC tR = 3.46 min.
25
30 Example 178
2-r(3S)-l-r6-CvclopentylsuIfanvI-5-[f(2r,5s)-5-(difluoromethoxy)-2- adamantyll carbarn oyll pyridin-2-vn -3-piperidyπ acetic acid
Figure imgf000157_0001
To a solution of methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl] -3 -piperidyl] acetate (700 mg, 1.21 mmol) in methanol (30 niL) was added 2M sodium hydroxide (6.06 mL, 12.12 mmol) and the mixture was stirred at ambient temperature for 20 hours.
The mixture was acidified with IM citric acid (30 mL), evaporated to approximately half volume then ethyl acetate(50 mL) was added and the mixture was washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford desired product (620 mg, 91%) as a white foam.
IH NMR (400.13 MHz, DMSO-d6) δ 1.23-1.35 (IH, m), 1.38-1.75 (1OH, m), 1.8-1.93 (6H, m), 1.95-2.06 (4H, m), 2.08-2.27 (7H, m), 2.75 (IH, dd), 2.98 (IH, dd), 3.9-4.03 (2H, m), 4.15-4.23 (IH, m), 4.25-4.34 (IH, m), 6.49 (IH, d), 6.87 (IH, t), 7.61 (IH, d), 7.68 (IH, d), 12.1 (IH, s). m/z (ESI+) (M+H)+ = 564; HPLC tR = 3.13 min.
Intermediate 87 methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin- 2-yl] -3 -piperidyl] acetate
Figure imgf000157_0002
Anhydrous potassium carbonate (1.019 g, 7.37 mmol) was added in one portion to (S)-methyl 2- (piperidin-3-yl)acetate hydrochloride (0.476 g, 2.46 mmol) and 6-chloro-2-cyclopenrylsulfanyl- N-((2r,5s)-5-hydroxy-2-adamantyl)pyridine-3-carboxamide (1.0 g, 2.46 mmol) in butyronitrile (15 mL). The resulting suspension was stirred at 115 0C for 3 days.
The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (2x30 mL) and brine (30 mL) and the organic phase was dried (MgSC^), filtered and evaporated to an orange oil.
The crude product was purified by flash silica chromatography with EtOAc. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)~l-[6-cyclopentylsulfanyl-5- [(2r,5s)- (5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]-3-piperidyl]acetate (1.15g, 89%) as a white foam.
IH NMR (400.13 MHz, DMSO-d6) δ 1.28-1.75 (17H, m), 1.79 - 2.2 (9H, m), 2.25-2.35 (2H, m), 2.77 (IH, dd), 2.92-3.02 (IH, m), 3.61 (3H, s), 3.84 - 3.87 (IH, m), 3.92-4.0 (IH, m), 4.12 - 4.18 (IH, m), 4.24 - 4.30 (IH, m), 4.37 (IH, s), 6.49 (IH, d), 7.59 (IH, d), 7.61 (IH, d) m/z (ESI+) (M+H)+ = 528; HPLC tR = 2.86 min.
Intermediate 88 methyl 2-[(3S)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]-3-piperidyl]acetate
Figure imgf000158_0001
A solution of 2-(fluorosulphonyl)difluoroacetic acid (0.431 mL, 4.17 mmol) in anhydrous acetonitrile (3 mL) was added dropwise to a solution of methyl 2-[(3S)-l-[6-cyclopentylsulfanyl- 5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]-3-piperidyl]acetate (1.1 g, 2.08 mmol) and copper (I) iodide (0.079 g, 0.42 mmol) in anhydrous acetonitrile (27 mL) warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 °C for 30 minutes.
The reaction mixture was concentrated and diluted with EtOAc (50 mL), and washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product as an orange oil. The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (750 mg, 62%) as a pale yellow foam.
IHNMR (400.13 MHz, DMSO-d6) δ 1.24 - 1.34 (IH, m), 1.40-1.74 (1OH, m), 1.81-1.94 (6H, m), 1.95 - 2.21 (9H, m), 2.23-2.37 (2H, m), 2.78 (IH, dd), 2.94 - 3.01 (IH, m), 3.62 (3H, s), 3.90 - 4.00 (2H, m), 4.16 - 4.19 (IH, m), 4.27 - 4.32 (IH, m), 6.49 (IH, d), 6.89 (IH, t), 7.61 - 7.63 (IH, d), 7.67 (IH, d) m/z (ESI+) (M+H)+ = 578; HPLC tR = 3.55 min.
Example 179
2-r(3S)-l-f5-[f(2r,5s)-5-(Difluoromethoxy)-2-adamantyl1carbamovIl-6-propyIsulfanyl- pyridin-2-vπ-3-piperidyriacetic acid
Figure imgf000159_0001
To a solution of methyl 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6- propylsulfanyl-pyridin-2-yl] -3 -piperidyl] acetate (850 mg, 1.54 mmol) in methanol (30 niL) was added 2M sodium hydroxide (7.70 mL, 15.41 mmol) and the mixture was stirred at ambient temperature for 20 hours.
The mixture was acidified with IM citric acid (30 mL), evaporated to approximately half volume then ethyl acetate(50 mL) was added and the mixture washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford desired product (750 mg, 91%) as a white foam.
IH NMR (400.13 MHz, DMSOd6) δ 0.96 (3H, t), 1.22 - 1.33 (IH, m), 1.40-1.52 (3H, m), 1.58 - 1.7 (3H, m), 1.8-1.94 (6H, m), 1.95-2.07 (4H, m), 2.11 - 2.3 (5H, m), 2.80 (IH, dd), 2.9-3.1 (3H, m), 3.9-3.98 (IH, m), 4.17-4.25 (IH, m), 4.27 - 4.32 (IH, m), 6.49 (IH, d), 6.87 (IH, t), 7.61 (IH, d), 7.68 (IH, d), 12.09 (IH, s) m/z (ESI+) (M+H)+ = 538; HPLC tR = 2.96 min. Intermediate 89 methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]- 3-piperidyl]acetate
Figure imgf000160_0001
Anhydrous potassium carbonate (1.088 g, 7.88 mmol) was added in one portion to (S)-methyl 2- (piperidin-3-yl)acetate hydrochloride (0.508 g, 2.63 mmol) and 6-chloro-N-(5-hydroxy-2- adamantyl)-2-propylsulfanyl-pyridine-3-carboxamide (1 g, 2.63 mmol) in butyronitrile (15 mL). The resulting suspension was stirred at 115 °C for 3 days.
The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (2x30 mL) and brine (30 mL), the organic phase dried (MgSO^.), filtered and evaporated to an orange oil.
The crude product was purified by flash silica chromatography with EtOAc. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2- adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetate (1.1 Ig, 84%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 0.96 (3H, t), 1.25 - 1.36 (3H, m), 1.40 - 1.46 (IH, m), 1.57 - 1.77 (9H, m), 1.79 -2.1 (7H, m), 2.24 - 2.38 (2H5 m), 2.7 (IH, dd), 2.93 - 3.06 (3H, m), 3.62 (3H, s), 3.82-3.9 (IH, m), 4.13-4.21 (IH, m), 4.24 - 4.3 (IH, m), 4.37 (IH, s), 6.50 (IH, d), 7.60 (IH, d), 7.62 (IH, d) m/z (ESI+) (M+H)+ = 502; HPLC tR = 2.64 min.
Intermediate 90 methyl 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl- pyridin-2-yl] -3 -piperidyl] acetate
Figure imgf000161_0001
A solution of 2-(fluorosulphonyl)difluoroacetic acid (0.453 mL, 4.39 mmol) in anhydrous acetonitrile (3 mL) was added dropwise to a solution of methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy- 2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetate (1.1 g, 2.19 mmol) and copper (I) iodide (0.084 g, 0.44 mmol) in anhydrous acetonitrile (27 mL) warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 0C for 30 minutes.
The reaction mixture was concentrated and diluted with EtOAc (50 mL), and washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product as an orange oil.
The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (875 mg, 72%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 0.96 (3H, t), 1.24 - 1.34 (IH, m), 1.38-1.5 (3H, m), 1.58 - 1.71 (3H, m), 1.76- 2.08 (1OH, m), 2.09-2.2 (3H, m), 2.24 - 2.35 (2H, m), 2.81 (IH, dd), 2.91 - 3.08 (3H, m), 3.62 (3H, s), 3.92-3.98 (IH, m), 4.15-4.22 (IH, m), 4.24 - 4.32 (IH, m), 6.50 (IH, d), 6.87 (IH, t), 7.61 (IH, d), 7.69 (IH, d) m/z (ESI+) (M+H)+ = 552; HPLC tR = 3.39 min.
Example 180
2-[(3SVl-r5-fr(2r,5s)-5-(Difluoromethoxy)-2-adamantvncarbamoyll-6-propylsulfanyl- pyridin-2-yπpyrrolidin-3-vπ acetic acid
Figure imgf000161_0002
To a solution of methyl 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6- propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl] acetate (760 mg, 1.41 mmol) in methanol (30 niL) was added 2M sodium hydroxide (7.07 mL, 14.14 mmol) and the mixture was stirred at ambient temperature for 20 hours. The mixture was acidified with IM citric acid (30 mL), evaporated to approximaetely half volume then ethyl acetate(50 mL) was added and the mixture was washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford desired product (670 mg, 91%) as a pale yellow powder.
IH NMR (400.13 MHz, DMSO-d6) δ 0.96 (3H, t), 1.40 - 1.47 (2H, m), 1.59 - 1.75 (3H, m), 1.85-
2.24 (12H, s), 2.41 - 2.47 (2H, m), 2.55-2.65 (IH, m), 3.03 (2H, t), 3.1 (IH3 dd), 3.37 - 3.41 (IH, m), 3.52-3.6 (IH, m), 3.7-3.78 (IH, m), 3.92-3.98 (IH, m), 6.13 (IH, d), 6.87 (IH, t), 7.60 (IH, d), 7.64 (IH, d), 12.15 (IH, s) m/z (ESI+) (M+H)+ = 524; HPLC tR = 2.86 min.
Intermediate 91 methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl]acetate
Figure imgf000162_0001
Anhydrous potassium carbonate (1.088 g, 7.88 mmol) was added in one portion to (S)-methyl 2- (pyrrolidin-3-yl)acetate hydrochloride (0.472 g, 2.63 mmol) and 6-chloro-N-((2r,5s)-5-hydroxy- 2-adamantyl)-2-propylsulfanyl-pyridine-3-carboxamide (1.0 g, 2.63 mmol) in butyronitrile (15 mL). The resulting suspension was stirred at 115 0C for 3 days.
The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (2x30 mL) and brine (30 mL), the organic phase dried (MgSO^.), filtered and evaporated to an orange oil.
The crude product was purified by flash silica chromatography with EtOAc. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2- adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetate (980 mg, 77%) as a pale yellow solid.
IH NMR (400.13 MHz, DMSOd6) δ 0.96 (3H, t), 1.33 - 1.36 (2H, m), 1.59 - 1.75 (9H, m), 1.92- 2.08 (5H5 m), 2.11-2.23 (IH, m), 2.53-2.7 (IH, m), 3.03 (2H, t), 3.08 - 3.13 (IH, m), 3.39 - 3.41 (IH, m), 3.52-3.61 (IH, m), 3.63 (3H5 s), 3.69 - 3.74 (IH, m), 3.85-3.92 (IH, m), 4.37 (IH, s), 6.13 (IH, d), 7.53 (IH, d), 7.64 (IH, d) m/z (ESI+) (M+H)+ = 488; HPLC tR = 2.52 min.
Intermediate 92 methyl 2- [(3 S)- 1 - [5 - [[(2r , 5 s)-5 -(difluoromethoxy)-2-adamantyl]carbamoy 1] -6-propy lsulfany 1- pyridin-2-yl]pyrrolidin-3-yl]acetate
Figure imgf000163_0001
A solution of 2-(fluorosulphonyl)difluoroacetic acid (0.411 mL, 3.98 mmol) in anhydrous acetonitrile (3 mL) was added dropwise to a solution of methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy- 2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetate (970 mg, 1.99 mmol) and copper (I) iodide (76 mg, 0.40 mmol) in anhydrous acetonitrile (27 mL) warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 °C for 30 minutes. The reaction mixture was concentrated and diluted with EtOAc (50 mL), and washed sequentially with water (2x25 mL) and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product as an orange oil. The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (790 mg, 74%) as a pale yellow foam.
IH NMR (400.13 MHz, DMSO-d6) δ 0.96 (3H, t), 1.39-1.48 (2H, m), 1.59 - 1.78 (3H, m), 1.84 - 1.95 (4H, m), 1.96-2.06 (5H, s), 2.07-2.22 (5H, t), 2.53 - 2.7 (IH, m), 3.03 (2H, t), 3.1 (IH, dd), 3.33 - 3.46 (IH, m), 3.52-3.6 (IH, m), 3.63 (3H, s), 3.70 - 3.77 (IH, m), 3.91 - 3.97 (IH, m), 6.13 (IH, d), 6.88 (IH, t), 7.60 (IH, d), 7.64 (IH, d) m/z (ESI+) (M+H)+ = 538; HPLC tR = 3.29 min.
5 Example 181
2-f(3S)-l-f5-[[(2r,5s)-5-(Difluoromethoxy)-2-adamantvncarbamoyll-6-propoxy-pyridiii-2- vn-3-piperidvn acetic acid
Figure imgf000164_0001
To a solution of methyl 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6- io propoxy-pyridin-2-yl] -3 -piperidyl] acetate (120 mg, 0.22 mmol) in MeOH (5 mL) was added 2M sodium hydroxide (1 mL, 2.00 mmol). The resulting solution was stirred at ambient temperature for 24 hours.
The mixture was evaporated to approximately quarter volume, water (5 mL) was added and the mixture acidified with IM citric acid (2 mL) causing formation of a white precipitate. i5 The mixture was stirred for 30 mins, filtered, washed with water and dried in vacuo at 5O0C to afford 2-[(3S)-l-[5-[[5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propoxy-pyridin-2-yl]-3- piperidyl]acetic acid (110 mg, 94%)
IH NMR (400.13 MHz, DMSOd6) δ 1.00 (3H, t), 1.2-1.35 (IH5 m), 1.37-1.49 (IH, m), 1.5-1.6 0 (2H, m), 1.61 - 1.96 (HH, m), 1.97-2.08 (2H, m), 2.1-2.3 (5H, m), 2.82 (IH, dd), 2.95-3.06 (IH, m), 4.03-4.09 (IH, m), 4.1 - 4.2 (IH, m), 4.25 - 4.28 (IH, m), 4.31 - 4.41 (2H, m), 6.45 (IH, d), 6.9 (IH, t), 7.97 (IH, d), 8.02 (IH, d), 12.2 (IH, s). m/z (ESI+) (M+H)+ = 522; HPLC tR = 2.97 min. 5 Intermediate 93 methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propoxy-pyridin-2-yl]-3- piperidyl] acetate.
Figure imgf000165_0001
A solution of trimethylsilyldiazomethane (2M solution in ether) (0.329 mL, 0.66 mmol) was added dropwise to a stirred solution of 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]- 6-propoxy-pyridin-2-yl] -3 -piperidyl] acetic acid (207 mg, 0.44 mmol) in 3:2 toluene:methanol (5 mL) at 220C, over a period of 1 minute. The resulting solution was stirred at ambient temperature for 1 hour.
A further 200μL of 2M TMSdiazomethane was added dropwise and the mixture was stirred at ambient temperature for 1 hour.
The mixture was evaporated and the crude product was purified by flash silica chromatography with EtOAc. Pure fractions were evaporated to dryness to afford methyl 2-[(3S)- l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propoxy-pyridin-2-yl]-3-piperidyl]acetate (210mg, 99%) as a colourless oil that crystallised on standing to a white solid.
IH NMR (400.13 MHz, DMSOd6) δ 1.00 (3H, t), 1.18 - 1.45 (4H, m), 57 - 1.9 (13H, m), 1.93 - 2.05 (3H, m), 2.2 - 2.32 (2H, m), 2.79 (IH, dd), 2.9 - 3.0 (IH, m), 3.6 (3H, s), 3.92-3.98 (IH, m), 4.04-4.1 (IH, m), 4.17 - 4.23 (IH, m), 4.26 - 4.35 (IH, m), 4.4 (IH, s), 6.4 (IH5 d), 7.92 (IH, d), 8.0 (IH, d) m/z (ESI+) (M+H)+ = 486; HPLC tR = 2.63 min.
Intermediate 94 methyl 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propoxy-pyridin-2- yl]-3-piperidyl]acetate
Figure imgf000165_0002
A solution of 2-(fluorosulphonyl)difluoiOacetic acid (0.128 mL, 1.24 mmol) in anhydrous acetonitrile (1 mL) was added dropwise to a solution of methyl 2-[(3S)-l-[5-[((2r,5s)-5-hydroxy- 2-adamantyl)carbamoyl]-6-propoxy-pyridin-2-yl]-3-piperidyl]acetate (200 mg, 0.41 mmol) and copper (I) iodide (15.69 mg, 0.08 mmol) in anhydrous acetonitrile (5 mL) warmed to 450C, over a period of 1 hour under nitrogen. The resulting solution was stirred at 45 °C for 30 minutes.
The reaction mixture was concentrated and diluted with EtOAc (25 mL), and washed sequentially with water (2x10 mL) and saturated brine (10 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product as an orange oil.
The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the desired product (120mg, 54%) as a pale yellow foam.
IH NMR (400.13 MHz, CDCl3) δ 1.06 (3H, t), 1.24-1.38 (IH, m), 1.5-1.64 (4H, m), 1.7 - 1.8 (IH, m), 1.82 -2.18 (HH, m), 2.2-2.32 (5H, m), 2.81 (IH, dd), 3.00 - 3.07 (IH, m), 3.69 (3H, s), 4.10 - 4.15 (IH, m), 4.24.3 (2H, m), 4.36 - 4.42 (2H, m), 6.28 (IH, d), 6.37 (IH, t), 8.10 (IH, d), 8.26 (IH, d) m/z (ESI+) (M+H)+ = 536; HPLC tR = 3.46 min. The following Examples were prepared in a similar manner to Example 175 from the corresponding acid compounds.
Figure imgf000166_0001
Figure imgf000167_0002
Example 186
(SV2-(l-(5-(CvclohexylcarbamoylV3-fluoro-6-(propylthio')r)yridin-2-yl>)piperidin-3-yl)acetic acid
Figure imgf000167_0001
A solution of aqueous 2N sodium hydroxide (1.6 niL, 3.19 mmol) was added to a stirred solution of (S)-methyl 2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6-(propylthio)pyridin-2-yl)piperidin-3- yl)acetate (240 mg, 0.53 mmol) in methanol (10 rtiL) at room temperature. The resulting solution was stirred at 20 °C for 18 hours. The reaction mixture was evaporated to dryness and dissolved in EtOAc (25 mL), and washed sequentially with 2M HCl (2 mL), and saturated brine (10 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford (S)-2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6- (propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid (225 mg, 97 %) as a white solid.
IH NMR (400.13 MHz, DMSO-d6) δ 0.95 (3H, t), 1.13 - 1.18 (IH, m), 1.22 - 1.30 (6H, m), 1.55 - 1.65 (4H, m), 1.70 - 1.84 (5H, m), 1.93 - 2.00 (IH, m), 2.13 - 2.24 (2H, m), 2.80 (IH, t), 2.93 - 3.02 (3H, m), 3.62 - 3.68 (IH, m), 4.03 (IH, d), 4.11 (IH, d), 7.63 (IH, d), 7.95 (IH, d), 12.17 (IH, s) m/z (ESI+) (M+H)+ = 438; HPLC tR -2.83min.
Intermediate 95
2,6-dichloro-N-cyclohexyl-5-fluoronicotinamide
Figure imgf000168_0001
Oxalyl chloride (3.74 mL, 42.86 mmol) was added portionwise to 2,6-dichloro-5-fluoronicotinic acid (3.00 g, 14.29 mmol) in dichloromethane (40 mL) at 2O0C. The resulting suspension was stirred at 20 °C for 1 hour. The reaction mixture was evaporated to dryness and dissolved in DCM (10 mL).
This solution was added portionwise to a stirred solution of cyclohexylamine (2.45 mL,
21.4 mmol) in dichloromethane (40 mL) at 2O0C. The resulting solution was stirred at 20 0C for 5 hours.
The reaction mixture was diluted with DCM (50 mL), and washed sequentially with IN HCl (10 mL), water (10 mL), saturated NaHCO3 (10 mL) and saturated brine (10 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product.
IH NMR (400.13 MHz, DMSO-d6) δ 1.28 (5H, t), 1.57 (IH, m), 1.70 (2H, m), 1.84 (2H, m), 3.72 (IH, m), 8.21 - 8.23 (IH, d), 8.54 - 8.58 (IH, d) m/z (ESI+) M+Acetonitrile = 332; HPLC tR = 2.33 min.
Intermediate 96
6-chloro-N-cyclohexyl-5-fluoro-2-(propylthio)nicotinamide
Figure imgf000168_0002
A solution of sodium bis(trimethylsilyl)amide (8.24 mL, 8.24 mmol) in THF (IM) was added to a stirred solution of 1-propanethiol (0.622 mL, 6.87 mmol) in DMF (30 mL) at 50C, over a period of 3 minutes under air. The resulting suspension was stirred at 20°C for 15 minutes. 2,6-dichloro- N-cyclohexyl-S-fluoronicotinamide (2.0 g, 6.87 mmol) in DMF (10 mL) was added at room temperature.
The reaction mixture was evaporated to dryness and dissolved in EtOAc (75 mL) and washed sequentially with water (20 mL) and saturated brine (15 mL). The organic layer was dried 5 over MgSO4, filtered and evaporated to afford crude product.
The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford ό-chloro-N-cvclohexyl-S- fluoro-2-(propylthio)nicotinamide ("0.900 g, 40 %) as a white solid.
io m/z (ESI+) (M+H)+ = 331; HPLC tR = 2.98 min.
Intermediate 97
(S)-methyl 2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6-(propylthio)pyridin-2-yl)piperidin-3- yl)acetate
Figure imgf000169_0001
(S)-methyl 2-(piperidin-3-yl)acetate hydrochloride (263 mg, 1.36 mmol) was added to 6-chloro- N-cyclohexyl-5-fluoro-2-(propylthio)nicotinamide (500 mg, 1.51 mmol) and potassium carbonate (418 μl, 3.02 mmol) in butyronitrile (20 ml) at room temperature and under air. The resulting suspension was stirred at 120 0C for 80 hours. 0 The reaction mixture was evaporated to dryness and dissolved in EtOAc (50 mL), and washed sequentially with water (20 mL) and saturated brine (10 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product.
The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford (S)-methyl 2-(l-(5-
25 (cvclohexylcarbamovD-3-fluoro-6-(ρropylthio)pyridin-2-yl)piperidin-3-yl)acetate (240 mg, 35 %") as a white solid.
IH NMR (500.13 MHz, DMSO-d6) δ 0.96 (3H, t), 1.10 - 1.17 (IH, m), 1.24 - 1.32 (5H, m), 1.54 - 1.64 (4H, m), 1.70 - 1.73 (3H, m), 1.80 - 1.84 (3H, m), 1.97 - 2.02 (IH, m), 2.26 - 2.31 (2H, m), 2.82 (IH, t), 2.96 (2H, t), 3.02 (IH, t), 3.61 (3H, s), 3.60 - 3.66 (IH, m), 4.02 (IH, d), 4.08 (IH, d), 7.63 (IH, d), 7.91 (IH, d) m/z (ESI+) (M+H)+ = 452; HPLC tR = 3.29 min.
Example 187
(R)-2-d-(5-(CvclohexylcarbamoylV3-fluoro-6-('propylthio)pyridin-2-yl>)piperidm-3-yl)acetic acid
Figure imgf000170_0001
Prepared in a similar manner to that described above from 6-chloro-N-cyclohexyl-5-fluoro-2- (propylthio)nicotinamide using (S)-methyl 2-(piperidin-3-yl)acetate hydrochloride followed by an ester hydrolysis as described above to give the desired compound (190 mg) as a white solid.
IH NMR (400.13 MHz, DMSO-d6) δ 0.95 (3H, t), 1.08 - 1.22 (2H, m), 1.26 - 1.30 (5H, m), 1.55
- 1.65 (4H, m), 1.70 - 1.84 (5H, m), 1.93 - 1.98 (IH, m), 2.16 - 2.21 (2H, m), 2.80 (IH, t), 2.93 - 3.00 (3H, m), 3.60 - 3.70 (IH, m), 4.02 (IH, d), 4.11 (IH, d), 7.63 (IH, d), 7.95 (IH5 d), 12.17
(IH, s) m/z (ESI+) (M+H)+ = 438; HPLC tR = 2.81 min.
As part of the above program of work, a number of aminoester starting materials were prepared and used according to the following procedures (R)-ethyl 2-(pyrrolidin-3-yloxy)acetate hydrochloride
Figure imgf000170_0002
tert-Butyl (3R)-3-(ethoxycarbonylmethoxy)pyrrolidine-l-carboxylate (4.Og, 15.42 mmol) was dissolved in 4N HCl in 1,4-dioxane (50 niL), stirred at ambient temperature for 3hrs, evaporated, co-evaporated with 1,4-dioxane (3x50 mL) and dried under high vacuum to give (R)-ethyl 2- (pyrrolidin-3-yloxy)acetate hydrochloride as an orange oil that solidifed on standing. (3.2 g, 100%).
IH NMR (400.13 MHz, DMSOd6) δ 1.21 (3H, t), 1.89 - 1.98 (IH, m), 2.05 - 2.10 (IH, m), 3.14 - 3.4 (4H, m), 4.14 (2H, q), 4.18 (2H, s), 4.29 - 4.33 (IH, m), 9.29 (IH, broad s), 9.65 (IH, broad s). the tert-butyl (3R)-3-(ethoxycarbonylmethoxy)pyrrolidine-l-carboxylate used as starting material was prepared as described below A solution of sodium bis(trimethylsilyl)amide in THF (58.7 mL, 58.75 mmol) was added dropwise to a stirred solution of (R)-tert-butyl 3-hydroxypyrrolidine-l-carboxylate (10 g, 53.41 mmol) in DMF (100 mL) over a period of 10 minutes under nitrogen. The resulting solution was stirred at ambient temperature for 10 minutes. Ethyl bromoacetate (8.92g, 53.41mmol) was added dropwise over 10 minutes (exotherm. Temperature kept below 3O0C using a cold water bath) and the reaction was stirred at ambient temperature for 20 hours.
The reaction mixture was evaporated, EtOAc (200 mL) added and washed sequentially with water (4x50 mL), and saturated brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product (14g) as an orange oil. The crude product was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford the product (4.Og, 28%) as a pale yellow oil.
IH NMR (400.13 MHz, DMSO-d6) δ 1.21 (3H, t), 1.41 (9H, s), 1.83-2.01 (2H, m), 3.2-3.32 (4H, m), 4.12 (2H, s), 4.1-4.2 (5H, m) (S)-ethyl 2-(pyrrolidin-3-yloxy)acetate hydrochloride
Figure imgf000171_0001
Prepared in a similar manner to that described above from (S)-tert-butyl 3-(2-ethoxy-2- oxoethoxy)pyrrolidine-l-carboxylate (4.7g, 17.2 mmol) to give the desired product (3.6g, 100%) as an oil that solidified on standing. IH NMR (400.13 MHz, DMSOd6) δ 1.21 (3H5 1), 1.86 - 1.97 (IH, m), 2.04 - 2.12 (IH, m), 3.1 - 3.3 (4H, m), 4.12 (2H, q), 4.17 (2H, s), 4.27 - 4.33 (IH, m), 9.3 (IH, broad s), 9.55 (IH, broad s) the (S)-tert-butyl 3 -(2-ethoxy-2-oxoethoxy pyrrolidine- 1-carboxylate used as starting material was prepared as described below
Prepared in a similar manner to that above from (S)-tert-butyl 3-hydroxypyrrolidine-l- carboxylate (10 g, 53.41 mmol) to give the desired product (4.7g, 32%) as a pale yellow oil. IH NMR (400.13 MHz, DMSOd6) δ 1.21 (3H, t), 1.41 (9H, s), 1.83-2.01 (2H, m), 3.2-3.32 (4H, m), 4.12 (2H, s), 4.1-4.2 (5H, m)
(R)-methyl 2-(pyrrolidin-3-yl)acetate hydrochloride
Figure imgf000172_0001
(R)-2-(l-(tert-butoxycarbonyl)pyrrolidin-3-yl)acetic acid (5.0 g, 21.81 mmol) in 4N HCl in dioxane (50 mL) was stirred at ambient temperature for 20 hours. The mixture was evaporated, coevaporated with dioxane (3x30 mL) and dried under high vacuum to give a yellow oil.
This was dissolved in methanol (50 mL) at 1O0C and the solution saturated with HCl gas.
The reaction mixture was then allowed to warm to ambient temperature and evaporated. The residue was co-evaporated with methanol (2x30 mL) and toluene (3x 30 mL) and dried under high vacuum to give a yellow oil (4.0 g). IH NMR (400.13 MHz, DMSO-d6) δ 1.52 - 1.57 (IH, m), 2.063- 2.13 (IH, m), 2.47 - 2.59 (3H, m), 2.7-2.8 (IH, m), 3.03 - 3.12 (IH, m), 3.14 - 3.25 (IH, m), 3.27 - 3.48 (3H, m), 3.61 (3H, s),
9.42 (2H, s)
(S)-methyl 2-(pyrrolidin-3-yl)acetate hydrochloride
Figure imgf000172_0002
Prepared in a similar manner to that described above from (S)-2-(l-(tert- butoxycarbonyl)pyrrolidin-3-yl)acetic acid (5.Og, 21.81 mmol) to give the desired compound (4.Og, 100%) as a yellow oil.
IH NMR (400.13 MHz, DMSOd6) δ 1.52 - 1.57 (IH, m), 2.063- 2.13 (IH, m), 2.47 - 2.59 (3H, m), 2.7-2.8 (IH, m), 3.03 - 3.12 (IH, m), 3.14 - 3.25 (IH, m), 3.27 - 3.48 (3H, m), 3.61 (3H5 s), 9.42 (2H, s).
Ethyl 2-methyl-2-(3-piperidyl)propanoate hydrochloride
Figure imgf000173_0001
H-Cl
Ethyl 2-methyl-2-pyridin-3-yl-propanoate (1.80 g, 9.3 mmol) in ethanol (100 ml) and 5% rhodium on alumina (180 mg, 0.09 mmol) were stirred under an atmosphere of hydrogen at a pressure of 4 bar and a temperature of 250C for 12 hours.
The reaction mixture was filtered through Celite to remove the catalyst. 10 mL of 4N HCl in dioxane was added to form the hydrochloride salt and the solvent was evaporated under reduced pressure to give ethyl 2-methyl-2-(3-piperidyl)propanoate hydrochloride as a brown oil (2.19 g,
100%).
IH NMR (300.073 MHz, DMSO-d6) δl.07 - 1.08 (6H, m), 1.20 (3H, t), 1.52 - 1.70 (2H, m), 1.80
(IH, m), 1.96 - 2.04 (IH, m), 2.60 - 2.80 (2H, m), 3.05 - 3.19 (2H, m), 4.08 (2H, q), 8.75 - 9.35 (2H, m)
The ethyl 2-methyl-2-pyridin-3-yl-propanoate used as starting material was prepared as described below
To a solution of ethyl 3-pyridyl acetate (3.30 g, 20.0 mmol) in DMF (30.0 mL) was added a
0.5M solution of potassium bis(trimethylsilyl)amide in toluene (80.0 mL, 40 mmol). The reaction mixture was stirred at room temperature for 30 minutes before adding MeI (3.99 mL, 64.0 mmol) in one portion. The reaction mixture was then stirred at room temperature for 18 hours.
The reaction mixture was evaporated to dryness and dissolved in DCM (150 mL), and washed sequentially with saturated NH4Cl (25 mL), water (50 mL), and saturated brine (25 mL).
The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford ethyl 2-methyl-2-pyridin-3-yl- propanoate (1.80 g, 9.3 mmol, 47%) as an orange oil.
s IHNMR (400.13 MHz, DMSO-d6) δl.14 (3H, t), 1.55 (6H, s), 4.08 (2H, q), 7.35 - 7.39 (IH, m), 7.70 - 7.75 (IH, m), 8.46 - 8.48 (IH, m), 8.56 (IH, d) m/z (ESI+) (M+H)+ = 194; HPLC tR = 0.71 min.
Ethyl l-(3-piperidyl)cycIopropane-l-carboxylate hydrochloride
Figure imgf000174_0001
Prepared in a similar manner to that described above by reacting ethyl 2-pyridin-3- ylacetate with 1,2-dibromoethane to give ethyl l-pyridin-3-y Icy clopropane-1-carboxy late which was then hydrogenated to give the desired compound as a brown oil (quantitative reaction). 5
1H NMR (400.13 MHz, DMSO-d6) 61.03 - 1.22 (5H, m), 1.23 - 1.28 (2H5 m), 1.45 - 1.83 (5H, m), 2.67 - 2.93 (2H, m), 3.02 - 3.36 (2H, m), 4.01 - 4.08 (2H, m), 8.75 - 9.35 (2H, m) Ethyl l-(3-piperidyl)cyclobutane-l-carboxylate hydrochloride
Figure imgf000174_0002
0 Prepared in a similar manner to that described above by reacting ethyl 2-pyridin-3- ylacetate with 1,3-dibromopropane to give ethyl l-pyridin-3-y Icy clobutane-1-carboxy late which was then hydrogenated to give the desired compound as a brown oil (quantitative reaction).
1H NMR (400.13 MHz, DMSOd6) δl.l l - 1.18 (IH, m), 1.20 - 1.26 (3H, t), 1.62 - 1.79 (5H, m),5 2.03 - 2.31 (5H, m), 2.58 - 2.78 (2H, m), 3.19 (2H, d), 4.13 (2H, q), 8.90 - 9.42 (2H, d) Ethyl 2-methyl-2-(4-piperidyl)propanoate
Figure imgf000175_0001
Ethyl 2-methyl-2-pyridin-4-yl-propanoate (1.50 g, 7.77 mmol) in ethanol (100 ml) and 5% rhodium on alumina (150 mg, 0.075 mmol) were stirred under an atmosphere of hydrogen at a pressure of 4 bars and a temperature of 25 °C for 12 hours. The reaction mixture was filtered through Celite to remove the catalyst. The solvent was evaporated under reduced pressure to give ethyl 2-methyl-2~(4-piperidyl)propanoate as a black oil (quantitative reaction).
IH NMR (300.073 MHz, DMSOd6) δ 1.04 (6H, s), 1.17 (3H, t), 1.25 - 1.33 (2H, m), 1.48 (IH, d), 1.52 - 1.64 (2H, m), 1.80 (IH, s), 2.55 - 2.61 (2H, m), 3.09 (2H, d), 4.05 (2H, q)
The ethyl 2-methyl-2-pyridin-4-yl-propanoate used as starting material was prepared as described below
To a solution of ethyl 4-pyridyl acetate (1.855 mL, 12.12 mmol) in DMF (30.0 mL) was added LiHMDS (15.15 mL, 15.15 mmol). The reaction was stirred at room temperature for 30 minutes before adding methyl iodide (1.21 mL, 19.4 mmol). The reaction mixture was stirred at room temperature for one hour before adding more LiHMDS (15.15 mL, 15.15 mmol). The reaction was stirred for another hour at room temperature before adding more methyl iodide (1.21 mL, 19.4 mmol). The reaction was then stirred at room temperature for two hours.
The reaction mixture was evaporated to dryness and dissolved in DCM (150 mL), and washed sequentially with saturated NH4Cl (25 mL), water (50 mL), and saturated brine (25 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was loaded on Celite and purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford ethyl 2- methyl-2-pyridin-4-yl-propanoate (1.061 g, 5.50 mmol, 45%) as a yellow oil. m/z (ESI+) (M+H)+ = 194; HPLC tR = 2.44 min. Ethyl l-(4-piperidyI)cyclobutane-l-carboxyIate
Figure imgf000176_0001
Prepared in a similar manner to that described above by reacting ethyl 4-pyridil acetate with 1,3- dibromopropane to give ethyl l-pyridin-4-ylcyclobutane-l-carboxylate which was then hydrogenated to give the desired compound as a black oil (quantitative reaction).
IH NMR (300.073 MHz, DMSOd6) δ 1.06 (2H, t), 1.10 - 1.23 (5H, m), 1.50 - 1.54 (2H, m), 1.63 - 1.75 (3H5 m), 1.83 (IH, s), 1.95 - 2.01 (2H, m), 2.22 - 2.28 (2H, m), 2.42 (IH, d), 2.99 (IH, d), 4.07 (2H, q)
Ethyl l-(4-piperidyl)cyclopropane-l-carboxylate
Figure imgf000176_0002
Prepared in a similar manner to that described above by reacting ethyl 4-pyridil acetate with 1,2 dibromoethane to give ethyl l-pyridin-4-y Icy clopropane-1-carboxy late which was then hydrogenated to give the desired compound as a black oil (quantitative reaction).
IH NMR (300.073 MHz, DMSO-d6) δ 0.73 - 0.78 (2H, m), 0.92 - 0.98 (2H3 m), 1.14 (3H, t), 1.23 - 1.32 (2H, m), 1.42 - 1.50 (2H, m), 2.38 (2H, t), 2.89 - 2.93 (4H, m), 4.01 (2H, q)
Ethyl 2-(3-piperidyloxy)propanoate
Figure imgf000176_0003
Prepared in a similar manner to that described above from ethyl 2-pyridin-3-yloxypropanoate to give the desired compound as a black gum (quantitative reaction).
IH NMR (300.073 MHz, DMSOd6) δ 1.17 - 1.22 (5H, m), 1.25 - 1.27 (2H, m), 1.38 (2H5 d), 1.64 - 1.68 (2H, m), 1.76 - 1.86 (2H, m), 2.76 - 3.05 (2H, m), 3.36 - 3.42 (IH, m), 4.03 - 4.18 (3H5 m)
Ethyl 2-methyl-2-(3-piperidyloxy)propanoate
Figure imgf000177_0001
Prepared in a similar manner to that described above from ethyl 2-methyl-2-pyridin-3-yloxy- propanoate to give the desired compound as a black gum (quantitative reaction).
IH NMR (300.073 MHz, DMSO-d6) δ 1.20 (3H, t), 1.23 - 1.28 (2H, m), 1.30 (6H, s), 1.54 - 1.59 (IH, m), 1.82 - 1.91 (IH, m), 2.20 - 2.29 (2H, m), 2.69 (IH, d), 2.95 - 2.97 (2H, m), 3.17 - 3. 28 (lH, m), 4.10 (2H, q)
Ethyl 2-(3~piperidyloxy)acetate
Figure imgf000177_0002
Prepared in a similar manner to that described above from ethyl 2-(2-chloropyridin-3- yl)oxyacetate to give the desired compound as a brown gum (quantitative reaction).
IH NMR (300.073 MHz, DMSO-d6) δ 1.20 (3H, t), 1.54 - 1.65 (2H, m), 1.76 - 1.84 (2H, m), 2.89 - 2.95 (4H,m), 3.13 - 3.19 (IH, m), 3.68 - 3.76 (IH, m), 4.12 (2H, q), 4.20 (2H, s)
As part of the above programme of work, a number of ester intermediates of final products were characterised. Representative examples are given below
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001

Claims

1. A compound of formula (1) :
Figure imgf000182_0001
(1)
wherein: o Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, C1-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring;
R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl, C3-7cycloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, phenyl, phenylC1-3alkyl, heteroaryl,s heteroarylC1-3alkyl, heterocyclyl, or heterocyclylC1-3alkyl [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C^alkoxy, carboxyC1-3alkyl, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5>)(R5")NC(O)-, R5>C(O)-, R5 OC(O)- and (R5')(R5")NSO2- (wherein R5 is C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl,Q halo and cyano; and
R5 and R5 are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-3alkoxy, carboxy and cyano or R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)] and optional substituents for heterocyclyl and the heterocyclyl group in 5 heterocyclic i-3alkyl are additionally selected from R21, R21CO- R21S(O)k (wherein k is 0, 1 or 2) and R21CH2OC(O)- wherein R21 is phenyl optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, cyano and trifluoromethyl; or when Q is a bond R1 may also be hydrogen; R2 is selected from C3-7cycloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein the cycloalkyl and polycycloalkyl rings optionally contain 1 or 2 ring atoms independently selected from nitrogen, oxygen and sulphur; m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from R6); R3 is selected from hydrogen, C1-4alkyl C3-5cycloalkyl and C3-5cycloalkylmethyl;
R2 and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7;
R4 is independently selected from halo, C1-2alkyl, cyano, C1-2alkoxy, and trifluoromethyl; R and R are independently selected from hydroxyl, halo, oxo, carboxy, cyano, trifluoromethyl, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9*)(R9")NC(O)~, (R9>)(R9")N-, R9S(O)a- wherein a is O to 2, R9 OC(O)-, (R9')(R9")NSO2-, R9SO2N(R9")-, (R9')(R9")NC(O)N(R9'")-, phenyl and heteroaryl [wherein the phenyl and heteroaryl groups are optionally fused to a phenyl, heteroaryl or a saturated or partially-saturated 5- or 6-membered ring optionally containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur and the resulting ring system is optionally substituted by 1, 2 or 3 substituents independently selected from C1-4alkyl, hydroxyl, cyano, trifluoromethyl, trifluoromoxy, halo, C1-4alkoxy, C1-4alkoxyC1-4alkyl, C1-4alkoxyCi-4alkyl, amino, N-C1-4alkylamino, di-N,N-(C1-4alkyl)amino, N-C1-4alkylcarbamoyl, di-N,N-(C1-4alkyl)carbamoyl, C1-4alkylS(O)r, C1-4alkylS(O)rC1-4alkyl (wherein r is 0, 1 and 2)]; R9 is independently C^alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-4alkoxy, carboxy and cyano; R9 , R9 and R9 are independently selected from hydrogen and C1-3 alky 1 optionally substituted by hydroxyl, halo, C1-4alkoxy, carboxy or cyano); p is O, 1 or 2; either X is -O(CH2)q-, -S(CH2) q- or -N(R12)(CH2) q- wherein R12 is hydrogen, Ci-3alkyl or C1. 3alkanoyl and q is 0 or 1; and Y is: 1) a C3-7cy cloalkdiyl ring, a phenylene ring, an adamantdiyl group, a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur, or -[C(Rx)(Ry)]v- (wherein Rx and Ry are independently selected from hydrogen, Ci-3alkyl, C1-3alkoxy and hydroxyl or Rx and Ry together with the carbon atom to which they are attached form a C3.7cycloalkdiyl ring and v is 1, 2, 3, 4 or 5) and when v is more than 1 the -[C(Rx)(Ry )]v- group may optionally be interrupted by a -O-, - S- or -N(R20)- group wherein R20 is hydrogen or C^aUcyl; or 2) -X-Y- together represents a group of the formula:
Figure imgf000184_0001
(Z)t[C(Ri3)(Ri4)]s.
wherein: ring A is linked to the pyridine group and -(Z)t[C(R13)(R14)]s- is linked to the carboxy group; and
A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
Z is -O-, -S- or-N(R16)- wherein R16 is hydrogen, C1-3alkyl or C1-3alkanoyl; t is 0 or 1 provided that when s is 0 then t is 0;
R10 is independently selected from C1-3alkyl, C2-3alkenyl, C2-3alkynyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R11CON(R11'),
(R11 XR1 r)NC(O)-, R11OC(O)- and (Ri r)(Rn")NSO2- (wherein R11 is C1-3alkyl optionally substituted by hydroxyl, halo or cyano; and R11 and R11 are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-3alkoxy, carboxy or cyano) or R11 and R11 together with the nitrogen atom to which they are attached form a 4-7 membered ring; u is 0, 1 or 2;
R13 and R14 are independently selected from hydrogen and C1-3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof; provided the compound is not:
{ (35)- 1 -[5-(adamantan- 1 -ylcarbamoyl)pyridin-2-yl]piperidin-3 -yl} acetic acid; or {(3S)-l-[5-(cyclohexylcarbamoyl)-6-(piperazin-l-yl)pyridin-2-yl]piperidin-3-yl}acetic acid; or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
2. A compound according to claim 1 wherein: Q is O, S or a single bond and R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3_7cycloalkyl, C3. 7cycloalkylC1-3alkyl, C3-7cycloalkylC2-3alkenyl or C3-7cycloalkylC2-3alkynyl, [each of which is optionally substituted by 1, 2 or 3 substituents independently selected from C1-3alkyl, hydroxy, halo, oxo, cyano, trifluoromethyl, C1-3alkoxy, C1-3alkylS(O)n- (wherein n is 0, 1, 2 or 3), R5CON(R5')-, (R5')(R5")NC(O)-, R5 OC(O)- and (R5')(R5")NSO2- (wherein R5 is C^alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy 1, halo and cyano; and R5 and R5 are independently selected from hydrogen and C 1-3alkyl optionally substituted by 1, 2 or 3 substituents independently hydroxyl, halo, Ci-3alkoxy, carboxy and cyano or R5 and R5 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)].
3. A compound according to claim 1 wherein Q is -S- and R1 is Ci-6alkyl, C3-7cycloalkyl or C3-7cycloalkylC1-3alkyl.
4. A compound according to any one of claims 1 to 3 wherein p is 0.
5. A compound according to any one of claims 1 to 4 wherein R2 is selected from C3-7cy cloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein m is 0, 1 or 2 and the rings are optionally substituted by 1 or 2 substituents independently selected from R6, and R6 is independently selected from hydroxyl, halo and trifluoromethyl).
6. A compound according to any one of claims 1 to 5 wherein R3 is hydrogen.
7. A compound according to any one of claims 1 to 4 wherein R2 and R3 together with the nitrogen atom to which they are attached form a saturated 5 or 6-membered mono, ring system optionally containing 1 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and is optionally substituted by 1 or 2 substituents independently selected from R wherein R7 is selected from hydroxy, halo and trifluoromethyl.
8. A compound according to any one of claims 1 to 7 wherein X is -O-, -S- or -N(R12)- wherein R12 is hydrogen, Ci-3alkyl or Ci-3alkanoyl and Y is a C3-7cycloalkdiyl ring or a 5-7 membered saturated heterocyclic ring (linked by a ring carbon atom) containing 1 or 2 ring heteroatoms selected from nitrogen, oxygen and sulphur.
9. A compound according to any one of claims 1 to 7 wherein -X-Y- together represents a group of the formula:
Figure imgf000186_0001
wherein: ring A is linked to the pyridine group and -[C(R13)(R14)]S- is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur;
R10 is independently selected from Ci-3alkyl, hydroxy, halo and trifluoromethyl; u is 0, or 1 ; R13 and R14 are independently selected from hydrogen and Ci_3alkyl or R13 and R14 may together with the carbon atom to which they are attached form a C3-7cycloalkyl ring; and s is 0, 1 or 2.
10. A compound according to claim 1 , which is: 2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid l-[5-(cyclohexylcarbamoyl)-6-piOpylsulfanyl-pyridin-2-yl]piperidine-3-carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperidine-4-carboxy lie acid 2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piρeridyl]acetic acid 2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid 1 - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-ρyridin-2-yl]pyrrolidine-3 -carboxylic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperazin-l-yl]acetic acid
(3 R,5 S)-4- [ [5 -(cyclohexylcarbamoy l)-6-ρropylsulfany l-pyridin-2-yl] amino] adamantane- 1 - carboxylic acid
(3R,5S)-4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]aπiino]adamantane-l- carboxylic acid
4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-methyl-amino]cyclohexane-l- carboxylic acid
2- [(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3 -yl] acetic acid
3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxybenzoic acid
3-[5-(cyclohexylcarbainoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylbenzoic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-ρyridin-2-yl]sulfanylbenzoic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxybenzoic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]acetic acid
3-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]propanoic acid
2- [4- [5 -(cy clohexy lcarbamoy l)-6-propy lsulfany l-pyridin-2-yl] sulfanylphenoxy] acetic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenoxy]acetic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]propanoic acid
2-[4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylphenyl]acetic acid
2-[3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxyphenyl]acetic acid
2-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]sulfanylbenzoic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]oxycyclohexane-l -carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]piperidine-2-carboxy lie acid
(2S)-l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-2-carboxy lie acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]propanoic acid
4-[[[5-(cyclohexylcarbamoyl)-6-proρylsulfanyl-pyridin-2-yl]amino]methyl]cyclohexane-l- carboxylic acid
3-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]amino]propanoic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]azepane-4-carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-methyl-piperidine-4-carboxylic acid (1 S,5R)-3-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-
6-carboxylic acid
4-[[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]amino]cyclohexane-l-carboxylic acid
1 - [5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl] -4~propan-2-yl-piperidine-4- carboxylic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-methyl-piperidine-4-carboxylic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]-2-methyl-piOpanoic acid
2-[(3R)- 1 -[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
3-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]propanoic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]azetidin-3-yl]oxyacetic acid
1 -[ 1 -[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]cyclobutane- 1 - carboxylic acid
1 - [ 1 - [5 -(cy clohexy lcarbamoyl)-6-propylsulfany l-pyridin-2-y 1] -3 -piperidy 1] cyclopropane- 1 - carboxylic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid
2-[[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]oxy]propanoic acid
2- [ [ 1 - [5 -(cy clohexy lcarbamoy l)-6-propy lsulfany l-pyridin-2-y 1] -3 -piperidy 1] oxy] -2-methy 1- propanoic acid
2-[[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]oxy]acetic acid l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-methyl-piperidine-3-carboxylic acid
2-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]-2-methyl-propanoic acid l-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]cyclobutane-l- carboxylic acid l-[l-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-4-piperidyl]cyclopropane-l- carboxylic acid
4-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]morpholine-2-carboxy lie acid 2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclohexylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclohexylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]-3-ρiperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid l-[l-[5-(cyclohexylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]-3-piperidyl]cyclopropane-l- carboxylic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]oxyacetic acid
2-[(3R)- 1 -[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3 -yljoxyacetic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxylic acid
2-[(3R)- 1 -[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(2S)- 1 -[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-2-carboxylic acid
(1 S,5R)-3-[5-(2-adamantylcarbamoyl)-6-ρropylsulfanyl-pyridin-2-yl]-3-azabicyclo[3.1.OJhexane-
6-carboxylic acid
(3S)-l-[5-(2-adamantylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxy lie acid
4- [5 -(2-adamantylcarbamoy l)-6-propylsulfanyl-pyridin-2-yl]morpholine-2-carboxylic acid
2-[(3S)-l-[5-(2-adamantylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3- yl]oxyacetic acid
2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-cyclopentylsulfanyl-pyridin-2-yl]pyrrolidin-3- yl]oxyacetic acid
2-[(3 S)- 1 - [5-(2-adamanty lcarbamoyl)-6-cyclohexylsulfanyl-pyridin-2-yl]pyrrolidin-3 - yljoxyacetic acid
2- [(3 R)- 1 - [5 -(2-adamantylcarbamoy l)-6-cyclohexylsulfanyl-pyridin-2-yl]pyrrolidin-3 - yljoxyacetic acid 2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxy lie acid
(3S)-I- [5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]pyrrolidine-3 -carboxylic acid
(lS,5R)-3-[5-(2-adamantylcarbamoyl)-6-ethylsulfanyl-pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-
6-carboxylic acid
2-[(3R)-l-[5-(2-adamantylcarbamoyl)-6-methylsulfanyl-pyridin-2-yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[5-(2-adamantylcarbamoyl)-6-methylsulfanyl-pyridin-2-yl]pyrrolidine-3-carboxylic acid
(lS,5R)-3-[5-(2-adamantylcarbamoyl)-6-methylsulfanyl-pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-proρylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl]acetic acid
4-[[[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2- yl]amino]methyl]cyclohexane- 1 -carboxylic acid
4-[[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2- yl]amino]cyclohexane- 1 -carboxylic acid
4- [ [5 - [((2r, 5 s)-5 -hy droxy-2-adamantyl)carbamoyl] -6-propylsulfany l-pyridin-2- yl]amino]cyclohexane- 1 -carboxylic acid
2-[(3S)-l-[5-[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]piperidine-4- carboxylic acid
2-[(3R)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-4- piperidyl] acetic acid
(lR,5S)-3-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxylic acid l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-4-methyl- piperidine-4-carboxylic acid l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2-yl]pyrrolidine-3- carboxylic acid 2-[(3R)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl] acetic acid
3 - [ 1 - [5 - [[(2r, 5 s)-5 -hydroxy-2-adamanty 1] carbamoyl] -6-propylsulfany l-pyridin-2-yl] -3 - piperidyl]propanoic acid
2-[l-[5- [((2r, 5 s)-5 -hydroxy-2-adamantyl)carbamoyl] -6-propylsulfanyl-pyridin-2-yl] -3 -piperidyl] -
2-methyl-propanoic acid
2-[(3S)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3-yl] acetic acid
2-[(3S)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3R)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3-yl]acetic acid
(3R)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-3-carboxylic acid
(2S)-l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-2-carboxylic acid
( 1 R,5 S)-3 -[6-cy clopentylsulfanyl-5 - [((2r,5s)-5 -hydroxy-2-adamanty l)carbamoyl]pyridin-2-yl]-3 - azabicyclo[3.1.0]hexane-6-carboxylic acid l-[6-cyclopentylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2-yl]piperidine-
4-carboxylic acid
2-[(3R)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidin-3-yl] acetic acid
(2S)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-2-carboxylic acid
(3R)-l-[6-cyclohexylsulfanyl-5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]pyridin-2- yl]pyrrolidine-3-carboxylic acid
2-[(3 S)- 1 -[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-(3-methylbutylsulfanyl)pyridin-2- yl]-3-piperidyl]acetic acid
(3R)-l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-(3-methylbutylsulfanyl)pyridin-2- yl]pyrrolidine-3-carboxylic acid (lR,5S)-3-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-(3-methylbutylsulfanyl)pyridin-2- yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[6-benzylsulfanyl-5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[5-[[(2r,5s)-5-hydiOxy-2-adamantyl]carbamoyl]-6-phenethylsulfanyl-pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[5-[[(2r,5s)-5-hydroxy-2-adamantyl]carbamoyl]-6-propoxy-pyridin-2-yl]-3- piperidyl] acetic acid
2-[l-[5-[((2r,5s)-5-hydroxy-2-adamantyl)carbamoyl]-6-propoxy-pyridin-2-yl]-3-piperidyl]-2- methyl-propanoic acid
( 1 R,5 S,6r)-3-(6-(cyclopentylthio)-5 -(3 -(pyridin-3-yl)pyrrolidine- 1 -carbonyl)pyridin-2-yl)-3 - azabicyclo [3.1.0]hexane-6-carboxylic acid
(lS,5R)-3-[6-cyclohexylsulfanyl-5-(3-pyridin-3-ylpyrrolidine-l-carbonyl)pyridin-2-yl]-3- azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[6-propylsulfanyl-5-(3-pyridin-3-ylpyπOlidine-l-carbonyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[6-propylsulfanyl-5-(3-pyridin-2-ylpyrrolidine-l-carbonyl)pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[5 -(piperidine- 1 -carbonyl)-6-propylsulfanyl-pyridin-2-yl] -3 -piperidyl] acetic acid
2-[(3S)-l-[6-propylsulfanyl-5-(3-pyrazin-2-ylpyrrolidine-l-carbonyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(4,4-difluoropiperidine-l-carbonyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[6-propylsulfanyl-5-[3-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[6-propylsulfanyl-5-[4-(trifluoromethyl)piperidine-l-carbonyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(4-carbamoylpiperidine-l-carbonyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-cyclopropyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyljacetic acid 2-[(3S)-l-[5-(cyclohexyl-(cyclopropylmethyl)carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexyl-ethyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-propan-2-yl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3- piperidyl] acetic acid
2- [(3 S)- 1 - [5 - [(4-hy droxycyclohexy l)carbamoy 1] -6-propy lsulfany l-pyridin-2-y 1] -3 - piperidyl]acetic acid
2-[(3S)-l-[6-propylsulfanyl-5-[3-[2-(trifluoromethyl)phenyl]pyrrolidine-l-carbonyl]pyridin-2- yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-[((2r,5s)-5-meth.ylsulfonyl-2-adamantyl)carbamoyl]-6-propylsulfanyl-pyridin-2-yl]-
3 -piperidyl] acetic acid
2-[(3S)-l-[6-cyclopentylsulfanyl-5-(3-pyridin-3-ylpyrrolidine-l-carbonyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3R)-l-[5-(cyclohexylcarbamoyl)-6-phenethylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid2~
[(3S)-l-[5-(cyclohexylcarbamoyl)-6-plienethylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(2-pyridin-3-ylethylsulfanyl)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(2-pyrazin-2-ylethylsulfanyl)pyridin-2-yl]-3- piperidyljacetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-[2-(4-fluorophenyl)ethoxy]pyridin-2-yl]-3-piperidyl]acetic acid 2- [(3 S)-I- [5-(cy clohexylcarbamoy l)-6-(3 -methylbutoxy)pyridin-2-yl] -3 -piperidyl] acetic acid
2- [(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6-(3 -phenylpropoxy)pyridin-2-yl]-3 -piperidyljacetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(2-pyridin-3-ylethoxy)pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6-methoxy-pyridin-2-yl]-3 -piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-propoxy-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(l-piperidyl)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[6-[2-(4-chlorophenyl)ethylamino]-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3- piperidyljacetic acid
2- [(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6- [3 -(4-fluorophenyl)pyrrolidin- 1 -yl]pyridin-2-yl]-3 - piperidyljacetic acid 2-[(3 S)-I- [5-(cy clohexylcarbamoyl)-6-(3 ,4-dihydro- 1 H-isoquinolin-2-yl)pyridin-2-yl]-3 - piperidyl] acetic acid
2-[(3S)-I- [5-(cyclohexylcarbamoyl)-6-(3 ,4-dihydro- 1 H-isoquinolin-2-yl)pyridin-2-yl]-3 - piperidyl] acetic acid 2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(4-phenylpiperazin-l-yl)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-[4-(4-fluorobenzoyl)piperazin-l-yl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[6-(4-acetylpiperazin-l-yl)-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)- 1 - [5 -(cy clohexy lcarbamoy l)-6-(4-ethylsulfony lpiperazin- 1 -yl)pyridin-2-yl] -3 - piperidyl]acetic acid
2-[(3S)-l-[6-[4-(benzenesulfonyl)piperazin-l-yl]-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3- piperidyl] acetic acid 2-[(3S)-l-[5-(cyclohexylcarbanioyl)-6-(4-phenylmetlioxycarbonylpiperazin-l-yl)pyridin-2-yl]-3- piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-propylamino-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(phenethylamino)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-(methyl-phenethyl-amino)pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)- 1 - [5 -(cyclohexylcarbamoyl)-6-(methyl-propyl-amino)pyridin-2-yl] -3 -piperidyl] acetic acid
2- [(3 S)- 1 - [5-(cyclohexylcarbamoyl)-6-pyrrolidin- 1 -yl-pyridin-2-yl] -3 -piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-morpholin-4-yl-pyridin-2-yl]-3-piperidyl]acetic acid 2-[(3S)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-propylamino-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-(methyl-propyl-amino)pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-metriyl-pyridin-2-yl]-3-ρiperidyl]acetic acid
2- [(3 S)- 1 - [5-( 1 -adamantylcarbamoyl)-6-methyl-pyridin-2-yl]-3 -piperidyl]acetic acid 2-[(3S)- 1 -[5-(2-adamantylcarbamoyl)-6-methyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-I- [5 -(2-adamantylcarbamoyl)-6-butyl-pyridin-2-yl] -3 -piperidyl] acetic acid 3-[5-(2-adamantylcarbamoyl)-6-butyl-pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid
2-[(3S)-l-[6-butyl-5-(cyclohexylcarbamoyl)pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexylcarbamoyl)-6-cyclopropyl-pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)- 1 - [5 -(2-adamantylcarbamoyl)-6-cy clopropyl-ρyridin-2-yl] -3 -piperidyl] acetic acid
2-[(3S)-l-[6-cyclopropyl-5-[[(2r,5s)-5-hydroxy-2-adaniantyl]carbamoyl]pyridin-2-yl]-3- piperidyl] acetic acid
2-[(3R)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-(cyclohexyl-methyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid [(35)-l-{5-[((2r,5s)-5-methoxyadamantan-2-yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2- yl}piperidin-3-yl] acetic acid
[(3<S)-l-{5-[((2r,5s)-5-hydroxyadamantan-2-yl)(methyl)carbamoyl]-6-(propylthio)pyridin-2- yl}piperidin-3-yl] acetic acid
{ (35)- 1 -[5 -(adamantan- 1 -ylcarbamoyl)-6-(propylthio)pyridin-2-yl]piperidin-3 -yl} acetic acid {(35)-l-[6-(propylthio)-5-(tetrahydro-2if-pyran-4-ylcarbamoyl)pyridin-2-yl]piperidin-3-yl}acetic acid
[(3S)-l-{5-[methyl(tetrahydro-2H-pyran-4-yl)carbamoyl]-6-(propylthio)pyridin-2-yl}piperidin-3- yl] acetic acid
2-[(3 S)- 1 -[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetic acid
2-[(3S)-l-[6-cyclohexylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]-3-piperidyl]acetic acid
2-[(3S)-l-[6-cycloρentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidin-3-yl]acetic acid 2-[(3S)-l-[6-cycloρentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]-3-piperidyl]acetic acid
2- [(3 S)- 1 - [5- [[(2r,5 s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl] -6-propylsulfanyl-pyridin-2- yl]-3-piperidyl]acetic acid
2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidin-3-yl]acetic acid 2-[(3S)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propoxy-pyridin-2-yl]-3- piperidyl] acetic acid
(3R)-l-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]pyrrolidine-3-carboxy lie acid (iR,5S)-3-[6-cyclopentylsulfanyl-5-[[(2r,5s)-5-(difluoromethoxy)-2- adamantyl]carbamoyl]pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid 2-[(3R)-l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl- pyridin-2-yl]pyrrolidin-3-yl]acetic acid l-[5-[[(2r,5s)-5-(difluoromethoxy)-2-adamantyl]carbamoyl]-6-propylsulfanyl-pyridin-2- yl]pyrrolidine-3-carboxylic acid
(S)-2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid or (R)-2-(l-(5-(cyclohexylcarbamoyl)-3-fluoro-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid or a pharmaceutically-acceptable salt thereof.
11. A pharmaceutical composition, which comprises a compound according to claim 1 in association with a pharmaceutically-acceptable diluent or carrier.
12. A compound according to claim 1, for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
13. A compound according to claim 1 for use as a medicament.
14. A compound according to claim 13, wherein the medicament is a medicament for treatment of metabolic syndrome, type II diabetes, obesity or atherosclerosis.
15. The use of a compound according to claim 1 in the manufacture of a medicament for use in the production of an 1 lβHSDl inhibitory effect in a warm-blooded animal, such as man.
16. A process for preparing a compound according to claim 1 , which process [wherein Z is -X-Y-COOH and other variable groups are, unless otherwise specified, as defined in formula (1) in claim 1] comprises any one of processes a) to e): a) reaction of a compound of Formula (2) with a compound of Formula (3):
Figure imgf000197_0001
b) reaction of a compound of Formula (4) with a compound of Formula (5) :
Figure imgf000197_0002
wherein X is a leaving group; or c) reaction of a compound of Formula (6) with a compound of Formula (7):
Figure imgf000197_0003
(6) (7)
wherein X' is a leaving group; or d) reaction of a compound of Formula (8) with a compound of Formula (9):
Figure imgf000197_0004
wherein X" is a leaving group; or e) reaction of a compound of Formula (10) with a compound of Formula (11):
Figure imgf000198_0001
(10) (11)
wherein X'" is a leaving group; and thereafter if necessary or desirable: i) converting a compound of the formula (1) into another compound of the formula (1);
10 ii) removing any protecting groups; iii) resolving enantiomers; iv) forming a pharmaceutically-acceptable salt or in vivo hydrolysable thereof.
I5
0
5
PCT/GB2007/004131 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors Ceased WO2008053194A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
BRPI0717970A BRPI0717970C1 (en) 2006-11-03 2007-10-31 11betahsd1 inhibitor compound, pharmaceutical composition, and use of the compound
AU2007315955A AU2007315955B2 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-HSD1 inhibitors
HR20100522T HRP20100522T1 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
PL07824375T PL2086939T3 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
UAA200903812A UA97119C2 (en) 2006-11-03 2007-10-31 Compounds exhibiting inhibiting activity to human 11beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd1)
HK10101460.7A HK1135090B (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
KR1020097010339A KR101465275B1 (en) 2006-11-03 2007-10-31 Pyridinecarboxamide as an 11-beta-HSDl inhibitor
AT07824375T ATE475649T1 (en) 2006-11-03 2007-10-31 PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS
CA2668006A CA2668006C (en) 2006-11-03 2007-10-31 Substituted pyridin-3-yl amides as 1.beta.hsd1 inhibitors
DE602007008137T DE602007008137D1 (en) 2006-11-03 2007-10-31 Pyridincarboxamide als 11-beta-hsd1-inhibitoren
SI200730335T SI2086939T1 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
JP2009535119A JP5165688B2 (en) 2006-11-03 2007-10-31 Compound
CN2007800491675A CN101573336B (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-HSD1 inhibitors
DK07824375.5T DK2086939T3 (en) 2006-11-03 2007-10-31 Pyridiacarboxamide as II-beta-HSDI inhibitors
NZ576501A NZ576501A (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
EP07824375A EP2086939B8 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
MX2009004707A MX2009004707A (en) 2006-11-03 2007-10-31 Chemical compounds.
IL198231A IL198231A0 (en) 2006-11-03 2009-04-20 Pyridine carboxamides as 11??hsd1 inhibitors
NO20091603A NO20091603L (en) 2006-11-03 2009-04-22 Chemical connections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86430306P 2006-11-03 2006-11-03
US86424706P 2006-11-03 2006-11-03
US60/864,247 2006-11-03
US60/864,303 2006-11-03

Publications (2)

Publication Number Publication Date
WO2008053194A2 true WO2008053194A2 (en) 2008-05-08
WO2008053194A3 WO2008053194A3 (en) 2008-10-02

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004131 Ceased WO2008053194A2 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors

Country Status (30)

Country Link
US (3) US7964618B2 (en)
EP (2) EP2233480B1 (en)
JP (1) JP5165688B2 (en)
KR (1) KR101465275B1 (en)
CN (3) CN101787016B (en)
AR (1) AR063458A1 (en)
AT (1) ATE475649T1 (en)
AU (1) AU2007315955B2 (en)
BR (1) BRPI0717970C1 (en)
CA (1) CA2668006C (en)
CL (1) CL2007003176A1 (en)
CO (1) CO6321130A2 (en)
CY (1) CY1110813T1 (en)
DE (1) DE602007008137D1 (en)
DK (1) DK2086939T3 (en)
ES (2) ES2347491T3 (en)
HR (1) HRP20100522T1 (en)
IL (1) IL198231A0 (en)
MX (1) MX2009004707A (en)
NO (1) NO20091603L (en)
NZ (1) NZ576501A (en)
PE (1) PE20081487A1 (en)
PL (1) PL2086939T3 (en)
PT (1) PT2086939E (en)
RS (1) RS51451B (en)
RU (1) RU2451674C2 (en)
SI (1) SI2086939T1 (en)
TW (1) TW200827346A (en)
UY (1) UY30681A1 (en)
WO (1) WO2008053194A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
US7816391B2 (en) 2007-02-12 2010-10-19 Astrazeneca Ab Chemical compounds
EP2243479A2 (en) 2009-04-20 2010-10-27 Abbott Laboratories Novel amide and amidine derivates and uses thereof
WO2011049520A1 (en) * 2009-10-20 2011-04-28 Astrazeneca Ab Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 1 1 betahsd1
US7951833B2 (en) 2008-02-04 2011-05-31 Astrazeneca Ab Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471
US7964618B2 (en) 2006-11-03 2011-06-21 Astrazeneca Ab Chemical compounds
EP2202228A4 (en) * 2007-10-15 2011-06-29 Takeda Pharmaceutical Amide compounds and use of the same
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8324265B2 (en) 2005-11-21 2012-12-04 Shionogi & Co., Ltd. Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
US8383622B2 (en) 2007-05-18 2013-02-26 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2013512243A (en) * 2009-11-24 2013-04-11 アラーガン インコーポレイテッド Novel compounds as receptor modulators with therapeutic utility
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2013189864A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists
WO2013189862A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as lpar antagonists
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
WO2024095003A1 (en) * 2022-11-02 2024-05-10 Cerevance, Inc. Nicotinamide derivatives for use in treating disorders associated with kcnk13 activity
WO2025257199A1 (en) 2024-06-11 2025-12-18 Astrazeneca Ab Therapies for wound treatment

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2719936A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
KR20110123657A (en) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 Picolinamide and pyrimidine-4-carboxamide compounds, methods for their preparation and pharmaceutical compositions containing the same
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
JP5697800B2 (en) * 2011-07-21 2015-04-08 シュエンジュウ・ファーマ・カンパニー・リミテッド Heterocyclic substituted pyrimidine compounds
CN102659657B (en) * 2012-04-24 2014-08-06 徐州医学院 Method for synthesizing protease inhibitor PF429242

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (en) 1978-02-21 1981-03-27 Delalande Sa
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
CN102584799A (en) 1999-09-16 2012-07-18 田边三菱制药株式会社 Aromatic nitrogenous six-membered ring compounds
FR2803592A1 (en) * 2000-01-06 2001-07-13 Aventis Cropscience Sa NOVEL DERIVATIVES OF 3-HYDROXYPICOLINIC ACID, PROCESS FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
WO2002034711A1 (en) 2000-10-20 2002-05-02 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003217046A1 (en) 2002-04-05 2003-10-27 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300458D0 (en) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (en) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
KR20050105488A (en) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 Heteroarylcarbamoylbenzene derivative
ATE482747T1 (en) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES
CA2534221A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
EA200600990A1 (en) 2003-12-19 2006-10-27 Пфайзер Инк. DERIVATIVES OF BENZOSULPHONILYAMINOPYRIDIN-2-EFFLES AND RELATED COMPOUNDS AS 11-BETA-HYDROXYSTEROID-DEGYDROGENASE 1 TYPE (11-BETA-HSD-1) INHIBITORS FOR TREATMENT OF DIABETES FOR TREATMENT OF DIABETES TYPE 1 (11-BETA-HSD-1) FOR DIABETES TREATMENT
DE602005009500D1 (en) 2004-02-24 2008-10-16 Glaxo Group Ltd Pyridine derivatives and their use as modulators of the CB2 receptor
EP1761496A2 (en) * 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
CA2565843A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
PT1763517E (en) 2004-06-28 2011-07-01 Hoffmann La Roche Pyrimidine derivatives as 11beta-hsd1 inhibitors
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
EP1809290A2 (en) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
MX2007008238A (en) 2005-01-05 2007-08-17 Abbott Lab Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme.
JP4880671B2 (en) 2005-04-05 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー 1H-pyrazole 4-carboxylamido process for its preparation and its use as 11β-hydroxysteroid dehydrogenase
WO2006106054A1 (en) 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
JP2008542247A (en) 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ 2-Phenyl substituted imidazole [4,5B] pyridine / pyrazine and purine derivatives as glucokinase modulators
EP1894919B1 (en) 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
KR100970294B1 (en) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 Heterocyclic compounds
ES2334518T3 (en) 2005-06-16 2010-03-11 Pfizer, Inc. DERIVATIVES OF N- (PIRIDIN-2-IL) -SULFONAMIDE.
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009504621A (en) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
US8680122B2 (en) 2005-11-01 2014-03-25 Janssen Pharmacetica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (en) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
JP4276280B2 (en) 2005-11-21 2009-06-10 塩野義製薬株式会社 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
EA200870216A1 (en) 2006-01-31 2009-02-27 Инсайт Корпорейшн AMIDO COMPOUNDS AND THEIR APPLICATION AS MEDICINES
PL1999114T3 (en) 2006-03-22 2015-12-31 Hoffmann La Roche Pyrazoles as 11-beta-hsd-1
KR20090014347A (en) 2006-04-07 2009-02-10 하이 포인트 파마슈티칼스, 엘엘씨 11β-hydroxysteroid dehydrogenase type 1 active compound
CN101431994A (en) 2006-04-27 2009-05-13 索尔瓦药物有限公司 Use of CBx cannabinoid receptor modulators as potassium channel modulators
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
RU2455285C2 (en) 2007-05-18 2012-07-10 Сионоги Энд Ко., Лтд. NITROGEN CONTAINING HETEROCYCLIC DERIVATIVE SHOWING TYPE I 11β -HYDROXYSTEROIDDEHYDROGENASE INHIBITORY ACTIVITY
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
CA2703781A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
CA2713409A1 (en) 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
CA2719936A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2391607A1 (en) 2009-01-30 2011-12-07 AstraZeneca AB Novel process for preparing carboxy-containing pyrazoleamido compounds 597
UY32954A (en) * 2009-10-20 2011-05-31 Astrazeneca Ab PYRIMIDINES REPLACED WITH ADAMANTILIMINOCARBONILO AS INHIBITORS OF 11-ß-HSD1 826 ?.

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324265B2 (en) 2005-11-21 2012-12-04 Shionogi & Co., Ltd. Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
US7964618B2 (en) 2006-11-03 2011-06-21 Astrazeneca Ab Chemical compounds
US8673938B2 (en) 2006-11-03 2014-03-18 Astrazeneca Ab Chemical compounds
US8987453B2 (en) 2006-11-06 2015-03-24 Abbvie Inc. Azaadamantane derivatives and methods of use
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8344016B2 (en) 2007-02-12 2013-01-01 Astrazeneca Ab Pyrazole derivatives as 11-beta-HSD1 inhibitors
US7816391B2 (en) 2007-02-12 2010-10-19 Astrazeneca Ab Chemical compounds
US8383622B2 (en) 2007-05-18 2013-02-26 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
EP2202228A4 (en) * 2007-10-15 2011-06-29 Takeda Pharmaceutical Amide compounds and use of the same
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
US7951833B2 (en) 2008-02-04 2011-05-31 Astrazeneca Ab Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
EP2243479A2 (en) 2009-04-20 2010-10-27 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2011049520A1 (en) * 2009-10-20 2011-04-28 Astrazeneca Ab Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 1 1 betahsd1
JP2013512243A (en) * 2009-11-24 2013-04-11 アラーガン インコーポレイテッド Novel compounds as receptor modulators with therapeutic utility
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013189862A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as lpar antagonists
WO2013189864A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
WO2021094390A1 (en) 2019-11-12 2021-05-20 University Of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
WO2022101361A2 (en) 2019-11-12 2022-05-19 Astrazeneca Ab Automated assessment of wound tissue
EP4002381A1 (en) 2019-11-12 2022-05-25 Astrazeneca AB Automated assessment of wound tissue
WO2024095003A1 (en) * 2022-11-02 2024-05-10 Cerevance, Inc. Nicotinamide derivatives for use in treating disorders associated with kcnk13 activity
WO2025257199A1 (en) 2024-06-11 2025-12-18 Astrazeneca Ab Therapies for wound treatment

Also Published As

Publication number Publication date
NZ576501A (en) 2011-03-31
PE20081487A1 (en) 2009-01-11
CA2668006C (en) 2016-05-24
JP2010508338A (en) 2010-03-18
KR101465275B1 (en) 2014-11-27
CN101787016A (en) 2010-07-28
HRP20100522T1 (en) 2010-11-30
DK2086939T3 (en) 2010-10-11
US20090312372A1 (en) 2009-12-17
CN102603711A (en) 2012-07-25
AU2007315955A1 (en) 2008-05-08
CN101573336B (en) 2012-03-21
WO2008053194A3 (en) 2008-10-02
US8673938B2 (en) 2014-03-18
SI2086939T1 (en) 2010-10-29
AR063458A1 (en) 2009-01-28
JP5165688B2 (en) 2013-03-21
IL198231A0 (en) 2009-12-24
EP2086939B1 (en) 2010-07-28
ES2347491T3 (en) 2010-10-29
CO6321130A2 (en) 2011-09-20
CN101573336A (en) 2009-11-04
CA2668006A1 (en) 2008-05-08
PL2086939T3 (en) 2011-09-30
PT2086939E (en) 2010-09-17
BRPI0717970A2 (en) 2013-11-05
AU2007315955B2 (en) 2011-04-14
RU2009115830A (en) 2010-12-10
UY30681A1 (en) 2008-07-03
BRPI0717970B1 (en) 2019-10-22
KR20090075865A (en) 2009-07-09
NO20091603L (en) 2009-05-28
US20080269288A1 (en) 2008-10-30
EP2086939A2 (en) 2009-08-12
US7964618B2 (en) 2011-06-21
ES2423206T3 (en) 2013-09-18
US20090306075A1 (en) 2009-12-10
DE602007008137D1 (en) 2010-09-09
CL2007003176A1 (en) 2008-07-25
BRPI0717970C1 (en) 2021-05-25
MX2009004707A (en) 2009-05-15
TW200827346A (en) 2008-07-01
EP2233480A1 (en) 2010-09-29
RU2451674C2 (en) 2012-05-27
CN101787016B (en) 2013-08-28
BRPI0717970B8 (en) 2020-12-01
RS51451B (en) 2011-04-30
EP2233480B1 (en) 2013-05-29
CY1110813T1 (en) 2015-06-10
HK1135090A1 (en) 2010-05-28
ATE475649T1 (en) 2010-08-15
EP2086939B8 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
EP2086939B1 (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
AU2021203497B2 (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
US20100022589A1 (en) Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
EP0783500B1 (en) Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
WO2009130496A1 (en) Substituted pyrimidin-5-carboxamides 281
WO2007135427A1 (en) 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
BRPI0808450A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND PROCESS TO PREPARE A COMPOUND
TW201605827A (en) New bis-amido pyridines
HK1135090B (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
SA07280596B1 (en) Pyridine Amide Compounds and Their Use as Inhibitors of 11- B- Hydroxysteroid Dehydrogenase Type 1 Enzyme

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780049167.5

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2009535119

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 198231

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007315955

Country of ref document: AU

Ref document number: 2607/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 576501

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009040602

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 09043382

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2668006

Country of ref document: CA

Ref document number: MX/A/2009/004707

Country of ref document: MX

Ref document number: 12009500835

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007824375

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097010339

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007315955

Country of ref document: AU

Date of ref document: 20071031

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009115830

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824375

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: P-2010/0422

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0717970

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090504